id	report_number	hb_report_number	data_provider	data_title	data_source	data_source_type	data_date	sample_source	sample_info	vac_prime	vac_prime_dose	vac_prime_dose_unit	vac_boost1	vac_boost1_dose	vac_boost1_dose_unit	boost1_info	boost1_class	vac_boost2	vac_boost2_dose	vac_boost2_dose_unit	boost2_class	boost2_info	experiment_id	assay_cat	assay_type	assay_type_mod	viral_name	viral_lineage	viral_sublineage	viral_mutation	vaccine_activity	vaccine_activity_unit	vaccine_activity_description	boost1_time_unit	boost1_time0	boost1_activity0	boost1_time1	boost1_time1_info	boost1_activity1	boost1_activitiy1_norm	boost1_effect1	boost1_time2	boost1_time2_info	boost1_activity2	boost1_activity2_norm	boost1_effect2	boost1_time3	boost1_time3_info	boost1_activity3	boost1_activity3_norm	boost1_effect3	boost2_time_unit	boost2_time0	boost2_activity0	boost2_time1	boost2_time1_info	boost2_activity1	boost2_activitiy1_norm	boost2_effect1	boost2_time2	boost2_time2_info	boost2_activity2	boost2_activity2_norm	boost2_effect2	boost2_time3	boost2_time3_info	boost2_activity3	boost2_activity3_norm	boost2_effect3	database_name	group_name	eb_group_number
4941		1	NIH	Heterologous SARS-CoV-2 Booster Vaccinations: Preliminary Report	https://doi.org/10.1056/NEJMoa2116414	Peer-reviewed publication	03/17/2022	human		mRNA-1273	100	?g	mRNA-1273	100	?g		Homologous						1	Binding	ECLIA						Anti-S-2P GMT	BAU/mL		days post booster1	0	872	14		6865	7.87	1.00	28		6224	7.14	1.00																							
4942		1	NIH	Heterologous SARS-CoV-2 Booster Vaccinations: Preliminary Report	https://doi.org/10.1056/NEJMoa2116414	Peer-reviewed publication	03/17/2022	human		mRNA-1273	100	?g	Ad26.COV2.S	5.00E+10	virus  particles		Heterologous						1	Binding	ECLIA						Anti-S-2P GMT	BAU/mL		days post booster1	0	639	14		3029	4.74	0.60	28		4560	7.14	1.00																							
4943		1	NIH	Heterologous SARS-CoV-2 Booster Vaccinations: Preliminary Report	https://doi.org/10.1056/NEJMoa2116414	Peer-reviewed publication	03/17/2022	human		mRNA-1273	100	?g	BNT162b2	30	?g		Heterologous						1	Binding	ECLIA						Anti-S-2P GMT	BAU/mL		days post booster1	0	534	14		5256	9.84	1.25	28		5273	9.87	1.38																							
4944		1	NIH	Heterologous SARS-CoV-2 Booster Vaccinations: Preliminary Report	https://doi.org/10.1056/NEJMoa2116414	Peer-reviewed publication	03/17/2022	human		Ad26.COV2.S	5.00E+10	virus  particles	Ad26.COV2.S	5.00E+10	virus  particles		Homologous						1	Binding	ECLIA						Anti-S-2P GMT	BAU/mL		days post booster1	0	71	14		326	4.59	1.00	28		369	5.20	1.00																							
4945		1	NIH	Heterologous SARS-CoV-2 Booster Vaccinations: Preliminary Report	https://doi.org/10.1056/NEJMoa2116414	Peer-reviewed publication	03/17/2022	human		Ad26.COV2.S	5.00E+10	virus  particles	BNT162b2	30	?g		Heterologous						1	Binding	ECLIA						Anti-S-2P GMT	BAU/mL		days post booster1	0	75	14		2563	34.17	7.45	28		2277	30.36	5.84																							
4946		1	NIH	Heterologous SARS-CoV-2 Booster Vaccinations: Preliminary Report	https://doi.org/10.1056/NEJMoa2116414	Peer-reviewed publication	03/17/2022	human		Ad26.COV2.S	5.00E+10	virus  particles	mRNA-1273	100	?g		Heterologous						1	Binding	ECLIA						Anti-S-2P GMT	BAU/mL		days post booster1	0	59	14		3244	54.98	11.98	28		2986	50.61	9.73																							
4947		1	NIH	Heterologous SARS-CoV-2 Booster Vaccinations: Preliminary Report	https://doi.org/10.1056/NEJMoa2116414	Peer-reviewed publication	03/17/2022	human		BNT162b2	30	?g	BNT162b2	30	?g		Homologous						1	Binding	ECLIA						Anti-S-2P GMT	BAU/mL		days post booster1	0	224	14		3345	14.93	1.00	28		3164	14.13	1.00																							
4948		1	NIH	Heterologous SARS-CoV-2 Booster Vaccinations: Preliminary Report	https://doi.org/10.1056/NEJMoa2116414	Peer-reviewed publication	03/17/2022	human		BNT162b2	30	?g	mRNA-1273	100	?g		Heterologous						1	Binding	ECLIA						Anti-S-2P GMT	BAU/mL		days post booster1	0	357	14		6155	17.24	1.15	28		5231	14.65	1.04																							
4949		1	NIH	Heterologous SARS-CoV-2 Booster Vaccinations: Preliminary Report	https://doi.org/10.1056/NEJMoa2116414	Peer-reviewed publication	03/17/2022	human		BNT162b2	30	?g	Ad26.COV2.S	5.00E+10	virus  particles		Heterologous						1	Binding	ECLIA						Anti-S-2P GMT	BAU/mL		days post booster1	0	321	14		1905	5.93	0.40	28		2600	8.10	0.57																							
4950		1	NIH	Heterologous SARS-CoV-2 Booster Vaccinations: Preliminary Report	https://doi.org/10.1056/NEJMoa2116414	Peer-reviewed publication	03/17/2022	human		mRNA-1273	100	?g	mRNA-1273	100	?g		Homologous						2	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	IU50/mL GMT		International Units/mL for 50% neutralization, calibration factor 0.242	days post booster1	0	89	14		902	10.13	1.00	28		700	7.87	1.00																							
4951		1	NIH	Heterologous SARS-CoV-2 Booster Vaccinations: Preliminary Report	https://doi.org/10.1056/NEJMoa2116414	Peer-reviewed publication	03/17/2022	human		mRNA-1273	100	?g	Ad26.COV2.S	5.00E+10	virus  particles		Heterologous						2	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	IU50/mL GMT		International Units/mL for 50% neutralization, calibration factor 0.243	days post booster1	0	62	14		382	6.16	0.61	28		528	8.52	1.08																							
4952		1	NIH	Heterologous SARS-CoV-2 Booster Vaccinations: Preliminary Report	https://doi.org/10.1056/NEJMoa2116414	Peer-reviewed publication	03/17/2022	human		mRNA-1273	100	?g	BNT162b2	30	?g		Heterologous						2	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	IU50/mL GMT		International Units/mL for 50% neutralization, calibration factor 0.244	days post booster1	0	58	14		694	11.97	1.94	28		515	8.88	1.04																							
4953		1	NIH	Heterologous SARS-CoV-2 Booster Vaccinations: Preliminary Report	https://doi.org/10.1056/NEJMoa2116414	Peer-reviewed publication	03/17/2022	human		Ad26.COV2.S	5.00E+10	virus  particles	Ad26.COV2.S	5.00E+10	virus  particles		Homologous						2	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	IU50/mL GMT		International Units/mL for 50% neutralization, calibration factor 0.245	days post booster1	0	8	14		31	3.88	1.00	28		30	3.75	1.00																							
4954		1	NIH	Heterologous SARS-CoV-2 Booster Vaccinations: Preliminary Report	https://doi.org/10.1056/NEJMoa2116414	Peer-reviewed publication	03/17/2022	human		Ad26.COV2.S	5.00E+10	virus  particles	BNT162b2	30	?g		Heterologous						2	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	IU50/mL GMT		International Units/mL for 50% neutralization, calibration factor 0.246	days post booster1	0	9	14		344	38.22	9.86	28		242	26.89	7.17																							
4955		1	NIH	Heterologous SARS-CoV-2 Booster Vaccinations: Preliminary Report	https://doi.org/10.1056/NEJMoa2116414	Peer-reviewed publication	03/17/2022	human		Ad26.COV2.S	5.00E+10	virus  particles	mRNA-1273	100	?g		Heterologous						2	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	IU50/mL GMT		International Units/mL for 50% neutralization, calibration factor 0.247	days post booster1	0	9	14		676	75.11	19.38	28		432	48.00	12.80																							
4956		1	NIH	Heterologous SARS-CoV-2 Booster Vaccinations: Preliminary Report	https://doi.org/10.1056/NEJMoa2116414	Peer-reviewed publication	03/17/2022	human		BNT162b2	30	?g	BNT162b2	30	?g		Homologous						2	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	IU50/mL GMT		International Units/mL for 50% neutralization, calibration factor 0.248	days post booster1	0	21	14		437	20.81	1.00	28		306	14.57	1.00																							
4957		1	NIH	Heterologous SARS-CoV-2 Booster Vaccinations: Preliminary Report	https://doi.org/10.1056/NEJMoa2116414	Peer-reviewed publication	03/17/2022	human		BNT162b2	30	?g	mRNA-1273	100	?g		Heterologous						2	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	IU50/mL GMT		International Units/mL for 50% neutralization, calibration factor 0.249	days post booster1	0	25	14		786	31.44	1.51	28		496	19.84	1.36																							
4975		4	Chulalongkorn University	Immunogenicity of heterologous prime/boost inactivated and mRNA COVID-19 vaccine	https://doi.org/10.1101/2021.11.20.21266644	Pre-print	11/21/2021	human		CoronaVac			BNT162b2			Long interval: 7 weeks	Heterologous						1	Neutralization	Pseudotyped virus assay	Surrogate Virus Neutralization	Alpha	B.1.1.7	B.1.1.7		sVNT50, % inhibition GM			weeks post booster1			4.5		97.85		2.32																												
4958		1	NIH	Heterologous SARS-CoV-2 Booster Vaccinations: Preliminary Report	https://doi.org/10.1056/NEJMoa2116414	Peer-reviewed publication	03/17/2022	human		BNT162b2	30	?g	Ad26.COV2.S	5.00E+10	virus  particles		Heterologous						2	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	IU50/mL GMT		International Units/mL for 50% neutralization, calibration factor 0.250	days post booster1	0	19	14		216	11.37	0.55	28		267	14.05	0.96																							
4959		2	Institute of Biological Products	Immunogenicity and adverse events of priming with inactivated whole SARS-CoV-2 vaccine (CoronaVac) followed by boosting the ChAdOx1 nCoV-19 vaccine	https://doi.org/10.1101/2021.11.05.21264700	Pre-print	11/08/2021	human		CoronaVac			CoronaVac				Homologous						1	Binding	ELISA						Anti-S RBD IgG GM	BAU/mL		days post booster1			28		160		1.00																												
4960		2	Institute of Biological Products	Immunogenicity and adverse events of priming with inactivated whole SARS-CoV-2 vaccine (CoronaVac) followed by boosting the ChAdOx1 nCoV-19 vaccine	https://doi.org/10.1101/2021.11.05.21264701	Pre-print	11/08/2021	human		ChAdOx1 nCoV-19			ChAdOx1 nCoV-19				Homologous						1	Binding	ELISA						Anti-S RBD IgG GM	BAU/mL		days post booster1			28		308.5																														
4961		2	Institute of Biological Products	Immunogenicity and adverse events of priming with inactivated whole SARS-CoV-2 vaccine (CoronaVac) followed by boosting the ChAdOx1 nCoV-19 vaccine	https://doi.org/10.1101/2021.11.05.21264701	Pre-print	11/08/2021	human		CoronaVac			ChAdOx1 nCoV-19				Heterologous						1	Binding	ELISA						Anti-S RBD IgG GM	BAU/mL		days post booster1			28		819.5		5.12																												
4962		3	Finlay Vaccine Institute	Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme	https://doi.org/10.1101/2021.11.14.21266309	Pre-print	11/15/2021	human		SOBERANA 02	25	?g	SOBERANA 02	25	?g		Homologous						1	Binding	ELISA						Anti-RBD IgG median	AU/mL		days post booster1			14		71.6		1.00	28		81.7		1.00																							
4963		3	Finlay Vaccine Institute	Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme	https://doi.org/10.1101/2021.11.14.21266309	Pre-print	11/15/2021	human		SOBERANA 02	25	?g	SOBERANA Plus	50	?g		Variant						1	Binding	ELISA						Anti-RBD IgG median	AU/mL		days post booster1			14		99.3		1.39	28		113.4		1.39																							
4964		3	Finlay Vaccine Institute	Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme	https://doi.org/10.1101/2021.11.14.21266309	Pre-print	11/15/2021	human		SOBERANA 02	25	?g	SOBERANA 02	25	?g		Homologous						2	Neutralization	Pseudotyped virus assay	Surrogate Virus Neutralization	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	sVNT50 GMT		Surrogate virus neutralization titre	days post booster1			14		220.2		1.00	28		202.2		1.00																							
4965		3	Finlay Vaccine Institute	Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme	https://doi.org/10.1101/2021.11.14.21266309	Pre-print	11/15/2021	human		SOBERANA 02	25	?g	SOBERANA Plus	50	?g		Variant						2	Neutralization	Pseudotyped virus assay	Surrogate Virus Neutralization	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	sVNT50 GMT		Surrogate virus neutralization titre	days post booster1			14		345.1		1.57	28		319		1.58																							
4966		3	Finlay Vaccine Institute	Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme	https://doi.org/10.1101/2021.11.14.21266309	Pre-print	11/15/2021	human		SOBERANA 02	25	?g	SOBERANA 02	25	?g		Homologous						3	Neutralization	Live virus replication assay	CPE	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	cVNT50 GMT		Conventional live-virus neutralization titre	days post booster1			14		32.8		1.00																												
4967		3	Finlay Vaccine Institute	Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme	https://doi.org/10.1101/2021.11.14.21266309	Pre-print	11/15/2021	human		SOBERANA 02	25	?g	SOBERANA Plus	50	?g		Variant						3	Neutralization	Live virus replication assay	CPE	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	cVNT50 GMT		Conventional live-virus neutralization titre	days post booster1			14		42.5		1.30																												
4968		4	Chulalongkorn University	Immunogenicity of heterologous prime/boost inactivated and mRNA COVID-19 vaccine	https://doi.org/10.1101/2021.11.20.21266644	Pre-print	11/21/2021	human		CoronaVac			CoronaVac			Short interval: 21-28 days	Homologous						1	Neutralization	Pseudotyped virus assay	Surrogate Virus Neutralization	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		sVNT50, % inhibition GM			weeks post booster1			4.5		66.6		1.00																												
4969		4	Chulalongkorn University	Immunogenicity of heterologous prime/boost inactivated and mRNA COVID-19 vaccine	https://doi.org/10.1101/2021.11.20.21266644	Pre-print	11/21/2021	human		BNT162b2			BNT162b2			Short interval: 21-28 days	Homologous						1	Neutralization	Pseudotyped virus assay	Surrogate Virus Neutralization	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		sVNT50, % inhibition GM			weeks post booster1			4.5		97.4																														
4970		4	Chulalongkorn University	Immunogenicity of heterologous prime/boost inactivated and mRNA COVID-19 vaccine	https://doi.org/10.1101/2021.11.20.21266644	Pre-print	11/21/2021	human		CoronaVac			BNT162b2			Short interval: 21-28 days	Heterologous						1	Neutralization	Pseudotyped virus assay	Surrogate Virus Neutralization	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		sVNT50, % inhibition GM			weeks post booster1			4.5		95.45		1.43																												
4971		4	Chulalongkorn University	Immunogenicity of heterologous prime/boost inactivated and mRNA COVID-19 vaccine	https://doi.org/10.1101/2021.11.20.21266644	Pre-print	11/21/2021	human		CoronaVac			BNT162b2			Long interval: 7 weeks	Heterologous						1	Neutralization	Pseudotyped virus assay	Surrogate Virus Neutralization	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		sVNT50, % inhibition GM			weeks post booster1			4.5		97.35		1.46																												
4972		4	Chulalongkorn University	Immunogenicity of heterologous prime/boost inactivated and mRNA COVID-19 vaccine	https://doi.org/10.1101/2021.11.20.21266644	Pre-print	11/21/2021	human		CoronaVac			CoronaVac			Short interval: 21-28 days	Homologous						1	Neutralization	Pseudotyped virus assay	Surrogate Virus Neutralization	Alpha	B.1.1.7	B.1.1.7		sVNT50, % inhibition GM			weeks post booster1			4.5		42.11		1.00																												
4973		4	Chulalongkorn University	Immunogenicity of heterologous prime/boost inactivated and mRNA COVID-19 vaccine	https://doi.org/10.1101/2021.11.20.21266644	Pre-print	11/21/2021	human		BNT162b2			BNT162b2			Short interval: 21-28 days	Homologous						1	Neutralization	Pseudotyped virus assay	Surrogate Virus Neutralization	Alpha	B.1.1.7	B.1.1.7		sVNT50, % inhibition GM			weeks post booster1			4.5		93.7																														
4974		4	Chulalongkorn University	Immunogenicity of heterologous prime/boost inactivated and mRNA COVID-19 vaccine	https://doi.org/10.1101/2021.11.20.21266644	Pre-print	11/21/2021	human		CoronaVac			BNT162b2			Short interval: 21-28 days	Heterologous						1	Neutralization	Pseudotyped virus assay	Surrogate Virus Neutralization	Alpha	B.1.1.7	B.1.1.7		sVNT50, % inhibition GM			weeks post booster1			4.5		84.7		2.01																												
4976		4	Chulalongkorn University	Immunogenicity of heterologous prime/boost inactivated and mRNA COVID-19 vaccine	https://doi.org/10.1101/2021.11.20.21266644	Pre-print	11/21/2021	human		CoronaVac			CoronaVac			Short interval: 21-28 days	Homologous						1	Neutralization	Pseudotyped virus assay	Surrogate Virus Neutralization	Beta	B.1.351	B.1.351		sVNT50, % inhibition GM			weeks post booster1			4.5		34.86		1.00																												
4977		4	Chulalongkorn University	Immunogenicity of heterologous prime/boost inactivated and mRNA COVID-19 vaccine	https://doi.org/10.1101/2021.11.20.21266644	Pre-print	11/21/2021	human		BNT162b2			BNT162b2			Short interval: 21-28 days	Homologous						1	Neutralization	Pseudotyped virus assay	Surrogate Virus Neutralization	Beta	B.1.351	B.1.351		sVNT50, % inhibition GM			weeks post booster1			4.5		88.6																														
4978		4	Chulalongkorn University	Immunogenicity of heterologous prime/boost inactivated and mRNA COVID-19 vaccine	https://doi.org/10.1101/2021.11.20.21266644	Pre-print	11/21/2021	human		CoronaVac			BNT162b2			Short interval: 21-28 days	Heterologous						1	Neutralization	Pseudotyped virus assay	Surrogate Virus Neutralization	Beta	B.1.351	B.1.351		sVNT50, % inhibition GM			weeks post booster1			4.5		77.25		2.22																												
4979		4	Chulalongkorn University	Immunogenicity of heterologous prime/boost inactivated and mRNA COVID-19 vaccine	https://doi.org/10.1101/2021.11.20.21266644	Pre-print	11/21/2021	human		CoronaVac			BNT162b2			Long interval: 7 weeks	Heterologous						1	Neutralization	Pseudotyped virus assay	Surrogate Virus Neutralization	Beta	B.1.351	B.1.351		sVNT50, % inhibition GM			weeks post booster1			4.5		95.4		2.74																												
4980		4	Chulalongkorn University	Immunogenicity of heterologous prime/boost inactivated and mRNA COVID-19 vaccine	https://doi.org/10.1101/2021.11.20.21266644	Pre-print	11/21/2021	human		CoronaVac			CoronaVac			Short interval: 21-28 days	Homologous						1	Neutralization	Pseudotyped virus assay	Surrogate Virus Neutralization	Delta	B.1.617.2	B.1.617.2		sVNT50, % inhibition GM			weeks post booster1			4.5		48.93		1.00																												
4981		4	Chulalongkorn University	Immunogenicity of heterologous prime/boost inactivated and mRNA COVID-19 vaccine	https://doi.org/10.1101/2021.11.20.21266644	Pre-print	11/21/2021	human		BNT162b2			BNT162b2			Short interval: 21-28 days	Homologous						1	Neutralization	Pseudotyped virus assay	Surrogate Virus Neutralization	Delta	B.1.617.2	B.1.617.2		sVNT50, % inhibition GM			weeks post booster1			4.5		97.1																														
4982		4	Chulalongkorn University	Immunogenicity of heterologous prime/boost inactivated and mRNA COVID-19 vaccine	https://doi.org/10.1101/2021.11.20.21266644	Pre-print	11/21/2021	human		CoronaVac			BNT162b2			Short interval: 21-28 days	Heterologous						1	Neutralization	Pseudotyped virus assay	Surrogate Virus Neutralization	Delta	B.1.617.2	B.1.617.2		sVNT50, % inhibition GM			weeks post booster1			4.5		92.95		1.90																												
4983		4	Chulalongkorn University	Immunogenicity of heterologous prime/boost inactivated and mRNA COVID-19 vaccine	https://doi.org/10.1101/2021.11.20.21266644	Pre-print	11/21/2021	human		CoronaVac			BNT162b2			Long interval: 7 weeks	Heterologous						1	Neutralization	Pseudotyped virus assay	Surrogate Virus Neutralization	Delta	B.1.617.2	B.1.617.2		sVNT50, % inhibition GM			weeks post booster1			4.5		97.35		1.99																												
4984		4	Chulalongkorn University	Immunogenicity of heterologous prime/boost inactivated and mRNA COVID-19 vaccine	https://doi.org/10.1101/2021.11.20.21266644	Pre-print	11/21/2021	human		CoronaVac			CoronaVac			Short interval: 21-28 days	Homologous						2	Binding	ELISA						Anti-RBD Ig GMT	U/mL		weeks post booster1			4.5		97.9		1.00																												
4985		4	Chulalongkorn University	Immunogenicity of heterologous prime/boost inactivated and mRNA COVID-19 vaccine	https://doi.org/10.1101/2021.11.20.21266644	Pre-print	11/21/2021	human		BNT162b2			BNT162b2			Short interval: 21-28 days	Homologous						2	Binding	ELISA						Anti-RBD Ig GMT	U/mL		weeks post booster1			4.5		196																														
4986		4	Chulalongkorn University	Immunogenicity of heterologous prime/boost inactivated and mRNA COVID-19 vaccine	https://doi.org/10.1101/2021.11.20.21266644	Pre-print	11/21/2021	human		CoronaVac			BNT162b2			Short interval: 21-28 days	Heterologous						2	Binding	ELISA						Anti-RBD Ig GMT	U/mL		weeks post booster1			4.5		1042		10.64																												
4987		4	Chulalongkorn University	Immunogenicity of heterologous prime/boost inactivated and mRNA COVID-19 vaccine	https://doi.org/10.1101/2021.11.20.21266644	Pre-print	11/21/2021	human		CoronaVac			BNT162b2			Long interval: 7 weeks	Heterologous						2	Binding	ELISA						Anti-RBD Ig GMT	U/mL		weeks post booster1			4.5		10485		107.10																												
4988		4	Chulalongkorn University	Immunogenicity of heterologous prime/boost inactivated and mRNA COVID-19 vaccine	https://doi.org/10.1101/2021.11.20.21266644	Pre-print	11/21/2021	human		CoronaVac			CoronaVac			Short interval: 21-28 days	Homologous						2	Binding	ELISA						Anti-S1 IgA, OD/CO ratio GM			weeks post booster1			4.5		0.88		1.00																												
4989		4	Chulalongkorn University	Immunogenicity of heterologous prime/boost inactivated and mRNA COVID-19 vaccine	https://doi.org/10.1101/2021.11.20.21266644	Pre-print	11/21/2021	human		BNT162b2			BNT162b2			Short interval: 21-28 days	Homologous						2	Binding	ELISA						Anti-S1 IgA, OD/CO ratio GM			weeks post booster1			4.5		5.62																														
4990		4	Chulalongkorn University	Immunogenicity of heterologous prime/boost inactivated and mRNA COVID-19 vaccine	https://doi.org/10.1101/2021.11.20.21266644	Pre-print	11/21/2021	human		CoronaVac			BNT162b2			Short interval: 21-28 days	Heterologous						2	Binding	ELISA						Anti-S1 IgA, OD/CO ratio GM			weeks post booster1			4.5		6.55		7.44																												
4991		4	Chulalongkorn University	Immunogenicity of heterologous prime/boost inactivated and mRNA COVID-19 vaccine	https://doi.org/10.1101/2021.11.20.21266644	Pre-print	11/21/2021	human		CoronaVac			BNT162b2			Long interval: 7 weeks	Heterologous						2	Binding	ELISA						Anti-S1 IgA, OD/CO ratio GM			weeks post booster1			4.5		9		10.23																												
4992		5	Mahidol University	The immunogenicity and reactogenicity of four COVID-19 booster vaccinations against SARS-CoV-2 variants of concerns (Delta, Beta, and Omicron) following CoronaVac or ChAdOx1 nCoV-19 primary series	https://doi.org/10.1101/2021.11.29.21266947	Pre-print	02/04/2021	human		ChAdOx1 nCoV-19			ChAdOx1 nCoV-19				Homologous						1	Neutralization	Live virus replication assay	CPE	Delta	B.1.617.2	B.1.617.2		PRNT50 GMT			days post booster1			14		69.1		1.00																												
4993		5	Mahidol University	The immunogenicity and reactogenicity of four COVID-19 booster vaccinations against SARS-CoV-2 variants of concerns (Delta, Beta, and Omicron) following CoronaVac or ChAdOx1 nCoV-19 primary series	https://doi.org/10.1101/2021.11.29.21266947	Pre-print	02/04/2021	human		ChAdOx1 nCoV-19			BBIBP-CorV				Heterologous						1	Neutralization	Live virus replication assay	CPE	Delta	B.1.617.2	B.1.617.2		PRNT50 GMT			days post booster1			14		49		0.71																												
5880																																																																					
4994		5	Mahidol University	The immunogenicity and reactogenicity of four COVID-19 booster vaccinations against SARS-CoV-2 variants of concerns (Delta, Beta, and Omicron) following CoronaVac or ChAdOx1 nCoV-19 primary series	https://doi.org/10.1101/2021.11.29.21266947	Pre-print	02/04/2021	human		ChAdOx1 nCoV-19			BNT162b2	30	?g		Heterologous						1	Neutralization	Live virus replication assay	CPE	Delta	B.1.617.2	B.1.617.2		PRNT50 GMT			days post booster1			14		470.1		6.80																												
4995		5	Mahidol University	The immunogenicity and reactogenicity of four COVID-19 booster vaccinations against SARS-CoV-2 variants of concerns (Delta, Beta, and Omicron) following CoronaVac or ChAdOx1 nCoV-19 primary series	https://doi.org/10.1101/2021.11.29.21266947	Pre-print	02/04/2021	human		ChAdOx1 nCoV-19			BNT162b2	15	?g		Heterologous						1	Neutralization	Live virus replication assay	CPE	Delta	B.1.617.2	B.1.617.2		PRNT50 GMT			days post booster1			14		358.4		5.19																												
4996		5	Mahidol University	The immunogenicity and reactogenicity of four COVID-19 booster vaccinations against SARS-CoV-2 variants of concerns (Delta, Beta, and Omicron) following CoronaVac or ChAdOx1 nCoV-19 primary series	https://doi.org/10.1101/2021.11.29.21266947	Pre-print	02/04/2021	human		ChAdOx1 nCoV-19			ChAdOx1 nCoV-19				Homologous						1	Neutralization	Live virus replication assay	CPE	Beta	B.1.351	B.1.351		PRNT50 GMT			days post booster1			14		38.2		1.00																												
4997		5	Mahidol University	The immunogenicity and reactogenicity of four COVID-19 booster vaccinations against SARS-CoV-2 variants of concerns (Delta, Beta, and Omicron) following CoronaVac or ChAdOx1 nCoV-19 primary series	https://doi.org/10.1101/2021.11.29.21266947	Pre-print	02/04/2021	human		ChAdOx1 nCoV-19			BBIBP-CorV				Heterologous						1	Neutralization	Live virus replication assay	CPE	Beta	B.1.351	B.1.351		PRNT50 GMT			days post booster1			14		28.1		0.74																												
4998		5	Mahidol University	The immunogenicity and reactogenicity of four COVID-19 booster vaccinations against SARS-CoV-2 variants of concerns (Delta, Beta, and Omicron) following CoronaVac or ChAdOx1 nCoV-19 primary series	https://doi.org/10.1101/2021.11.29.21266947	Pre-print	02/04/2021	human		ChAdOx1 nCoV-19			BNT162b2	30	?g		Heterologous						1	Neutralization	Live virus replication assay	CPE	Beta	B.1.351	B.1.351		PRNT50 GMT			days post booster1			14		292.9		7.67																												
4999		5	Mahidol University	The immunogenicity and reactogenicity of four COVID-19 booster vaccinations against SARS-CoV-2 variants of concerns (Delta, Beta, and Omicron) following CoronaVac or ChAdOx1 nCoV-19 primary series	https://doi.org/10.1101/2021.11.29.21266947	Pre-print	02/04/2021	human		ChAdOx1 nCoV-19			BNT162b2	15	?g		Heterologous						1	Neutralization	Live virus replication assay	CPE	Beta	B.1.351	B.1.351		PRNT50 GMT			days post booster1			14		250		6.54																												
5000		5	Mahidol University	The immunogenicity and reactogenicity of four COVID-19 booster vaccinations against SARS-CoV-2 variants of concerns (Delta, Beta, and Omicron) following CoronaVac or ChAdOx1 nCoV-19 primary series	https://doi.org/10.1101/2021.11.29.21266947	Pre-print	02/04/2021	human		ChAdOx1 nCoV-19			ChAdOx1 nCoV-19				Homologous						2	Neutralization	Pseudotyped virus assay	Luciferase	Delta	B.1.617.2	B.1.617.2		PVNT50 GMT			weeks post booster1			2		120.6		1.00	18	16-20 weeks post booster1	0																									
5001		5	Mahidol University	The immunogenicity and reactogenicity of four COVID-19 booster vaccinations against SARS-CoV-2 variants of concerns (Delta, Beta, and Omicron) following CoronaVac or ChAdOx1 nCoV-19 primary series	https://doi.org/10.1101/2021.11.29.21266947	Pre-print	02/04/2021	human		ChAdOx1 nCoV-19			BBIBP-CorV				Heterologous						2	Neutralization	Pseudotyped virus assay	Luciferase	Delta	B.1.617.2	B.1.617.2		PVNT50 GMT			weeks post booster1			2		17.15		0.14	18	16-20 weeks post booster1	0																									
5002		5	Mahidol University	The immunogenicity and reactogenicity of four COVID-19 booster vaccinations against SARS-CoV-2 variants of concerns (Delta, Beta, and Omicron) following CoronaVac or ChAdOx1 nCoV-19 primary series	https://doi.org/10.1101/2021.11.29.21266947	Pre-print	02/04/2021	human		ChAdOx1 nCoV-19			BNT162b2	30	?g		Heterologous						2	Neutralization	Pseudotyped virus assay	Luciferase	Delta	B.1.617.2	B.1.617.2		PVNT50 GMT			weeks post booster1			2		1081.2		8.97	18	16-20 weeks post booster1	207.1																									
5003		5	Mahidol University	The immunogenicity and reactogenicity of four COVID-19 booster vaccinations against SARS-CoV-2 variants of concerns (Delta, Beta, and Omicron) following CoronaVac or ChAdOx1 nCoV-19 primary series	https://doi.org/10.1101/2021.11.29.21266947	Pre-print	02/04/2021	human		ChAdOx1 nCoV-19			BNT162b2	15	?g		Heterologous						2	Neutralization	Pseudotyped virus assay	Luciferase	Delta	B.1.617.2	B.1.617.2		PVNT50 GMT			weeks post booster1			2		720.66		5.98	18	16-20 weeks post booster1	178.63																									
5004		5	Mahidol University	The immunogenicity and reactogenicity of four COVID-19 booster vaccinations against SARS-CoV-2 variants of concerns (Delta, Beta, and Omicron) following CoronaVac or ChAdOx1 nCoV-19 primary series	https://doi.org/10.1101/2021.11.29.21266947	Pre-print	02/04/2021	human		ChAdOx1 nCoV-19			ChAdOx1 nCoV-19				Homologous						2	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.1		PVNT50 GMT			weeks post booster1			2		3.25		1.00	18	16-20 weeks post booster1	0																									
5005		5	Mahidol University	The immunogenicity and reactogenicity of four COVID-19 booster vaccinations against SARS-CoV-2 variants of concerns (Delta, Beta, and Omicron) following CoronaVac or ChAdOx1 nCoV-19 primary series	https://doi.org/10.1101/2021.11.29.21266947	Pre-print	02/04/2021	human		ChAdOx1 nCoV-19			BBIBP-CorV				Heterologous						2	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.1		PVNT50 GMT			weeks post booster1			2		0.1		0.03	18	16-20 weeks post booster1	0																									
5006		5	Mahidol University	The immunogenicity and reactogenicity of four COVID-19 booster vaccinations against SARS-CoV-2 variants of concerns (Delta, Beta, and Omicron) following CoronaVac or ChAdOx1 nCoV-19 primary series	https://doi.org/10.1101/2021.11.29.21266947	Pre-print	02/04/2021	human		ChAdOx1 nCoV-19			BNT162b2	30	?g		Heterologous						2	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.1		PVNT50 GMT			weeks post booster1			2		521.16		160.36	18	16-20 weeks post booster1	116.88																									
5007		5	Mahidol University	The immunogenicity and reactogenicity of four COVID-19 booster vaccinations against SARS-CoV-2 variants of concerns (Delta, Beta, and Omicron) following CoronaVac or ChAdOx1 nCoV-19 primary series	https://doi.org/10.1101/2021.11.29.21266947	Pre-print	02/04/2021	human		ChAdOx1 nCoV-19			BNT162b2	15	?g		Heterologous						2	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.1		PVNT50 GMT			weeks post booster1			2		232.31		71.48	18	16-20 weeks post booster1	14.04																									
5881																																																																					
5882																																																																					
5883																																																																					
5008		5	Mahidol University	The immunogenicity and reactogenicity of four COVID-19 booster vaccinations against SARS-CoV-2 variants of concerns (Delta, Beta, and Omicron) following CoronaVac or ChAdOx1 nCoV-19 primary series	https://doi.org/10.1101/2021.11.29.21266947	Pre-print	02/04/2021	human		ChAdOx1 nCoV-19			ChAdOx1 nCoV-19				Homologous						3	Binding	ELISA						Anti-RBD IgG GMC	BAU/mL		days post booster1	0	105.7	14		246.4	2.33	1.00																												
5009		5	Mahidol University	The immunogenicity and reactogenicity of four COVID-19 booster vaccinations against SARS-CoV-2 variants of concerns (Delta, Beta, and Omicron) following CoronaVac or ChAdOx1 nCoV-19 primary series	https://doi.org/10.1101/2021.11.29.21266947	Pre-print	02/04/2021	human		ChAdOx1 nCoV-19			BBIBP-CorV				Heterologous						3	Binding	ELISA						Anti-RBD IgG GMC	BAU/mL		days post booster1	0	106.5	14		126.1	1.18	0.51																												
5010		5	Mahidol University	The immunogenicity and reactogenicity of four COVID-19 booster vaccinations against SARS-CoV-2 variants of concerns (Delta, Beta, and Omicron) following CoronaVac or ChAdOx1 nCoV-19 primary series	https://doi.org/10.1101/2021.11.29.21266947	Pre-print	02/04/2021	human		ChAdOx1 nCoV-19			BNT162b2	30	?g		Heterologous						3	Binding	ELISA						Anti-RBD IgG GMC	BAU/mL		days post booster1	0	94.23	14		2364	25.09	10.77																												
5011		5	Mahidol University	The immunogenicity and reactogenicity of four COVID-19 booster vaccinations against SARS-CoV-2 variants of concerns (Delta, Beta, and Omicron) following CoronaVac or ChAdOx1 nCoV-19 primary series	https://doi.org/10.1101/2021.11.29.21266947	Pre-print	02/04/2021	human		ChAdOx1 nCoV-19			BNT162b2	15	?g		Heterologous						3	Binding	ELISA						Anti-RBD IgG GMC	BAU/mL		days post booster1	0	90.11	14		1962	21.77	9.34																												
5012		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	MenACWY	0.5	mL		Control						1	Binding	ELISA						Anti-spike IgG GMC	ELU/mL		days post booster1			28		801	REF																													
5013		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	ChAdOx1 nCoV-19	5.00E+10	virus  particles		Homologous						1	Binding	ELISA						Anti-spike IgG GMC	ELU/mL		days post booster1			28		2457	3.25																													
5014		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	NVX-CoV2373	5	?g		Heterologous						1	Binding	ELISA						Anti-spike IgG GMC	ELU/mL		days post booster1			28		6975	8.75	2.69																												
5015		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	NVX-CoV2373	2.5	?g		Heterologous						1	Binding	ELISA						Anti-spike IgG GMC	ELU/mL		days post booster1			28		4634	5.82	1.79																												
5016		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	MenACWY	0.5	mL		Control						1	Binding	ELISA						Anti-spike IgG GMC	ELU/mL		days post booster1			28		763	REF																													
5017		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	BNT162b2	30	?g		Heterologous						1	Binding	ELISA						Anti-spike IgG GMC	ELU/mL		days post booster1			28		20517	24.48	7.53																												
5018		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	VLA2001	33	antigen units		Heterologous						1	Binding	ELISA						Anti-spike IgG GMC	ELU/mL		days post booster1			28		1835	2.20	0.68																												
5019		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	VLA2001	16.5	antigen units		Heterologous						1	Binding	ELISA						Anti-spike IgG GMC	ELU/mL		days post booster1			28		1430	1.81	0.56																												
5020		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	Ad26.COV2.S	5.00E+10	virus  particles		Heterologous						1	Binding	ELISA						Anti-spike IgG GMC	ELU/mL		days post booster1			28		5517	5.84	1.80																												
5021		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	MenACWY	0.5	mL		Control						1	Binding	ELISA						Anti-spike IgG GMC	ELU/mL		days post booster1			28		852	REF																													
5884																																																																					
5885																																																																					
5886																																																																					
5022		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	BNT162b2	15	?g		Heterologous						1	Binding	ELISA						Anti-spike IgG GMC	ELU/mL		days post booster1			28		16045	16.80	5.17																												
5023		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	mRNA-1273	100	?g		Heterologous						1	Binding	ELISA						Anti-spike IgG GMC	ELU/mL		days post booster1			28		31111	32.30	9.94																												
5024		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	CVnCoV	12	?g		Heterologous						1	Binding	ELISA						Anti-spike IgG GMC	ELU/mL		days post booster1			28		3996	5.05	1.55																												
5025		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		BNT162b2	30	?g	MenACWY	0.5	mL		Control						1	Binding	ELISA						Anti-spike IgG GMC	ELU/mL		days post booster1			28		2541	REF																													
5026		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		BNT162b2	30	?g	ChAdOx1 nCoV-19	5.00E+10	virus  particles		Heterologous						1	Binding	ELISA						Anti-spike IgG GMC	ELU/mL		days post booster1			28		13424	5.33	0.66																												
5027		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		BNT162b2	30	?g	NVX-CoV2373	5	?g		Heterologous						1	Binding	ELISA						Anti-spike IgG GMC	ELU/mL		days post booster1			28		10862	4.78	0.59																												
5028		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		BNT162b2	30	?g	NVX-CoV2373	2.5	?g		Heterologous						1	Binding	ELISA						Anti-spike IgG GMC	ELU/mL		days post booster1			28		8550	3.07	0.38																												
5029		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		BNT162b2	30	?g	MenACWY	0.5	mL		Control						1	Binding	ELISA						Anti-spike IgG GMC	ELU/mL		days post booster1			28		3197	REF																													
5030		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		BNT162b2	30	?g	BNT162b2	30	?g		Homologous						1	Binding	ELISA						Anti-spike IgG GMC	ELU/mL		days post booster1			28		27242	8.11	1.00																												
5031		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		BNT162b2	30	?g	VLA2001	33	antigen units		Heterologous						1	Binding	ELISA						Anti-spike IgG GMC	ELU/mL		days post booster1			28		4202	1.31	0.16																												
5032		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		BNT162b2	30	?g	VLA2001	16.5	antigen units		Heterologous						1	Binding	ELISA						Anti-spike IgG GMC	ELU/mL		days post booster1			28		3721	1.25	0.15																												
5033		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		BNT162b2	30	?g	Ad26.COV2.S	5.00E+10	virus  particles		Heterologous						1	Binding	ELISA						Anti-spike IgG GMC	ELU/mL		days post booster1			28		17079	5.63	0.69																												
5034		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		BNT162b2	30	?g	MenACWY	0.5	mL		Control						1	Binding	ELISA						Anti-spike IgG GMC	ELU/mL		days post booster1			28		3029	REF																													
5035		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		BNT162b2	30	?g	BNT162b2	15	?g		Homologous						1	Binding	ELISA						Anti-spike IgG GMC	ELU/mL		days post booster1			28		23082	6.78	0.84																												
5481		26	Fudan University	Antibody Resistance of SARS-CoV-2 Omicron BA.1, BA.1.1, BA.2 and BA.3 Sub-lineages	https://doi.org/10.1101/2022.04.06.22273503	Pre-print	04/06/2022	human		BBIBP-CorV			BBIBP-CorV				Homologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.3		Reciprocal ID50 GMT			days post booster1			14		57		1.00																												
5036		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		BNT162b2	30	?g	mRNA-1273	100	?g		Heterologous						1	Binding	ELISA						Anti-spike IgG GMC	ELU/mL		days post booster1			28		33768	11.49	1.42																												
5037		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		BNT162b2	30	?g	CVnCoV	12	?g		Heterologous						1	Binding	ELISA						Anti-spike IgG GMC	ELU/mL		days post booster1			28		7613	2.30	0.28																												
5038		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	MenACWY	0.5	mL		Control						2	Neutralization	Pseudotyped virus assay	Chemiluminescence	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		NT50 GMT		50% neutralising antibody titre	days post booster1			28		84.9	REF																													
5039		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	ChAdOx1 nCoV-19	5.00E+10	virus  particles		Homologous						2	Neutralization	Pseudotyped virus assay	Chemiluminescence	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		NT50 GMT		50% neutralising antibody titre	days post booster1			28		193	2.47	1.00																												
5040		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	NVX-CoV2373	5	?g		Heterologous						2	Neutralization	Pseudotyped virus assay	Chemiluminescence	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		NT50 GMT		50% neutralising antibody titre	days post booster1			28		727	8.86	3.59																												
5041		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	NVX-CoV2373	2.5	?g		Heterologous						2	Neutralization	Pseudotyped virus assay	Chemiluminescence	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		NT50 GMT		50% neutralising antibody titre	days post booster1			28		470	5.89	2.38																												
5042		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	MenACWY	0.5	mL		Control						2	Neutralization	Pseudotyped virus assay	Chemiluminescence	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		NT50 GMT		50% neutralising antibody titre	days post booster1			28		69.6	REF																													
5043		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	BNT162b2	30	?g		Heterologous						2	Neutralization	Pseudotyped virus assay	Chemiluminescence	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		NT50 GMT		50% neutralising antibody titre	days post booster1			28		1621	27.51	11.14																												
5044		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	VLA2001	33	antigen units		Heterologous						2	Neutralization	Pseudotyped virus assay	Chemiluminescence	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		NT50 GMT		50% neutralising antibody titre	days post booster1			28		202	2.68	1.09																												
5045		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	VLA2001	16.5	antigen units		Heterologous						2	Neutralization	Pseudotyped virus assay	Chemiluminescence	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		NT50 GMT		50% neutralising antibody titre	days post booster1			28		147	2.01	0.81																												
5046		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	Ad26.COV2.S	5.00E+10	virus  particles		Heterologous						2	Neutralization	Pseudotyped virus assay	Chemiluminescence	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		NT50 GMT		50% neutralising antibody titre	days post booster1			28		563	6.85	2.77																												
5047		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	MenACWY	0.5	mL		Control						2	Neutralization	Pseudotyped virus assay	Chemiluminescence	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		NT50 GMT		50% neutralising antibody titre	days post booster1			28		80.4	REF																													
5162		8	Adimab LLC	Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination	https://doi.org/10.1101/2021.12.13.21267598	Pre-print	12/14/2021	human		ChAdOx1 nCoV-19			ChAdOx1 nCoV-19			9-12 weeks	Homologous						1	Binding	ELISA						Anti-RBD IgG GM	AUC		days post booster1	0	258	8	7-9 days post booster	467	1.81	1.00																												
5048		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	BNT162b2	15	?g		Heterologous						2	Neutralization	Pseudotyped virus assay	Chemiluminescence	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		NT50 GMT		50% neutralising antibody titre	days post booster1			28		1344	15.14	6.13																												
5049		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	mRNA-1273	100	?g		Heterologous						2	Neutralization	Pseudotyped virus assay	Chemiluminescence	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		NT50 GMT		50% neutralising antibody titre	days post booster1			28		2368	26.98	10.92																												
5050		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	CVnCoV	12	?g		Heterologous						2	Neutralization	Pseudotyped virus assay	Chemiluminescence	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		NT50 GMT		50% neutralising antibody titre	days post booster1			28		373	5.05	2.04																												
5051		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		BNT162b2	30	?g	MenACWY	0.5	mL		Control						2	Neutralization	Pseudotyped virus assay	Chemiluminescence	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		NT50 GMT		50% neutralising antibody titre	days post booster1			28		157	REF																													
5052		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		BNT162b2	30	?g	ChAdOx1 nCoV-19	5.00E+10	virus  particles		Heterologous						2	Neutralization	Pseudotyped virus assay	Chemiluminescence	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		NT50 GMT		50% neutralising antibody titre	days post booster1			28		950	6.01	0.72																												
5053		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		BNT162b2	30	?g	NVX-CoV2373	5	?g		Heterologous						2	Neutralization	Pseudotyped virus assay	Chemiluminescence	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		NT50 GMT		50% neutralising antibody titre	days post booster1			28		766	5.39	0.65																												
5054		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		BNT162b2	30	?g	NVX-CoV2373	2.5	?g		Heterologous						2	Neutralization	Pseudotyped virus assay	Chemiluminescence	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		NT50 GMT		50% neutralising antibody titre	days post booster1			28		606	3.50	0.42																												
5055		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		BNT162b2	30	?g	MenACWY	0.5	mL		Control						2	Neutralization	Pseudotyped virus assay	Chemiluminescence	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		NT50 GMT		50% neutralising antibody titre	days post booster1			28		205	REF																													
5056		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		BNT162b2	30	?g	BNT162b2	30	?g		Homologous						2	Neutralization	Pseudotyped virus assay	Chemiluminescence	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		NT50 GMT		50% neutralising antibody titre	days post booster1			28		1789	8.35	1.00																												
5057		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		BNT162b2	30	?g	VLA2001	33	antigen units		Heterologous						2	Neutralization	Pseudotyped virus assay	Chemiluminescence	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		NT50 GMT		50% neutralising antibody titre	days post booster1			28		289	1.38	0.17																												
5058		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		BNT162b2	30	?g	VLA2001	16.5	antigen units		Heterologous						2	Neutralization	Pseudotyped virus assay	Chemiluminescence	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		NT50 GMT		50% neutralising antibody titre	days post booster1			28		234	1.22	0.15																												
5059		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		BNT162b2	30	?g	Ad26.COV2.S	5.00E+10	virus  particles		Heterologous						2	Neutralization	Pseudotyped virus assay	Chemiluminescence	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		NT50 GMT		50% neutralising antibody titre	days post booster1			28		1441	7.84	0.94																												
5163		8	Adimab LLC	Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination	https://doi.org/10.1101/2021.12.13.21267598	Pre-print	12/14/2021	human		ChAdOx1 nCoV-19			mRNA-1273			9-12 weeks	Heterologous						1	Binding	ELISA						Anti-RBD IgG GM	AUC		days post booster1	0	243	8	7-9 days post booster	6102	25.11	13.87																												
5060		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		BNT162b2	30	?g	MenACWY	0.5	mL		Control						2	Neutralization	Pseudotyped virus assay	Chemiluminescence	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		NT50 GMT		50% neutralising antibody titre	days post booster1			28		175	REF																													
5061		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		BNT162b2	30	?g	BNT162b2	15	?g		Homologous						2	Neutralization	Pseudotyped virus assay	Chemiluminescence	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		NT50 GMT		50% neutralising antibody titre	days post booster1			28		1339	6.91	0.83																												
5062		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		BNT162b2	30	?g	mRNA-1273	100	?g		Heterologous						2	Neutralization	Pseudotyped virus assay	Chemiluminescence	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		NT50 GMT		50% neutralising antibody titre	days post booster1			28		2019	12.04	1.44																												
5063		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		BNT162b2	30	?g	CVnCoV	12	?g		Heterologous						2	Neutralization	Pseudotyped virus assay	Chemiluminescence	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		NT50 GMT		50% neutralising antibody titre	days post booster1			28		487	2.57	0.31																												
5064		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	MenACWY	0.5	mL		Control						2	Neutralization	Pseudotyped virus assay	Chemiluminescence	Delta	B.1.617.2	B.1.617.2		NT50 GMT		50% neutralising antibody titre	days post booster1			28		20	REF																													
5065		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	ChAdOx1 nCoV-19	5.00E+10	virus  particles		Homologous						2	Neutralization	Pseudotyped virus assay	Chemiluminescence	Delta	B.1.617.2	B.1.617.2		NT50 GMT		50% neutralising antibody titre	days post booster1			28		48.9	2.58	1.00																												
5066		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	NVX-CoV2373	5	?g		Heterologous						2	Neutralization	Pseudotyped virus assay	Chemiluminescence	Delta	B.1.617.2	B.1.617.2		NT50 GMT		50% neutralising antibody titre	days post booster1			28		124	6.25	2.42																												
5067		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	NVX-CoV2373	2.5	?g		Heterologous						2	Neutralization	Pseudotyped virus assay	Chemiluminescence	Delta	B.1.617.2	B.1.617.2		NT50 GMT		50% neutralising antibody titre	days post booster1			28		87.2	4.40	1.71																												
5068		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	MenACWY	0.5	mL		Control						2	Neutralization	Pseudotyped virus assay	Chemiluminescence	Delta	B.1.617.2	B.1.617.2		NT50 GMT		50% neutralising antibody titre	days post booster1			28		20.4	REF																													
5069		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	BNT162b2	30	?g		Heterologous						2	Neutralization	Pseudotyped virus assay	Chemiluminescence	Delta	B.1.617.2	B.1.617.2		NT50 GMT		50% neutralising antibody titre	days post booster1			28		315	14.43	5.59																												
5070		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	VLA2001	33	antigen units		Heterologous						2	Neutralization	Pseudotyped virus assay	Chemiluminescence	Delta	B.1.617.2	B.1.617.2		NT50 GMT		50% neutralising antibody titre	days post booster1			28		35.2	1.65	0.64																												
5071		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	VLA2001	16.5	antigen units		Heterologous						2	Neutralization	Pseudotyped virus assay	Chemiluminescence	Delta	B.1.617.2	B.1.617.2		NT50 GMT		50% neutralising antibody titre	days post booster1			28		31.1	1.50	0.58																												
5482		26	Fudan University	Antibody Resistance of SARS-CoV-2 Omicron BA.1, BA.1.1, BA.2 and BA.3 Sub-lineages	https://doi.org/10.1101/2022.04.06.22273503	Pre-print	04/06/2022	human		BBIBP-CorV			ZF001				Heterologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.3		Reciprocal ID50 GMT			days post booster1			14		69		1.21																												
5072		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	Ad26.COV2.S	5.00E+10	virus  particles		Heterologous						2	Neutralization	Pseudotyped virus assay	Chemiluminescence	Delta	B.1.617.2	B.1.617.2		NT50 GMT		50% neutralising antibody titre	days post booster1			28		125	5.33	2.07																												
5073		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	MenACWY	0.5	mL		Control						2	Neutralization	Pseudotyped virus assay	Chemiluminescence	Delta	B.1.617.2	B.1.617.2		NT50 GMT		50% neutralising antibody titre	days post booster1			28		18.6	REF																													
5074		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	BNT162b2	15	?g		Heterologous						2	Neutralization	Pseudotyped virus assay	Chemiluminescence	Delta	B.1.617.2	B.1.617.2		NT50 GMT		50% neutralising antibody titre	days post booster1			28		321.3	15.71	6.09																												
5075		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	mRNA-1273	100	?g		Heterologous						2	Neutralization	Pseudotyped virus assay	Chemiluminescence	Delta	B.1.617.2	B.1.617.2		NT50 GMT		50% neutralising antibody titre	days post booster1			28		559.7	27.17	10.53																												
5076		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	CVnCoV	12	?g		Heterologous						2	Neutralization	Pseudotyped virus assay	Chemiluminescence	Delta	B.1.617.2	B.1.617.2		NT50 GMT		50% neutralising antibody titre	days post booster1			28		64.5	3.76	1.46																												
5077		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		BNT162b2	30	?g	MenACWY	0.5	mL		Control						2	Neutralization	Pseudotyped virus assay	Chemiluminescence	Delta	B.1.617.2	B.1.617.2		NT50 GMT		50% neutralising antibody titre	days post booster1			28		37.9	REF																													
5078		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		BNT162b2	30	?g	ChAdOx1 nCoV-19	5.00E+10	virus  particles		Heterologous						2	Neutralization	Pseudotyped virus assay	Chemiluminescence	Delta	B.1.617.2	B.1.617.2		NT50 GMT		50% neutralising antibody titre	days post booster1			28		260	6.84	1.04																												
5079		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		BNT162b2	30	?g	NVX-CoV2373	5	?g		Heterologous						2	Neutralization	Pseudotyped virus assay	Chemiluminescence	Delta	B.1.617.2	B.1.617.2		NT50 GMT		50% neutralising antibody titre	days post booster1			28		165	4.94	0.75																												
5080		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		BNT162b2	30	?g	NVX-CoV2373	2.5	?g		Heterologous						2	Neutralization	Pseudotyped virus assay	Chemiluminescence	Delta	B.1.617.2	B.1.617.2		NT50 GMT		50% neutralising antibody titre	days post booster1			28		131	3.27	0.50																												
5081		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		BNT162b2	30	?g	MenACWY	0.5	mL		Control						2	Neutralization	Pseudotyped virus assay	Chemiluminescence	Delta	B.1.617.2	B.1.617.2		NT50 GMT		50% neutralising antibody titre	days post booster1			28		56.5	REF																													
5082		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		BNT162b2	30	?g	BNT162b2	30	?g		Homologous						2	Neutralization	Pseudotyped virus assay	Chemiluminescence	Delta	B.1.617.2	B.1.617.2		NT50 GMT		50% neutralising antibody titre	days post booster1			28		392	6.60	1.00																												
5083		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		BNT162b2	30	?g	VLA2001	33	antigen units		Heterologous						2	Neutralization	Pseudotyped virus assay	Chemiluminescence	Delta	B.1.617.2	B.1.617.2		NT50 GMT		50% neutralising antibody titre	days post booster1			28		67.1	1.19	0.18																												
5164		8	Adimab LLC	Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination	https://doi.org/10.1101/2021.12.13.21267598	Pre-print	12/14/2021	human		ChAdOx1 nCoV-19			ChAdOx1 nCoV-19			9-12 weeks	Homologous						2	Neutralization	Live virus replication assay	Plaque reduction assay	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	Neutralization IC50	1/dilution		days post booster1	0	18	8	7-9 days post booster	82	4.56	1.00																												
5084		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		BNT162b2	30	?g	VLA2001	16.5	antigen units		Heterologous						2	Neutralization	Pseudotyped virus assay	Chemiluminescence	Delta	B.1.617.2	B.1.617.2		NT50 GMT		50% neutralising antibody titre	days post booster1			28		54.7	1.02	0.15																												
5085		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		BNT162b2	30	?g	Ad26.COV2.S	5.00E+10	virus  particles		Heterologous						2	Neutralization	Pseudotyped virus assay	Chemiluminescence	Delta	B.1.617.2	B.1.617.2		NT50 GMT		50% neutralising antibody titre	days post booster1			28		418	8.02	1.22																												
5086		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		BNT162b2	30	?g	MenACWY	0.5	mL		Control						2	Neutralization	Pseudotyped virus assay	Chemiluminescence	Delta	B.1.617.2	B.1.617.2		NT50 GMT		50% neutralising antibody titre	days post booster1			28		41.6	REF																													
5087		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		BNT162b2	30	?g	BNT162b2	15	?g		Homologous						2	Neutralization	Pseudotyped virus assay	Chemiluminescence	Delta	B.1.617.2	B.1.617.2		NT50 GMT		50% neutralising antibody titre	days post booster1			28		352.6	7.39	1.12																												
5088		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		BNT162b2	30	?g	mRNA-1273	100	?g		Heterologous						2	Neutralization	Pseudotyped virus assay	Chemiluminescence	Delta	B.1.617.2	B.1.617.2		NT50 GMT		50% neutralising antibody titre	days post booster1			28		508.7	12.58	1.91																												
5089		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		BNT162b2	30	?g	CVnCoV	12	?g		Heterologous						2	Neutralization	Pseudotyped virus assay	Chemiluminescence	Delta	B.1.617.2	B.1.617.2		NT50 GMT		50% neutralising antibody titre	days post booster1			28		119.1	2.59	0.39																												
5090		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	MenACWY	0.5	mL		Control						3	Neutralization	Live virus replication assay	Microneutralization	VIC	VIC	VIC		NT80 GMT		80% neutralising antibody titre	days post booster1			28		146	REF																													
5091		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	ChAdOx1 nCoV-19	5.00E+10	virus  particles		Homologous						3	Neutralization	Live virus replication assay	Microneutralization	VIC	VIC	VIC		NT80 GMT		80% neutralising antibody titre	days post booster1			28		346	2.57	1.00																												
5092		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	NVX-CoV2373	5	?g		Heterologous						3	Neutralization	Live virus replication assay	Microneutralization	VIC	VIC	VIC		NT80 GMT		80% neutralising antibody titre	days post booster1			28		837	6.29	2.45																												
5093		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	NVX-CoV2373	2.5	?g		Heterologous						3	Neutralization	Live virus replication assay	Microneutralization	VIC	VIC	VIC		NT80 GMT		80% neutralising antibody titre	days post booster1			28		713	5.30	2.06																												
5094		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	MenACWY	0.5	mL		Control						3	Neutralization	Live virus replication assay	Microneutralization	VIC	VIC	VIC		NT80 GMT		80% neutralising antibody titre	days post booster1			28		174	REF																													
5095		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	BNT162b2	30	?g		Heterologous						3	Neutralization	Live virus replication assay	Microneutralization	VIC	VIC	VIC		NT80 GMT		80% neutralising antibody titre	days post booster1			28		4899	25.61	9.96																												
5165		8	Adimab LLC	Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination	https://doi.org/10.1101/2021.12.13.21267598	Pre-print	12/14/2021	human		ChAdOx1 nCoV-19			mRNA-1273			9-12 weeks	Heterologous						2	Neutralization	Live virus replication assay	Plaque reduction assay	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	Neutralization IC50	1/dilution		days post booster1	0	19	8	7-9 days post booster	1595	83.95	18.41																												
5096		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	VLA2001	33	antigen units		Heterologous						3	Neutralization	Live virus replication assay	Microneutralization	VIC	VIC	VIC		NT80 GMT		80% neutralising antibody titre	days post booster1			28		354	2.04	0.79																												
5097		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	VLA2001	16.5	antigen units		Heterologous						3	Neutralization	Live virus replication assay	Microneutralization	VIC	VIC	VIC		NT80 GMT		80% neutralising antibody titre	days post booster1			28		301	1.81	0.70																												
5098		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	Ad26.COV2.S	5.00E+10	virus  particles		Heterologous						3	Neutralization	Live virus replication assay	Microneutralization	VIC	VIC	VIC		NT80 GMT		80% neutralising antibody titre	days post booster1			28		1053	5.97	2.32																												
5099		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	MenACWY	0.5	mL		Control						3	Neutralization	Live virus replication assay	Microneutralization	VIC	VIC	VIC		NT80 GMT		80% neutralising antibody titre	days post booster1			28		152	REF																													
5100		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	BNT162b2	15	?g		Heterologous						3	Neutralization	Live virus replication assay	Microneutralization	VIC	VIC	VIC		NT80 GMT		80% neutralising antibody titre	days post booster1			28		2501	12.93	5.03																												
5101		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	mRNA-1273	100	?g		Heterologous						3	Neutralization	Live virus replication assay	Microneutralization	VIC	VIC	VIC		NT80 GMT		80% neutralising antibody titre	days post booster1			28		5421	28.26	11.00																												
5102		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	CVnCoV	12	?g		Heterologous						3	Neutralization	Live virus replication assay	Microneutralization	VIC	VIC	VIC		NT80 GMT		80% neutralising antibody titre	days post booster1			28		774	5.00	1.95																												
5103		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		BNT162b2	30	?g	MenACWY	0.5	mL		Control						3	Neutralization	Live virus replication assay	Microneutralization	VIC	VIC	VIC		NT80 GMT		80% neutralising antibody titre	days post booster1			28		531	REF																													
5104		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		BNT162b2	30	?g	ChAdOx1 nCoV-19	5.00E+10	virus  particles		Heterologous						3	Neutralization	Live virus replication assay	Microneutralization	VIC	VIC	VIC		NT80 GMT		80% neutralising antibody titre	days post booster1			28		2614	5.01	0.87																												
5105		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		BNT162b2	30	?g	NVX-CoV2373	5	?g		Heterologous						3	Neutralization	Live virus replication assay	Microneutralization	VIC	VIC	VIC		NT80 GMT		80% neutralising antibody titre	days post booster1			28		1454	2.65	0.46																												
5106		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		BNT162b2	30	?g	NVX-CoV2373	2.5	?g		Heterologous						3	Neutralization	Live virus replication assay	Microneutralization	VIC	VIC	VIC		NT80 GMT		80% neutralising antibody titre	days post booster1			28		1792	2.81	0.49																												
5107		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		BNT162b2	30	?g	MenACWY	0.5	mL		Control						3	Neutralization	Live virus replication assay	Microneutralization	VIC	VIC	VIC		NT80 GMT		80% neutralising antibody titre	days post booster1			28		756	REF																													
5166		8	Adimab LLC	Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination	https://doi.org/10.1101/2021.12.13.21267598	Pre-print	12/14/2021	human		ChAdOx1 nCoV-19			ChAdOx1 nCoV-19			9-12 weeks	Homologous						2	Neutralization	Live virus replication assay	Plaque reduction assay	Beta	B.1.351	B.1.351		Neutralization IC50	1/dilution		days post booster1			8	7-9 days post booster	37		1.00																												
5108		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		BNT162b2	30	?g	BNT162b2	30	?g		Homologous						3	Neutralization	Live virus replication assay	Microneutralization	VIC	VIC	VIC		NT80 GMT		80% neutralising antibody titre	days post booster1			28		4603	5.79	1.00																												
5109		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		BNT162b2	30	?g	VLA2001	33	antigen units		Heterologous						3	Neutralization	Live virus replication assay	Microneutralization	VIC	VIC	VIC		NT80 GMT		80% neutralising antibody titre	days post booster1			28		836	1.42	0.25																												
5110		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		BNT162b2	30	?g	VLA2001	16.5	antigen units		Heterologous						3	Neutralization	Live virus replication assay	Microneutralization	VIC	VIC	VIC		NT80 GMT		80% neutralising antibody titre	days post booster1			28		555	0.93	0.16																												
5111		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		BNT162b2	30	?g	Ad26.COV2.S	5.00E+10	virus  particles		Heterologous						3	Neutralization	Live virus replication assay	Microneutralization	VIC	VIC	VIC		NT80 GMT		80% neutralising antibody titre	days post booster1			28		3535	5.36	0.93																												
5112		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		BNT162b2	30	?g	MenACWY	0.5	mL		Control						3	Neutralization	Live virus replication assay	Microneutralization	VIC	VIC	VIC		NT80 GMT		80% neutralising antibody titre	days post booster1			28		469	REF																													
5113		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		BNT162b2	30	?g	BNT162b2	15	?g		Homologous						3	Neutralization	Live virus replication assay	Microneutralization	VIC	VIC	VIC		NT80 GMT		80% neutralising antibody titre	days post booster1			28		3263	5.18	0.89																												
5114		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		BNT162b2	30	?g	mRNA-1273	100	?g		Heterologous						3	Neutralization	Live virus replication assay	Microneutralization	VIC	VIC	VIC		NT80 GMT		80% neutralising antibody titre	days post booster1			28		5354	9.32	1.61																												
5115		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		BNT162b2	30	?g	CVnCoV	12	?g		Heterologous						3	Neutralization	Live virus replication assay	Microneutralization	VIC	VIC	VIC		NT80 GMT		80% neutralising antibody titre	days post booster1			28		1960	3.26	0.56																												
5116		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	ChAdOx1 nCoV-19	5.00E+10	virus  particles		Homologous						4	Binding	ELISA						Anti-spike IgG GMC	ELU/mL		days post booster1	0	786	7		1242	1.58	1.00	28		1321	1.68	1.00																							
5117		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	NVX-CoV2373	5	?g		Heterologous						4	Binding	ELISA						Anti-spike IgG GMC	ELU/mL		days post booster1	0	1053	7		2935	2.79	1.76	28		4791	4.55	2.71																							
5118		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	NVX-CoV2373	2.5	?g		Heterologous						4	Binding	ELISA						Anti-spike IgG GMC	ELU/mL		days post booster1	0	1073	7		3543	3.30	2.09	28		4959	4.62	2.75																							
5119		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	BNT162b2	30	?g		Heterologous						4	Binding	ELISA						Anti-spike IgG GMC	ELU/mL		days post booster1	0	1443	7		15524	10.76	6.81	28		21824	15.12	9.00																							
5120		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	VLA2001	33	antigen units		Heterologous						4	Binding	ELISA						Anti-spike IgG GMC	ELU/mL		days post booster1	0	1211	7		1299	1.07	0.68	28		1599	1.32	0.79																							
5887																																																																					
5888																																																																					
5121		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	VLA2001	16.5	antigen units		Heterologous						4	Binding	ELISA						Anti-spike IgG GMC	ELU/mL		days post booster1	0	1334	7		1292	0.97	0.61	28		1537	1.15	0.69																							
5122		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	Ad26.COV2.S	5.00E+10	virus  particles		Heterologous						4	Binding	ELISA						Anti-spike IgG GMC	ELU/mL		days post booster1	0	1555	7		2735	1.76	1.11	28		5673	3.65	2.17																							
5123		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	BNT162b2	15	?g		Heterologous						4	Binding	ELISA						Anti-spike IgG GMC	ELU/mL		days post booster1	0	1485	7		13078	8.81	5.57	28		13951	9.39	5.59																							
5124		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	mRNA-1273	100	?g		Heterologous						4	Binding	ELISA						Anti-spike IgG GMC	ELU/mL		days post booster1	0	1265	7		22134	17.50	11.07	28		23771	18.79	11.19																							
5125		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	CVnCoV	12	?g		Heterologous						4	Binding	ELISA						Anti-spike IgG GMC	ELU/mL		days post booster1	0	920	7		2466	2.68	1.70	28		4241	4.61	2.74																							
5126		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		BNT162b2	30	?g	ChAdOx1 nCoV-19	5.00E+10	virus  particles		Heterologous						4	Binding	ELISA						Anti-spike IgG GMC	ELU/mL		days post booster1	0	3196	7		8624	2.70	0.53	28		13708	4.29	0.89																							
5127		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		BNT162b2	30	?g	NVX-CoV2373	5	?g		Heterologous						4	Binding	ELISA						Anti-spike IgG GMC	ELU/mL		days post booster1	0	3512	7		5080	1.45	0.28	28		8754	2.49	0.52																							
5128		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		BNT162b2	30	?g	NVX-CoV2373	2.5	?g		Heterologous						4	Binding	ELISA						Anti-spike IgG GMC	ELU/mL		days post booster1	0	4469	7		4481	1.00	0.20	28		10171	2.28	0.47																							
5129		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		BNT162b2	30	?g	BNT162b2	30	?g		Homologous						4	Binding	ELISA						Anti-spike IgG GMC	ELU/mL		days post booster1	0	5422	7		27551	5.08	1.00	28		26171	4.83	1.00																							
5130		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		BNT162b2	30	?g	VLA2001	33	antigen units		Heterologous						4	Binding	ELISA						Anti-spike IgG GMC	ELU/mL		days post booster1	0	3352	7		3829	1.14	0.22	28		4428	1.32	0.27																							
5131		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		BNT162b2	30	?g	VLA2001	16.5	antigen units		Heterologous						4	Binding	ELISA						Anti-spike IgG GMC	ELU/mL		days post booster1	0	3460	7		3415	0.99	0.19	28		3500	1.01	0.21																							
5132		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		BNT162b2	30	?g	Ad26.COV2.S	5.00E+10	virus  particles		Heterologous						4	Binding	ELISA						Anti-spike IgG GMC	ELU/mL		days post booster1	0	4181	7		7726	1.85	0.36	28		18631	4.46	0.92																							
5133		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		BNT162b2	30	?g	BNT162b2	15	?g		Homologous						4	Binding	ELISA						Anti-spike IgG GMC	ELU/mL		days post booster1	0	4060	7		24315	5.99	1.18	28		27498	6.77	1.40																							
5134		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		BNT162b2	30	?g	mRNA-1273	100	?g		Heterologous						4	Binding	ELISA						Anti-spike IgG GMC	ELU/mL		days post booster1	0	3271	7		20930	6.40	1.26	28		30654	9.37	1.94																							
5135		6	University of Southampton	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(21)02717-3	Peer-reviewed publication	12/02/2021	human		BNT162b2	30	?g	CVnCoV	12	?g		Heterologous						4	Binding	ELISA						Anti-spike IgG GMC	ELU/mL		days post booster1	0	4175	7		6756	1.62	0.32	28		8385	2.01	0.42																							
5136		7	University of Oxford	Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial	https://doi.org/10.1016/S0140-6736(21)02718-5	Peer-reviewed publication	12/06/2021	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	ChAdOx1 nCoV-19	5.00E+10	virus  particles		Homologous						1	Binding	ELISA						Anti-spike IgG GMC	ELU/mL		days post booster1			28		1959		1.00																												
5137		7	University of Oxford	Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial	https://doi.org/10.1016/S0140-6736(21)02718-5	Peer-reviewed publication	12/06/2021	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	mRNA-1273	100	?g		Heterologous						1	Binding	ELISA						Anti-spike IgG GMC	ELU/mL		days post booster1			28		20360		10.50																												
5138		7	University of Oxford	Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial	https://doi.org/10.1016/S0140-6736(21)02718-5	Peer-reviewed publication	12/06/2021	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	NVX-CoV2373	5	?g		Heterologous						1	Binding	ELISA						Anti-spike IgG GMC	ELU/mL		days post booster1			28		5440		2.80																												
5139		7	University of Oxford	Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial	https://doi.org/10.1016/S0140-6736(21)02718-5	Peer-reviewed publication	12/06/2021	human		BNT162b2	30	?g	BNT162b2	30	?g		Homologous						1	Binding	ELISA						Anti-spike IgG GMC	ELU/mL		days post booster1			28		16838		1.00																												
5140		7	University of Oxford	Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial	https://doi.org/10.1016/S0140-6736(21)02718-5	Peer-reviewed publication	12/06/2021	human		BNT162b2	30	?g	mRNA-1273	100	?g		Heterologous						1	Binding	ELISA						Anti-spike IgG GMC	ELU/mL		days post booster1			28		23187		1.30																												
5141		7	University of Oxford	Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial	https://doi.org/10.1016/S0140-6736(21)02718-5	Peer-reviewed publication	12/06/2021	human		BNT162b2	30	?g	NVX-CoV2373	5	?g		Heterologous						1	Binding	ELISA						Anti-spike IgG GMC	ELU/mL		days post booster1			28		8913		0.53																												
5142		7	University of Oxford	Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial	https://doi.org/10.1016/S0140-6736(21)02718-5	Peer-reviewed publication	12/06/2021	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	ChAdOx1 nCoV-19	5.00E+10	virus  particles		Homologous						2	Neutralization	Live virus replication assay	CPE	VIC	VIC	VIC		FRNT50 GMT		50% focus reduction neutralising antibody titre	days post booster1			28		109		1.00																												
5143		7	University of Oxford	Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial	https://doi.org/10.1016/S0140-6736(21)02718-5	Peer-reviewed publication	12/06/2021	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	mRNA-1273	100	?g		Heterologous						2	Neutralization	Live virus replication assay	CPE	VIC	VIC	VIC		FRNT50 GMT		50% focus reduction neutralising antibody titre	days post booster1			28		1684		16.90																												
5144		7	University of Oxford	Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial	https://doi.org/10.1016/S0140-6736(21)02718-5	Peer-reviewed publication	12/06/2021	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	NVX-CoV2373	5	?g		Heterologous						2	Neutralization	Live virus replication assay	CPE	VIC	VIC	VIC		FRNT50 GMT		50% focus reduction neutralising antibody titre	days post booster1			28		432		4.20																												
5145		7	University of Oxford	Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial	https://doi.org/10.1016/S0140-6736(21)02718-5	Peer-reviewed publication	12/06/2021	human		BNT162b2	30	?g	BNT162b2	30	?g		Homologous						2	Neutralization	Live virus replication assay	CPE	VIC	VIC	VIC		FRNT50 GMT		50% focus reduction neutralising antibody titre	days post booster1			28		1501		1.00																												
5146		7	University of Oxford	Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial	https://doi.org/10.1016/S0140-6736(21)02718-5	Peer-reviewed publication	12/06/2021	human		BNT162b2	30	?g	mRNA-1273	100	?g		Heterologous						2	Neutralization	Live virus replication assay	CPE	VIC	VIC	VIC		FRNT50 GMT		50% focus reduction neutralising antibody titre	days post booster1			28		1883		1.30																												
5147		7	University of Oxford	Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial	https://doi.org/10.1016/S0140-6736(21)02718-5	Peer-reviewed publication	12/06/2021	human		BNT162b2	30	?g	NVX-CoV2373	5	?g		Heterologous						2	Neutralization	Live virus replication assay	CPE	VIC	VIC	VIC		FRNT50 GMT		50% focus reduction neutralising antibody titre	days post booster1			28		1109		0.80																												
5889																																																																					
5890																																																																					
5891																																																																					
5148		7	University of Oxford	Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial	https://doi.org/10.1016/S0140-6736(21)02718-5	Peer-reviewed publication	12/06/2021	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	ChAdOx1 nCoV-19	5.00E+10	virus  particles		Homologous						3	Neutralization	Live virus replication assay	Microneutralization	VIC	VIC	VIC		NT80 GMT			days post booster1			28		331		1.00																												
5149		7	University of Oxford	Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial	https://doi.org/10.1016/S0140-6736(21)02718-5	Peer-reviewed publication	12/06/2021	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	mRNA-1273	100	?g		Heterologous						3	Neutralization	Live virus replication assay	Microneutralization	VIC	VIC	VIC		NT80 GMT			days post booster1			28		2244		7.50																												
5150		7	University of Oxford	Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial	https://doi.org/10.1016/S0140-6736(21)02718-5	Peer-reviewed publication	12/06/2021	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	NVX-CoV2373	5	?g		Heterologous						3	Neutralization	Live virus replication assay	Microneutralization	VIC	VIC	VIC		NT80 GMT			days post booster1			28		630		2.00																												
5151		7	University of Oxford	Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial	https://doi.org/10.1016/S0140-6736(21)02718-5	Peer-reviewed publication	12/06/2021	human		BNT162b2	30	?g	BNT162b2	30	?g		Homologous						3	Neutralization	Live virus replication assay	Microneutralization	VIC	VIC	VIC		NT80 GMT			days post booster1			28		3216		1.00																												
5152		7	University of Oxford	Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial	https://doi.org/10.1016/S0140-6736(21)02718-5	Peer-reviewed publication	12/06/2021	human		BNT162b2	30	?g	mRNA-1273	100	?g		Heterologous						3	Neutralization	Live virus replication assay	Microneutralization	VIC	VIC	VIC		NT80 GMT			days post booster1			28		3252		1.00																												
5153		7	University of Oxford	Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial	https://doi.org/10.1016/S0140-6736(21)02718-5	Peer-reviewed publication	12/06/2021	human		BNT162b2	30	?g	NVX-CoV2373	5	?g		Heterologous						3	Neutralization	Live virus replication assay	Microneutralization	VIC	VIC	VIC		NT80 GMT			days post booster1			28		868		0.30																												
5154		7	University of Oxford	Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial	https://doi.org/10.1016/S0140-6736(21)02718-5	Peer-reviewed publication	12/06/2021	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	ChAdOx1 nCoV-19	5.00E+10	virus  particles		Homologous						4	Neutralization	Pseudotyped virus assay	Chemiluminescence	VIC	VIC	VIC		NT50 GMT			days post booster1			28		132		1.00																												
5155		7	University of Oxford	Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial	https://doi.org/10.1016/S0140-6736(21)02718-5	Peer-reviewed publication	12/06/2021	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	mRNA-1273	100	?g		Heterologous						4	Neutralization	Pseudotyped virus assay	Chemiluminescence	VIC	VIC	VIC		NT50 GMT			days post booster1			28		1358		10.00																												
5156		7	University of Oxford	Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial	https://doi.org/10.1016/S0140-6736(21)02718-5	Peer-reviewed publication	12/06/2021	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	NVX-CoV2373	5	?g		Heterologous						4	Neutralization	Pseudotyped virus assay	Chemiluminescence	VIC	VIC	VIC		NT50 GMT			days post booster1			28		473		3.40																												
5157		7	University of Oxford	Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial	https://doi.org/10.1016/S0140-6736(21)02718-5	Peer-reviewed publication	12/06/2021	human		BNT162b2	30	?g	BNT162b2	30	?g		Homologous						4	Neutralization	Pseudotyped virus assay	Chemiluminescence	VIC	VIC	VIC		NT50 GMT			days post booster1			28		883		1.00																												
5158		7	University of Oxford	Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial	https://doi.org/10.1016/S0140-6736(21)02718-5	Peer-reviewed publication	12/06/2021	human		BNT162b2	30	?g	mRNA-1273	100	?g		Heterologous						4	Neutralization	Pseudotyped virus assay	Chemiluminescence	VIC	VIC	VIC		NT50 GMT			days post booster1			28		1260		1.40																												
5159		7	University of Oxford	Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial	https://doi.org/10.1016/S0140-6736(21)02718-5	Peer-reviewed publication	12/06/2021	human		BNT162b2	30	?g	NVX-CoV2373	5	?g		Heterologous						4	Neutralization	Pseudotyped virus assay	Chemiluminescence	VIC	VIC	VIC		NT50 GMT			days post booster1			28		787		0.90																												
5160		8	Adimab LLC	Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination	https://doi.org/10.1101/2021.12.13.21267598	Pre-print	12/14/2021	human		ChAdOx1 nCoV-19			ChAdOx1 nCoV-19			9-12 weeks	Homologous						1	Binding	ELISA						Anti-spike IgG GM	AUC		days post booster1	0	961	8	7-9 days post booster	4772	4.97	1.00																												
5161		8	Adimab LLC	Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination	https://doi.org/10.1101/2021.12.13.21267598	Pre-print	12/14/2021	human		ChAdOx1 nCoV-19			mRNA-1273			9-12 weeks	Heterologous						1	Binding	ELISA						Anti-spike IgG GM	AUC		days post booster1	0	1433	8	7-9 days post booster	123254	86.01	17.31																												
5167		8	Adimab LLC	Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination	https://doi.org/10.1101/2021.12.13.21267598	Pre-print	12/14/2021	human		ChAdOx1 nCoV-19			mRNA-1273			9-12 weeks	Heterologous						2	Neutralization	Live virus replication assay	Plaque reduction assay	Beta	B.1.351	B.1.351		Neutralization IC50	1/dilution		days post booster1			8	7-9 days post booster	727		19.65																												
5168		8	Adimab LLC	Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination	https://doi.org/10.1101/2021.12.13.21267598	Pre-print	12/14/2021	human		ChAdOx1 nCoV-19			ChAdOx1 nCoV-19			9-12 weeks	Homologous						2	Neutralization	Live virus replication assay	CPE	Delta	B.1.617.2	B.1.617.2		Neutralization IC50	1/dilution		days post booster1			8	7-9 days post booster	56		1.00																												
5169		8	Adimab LLC	Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination	https://doi.org/10.1101/2021.12.13.21267598	Pre-print	12/14/2021	human		ChAdOx1 nCoV-19			mRNA-1273			9-12 weeks	Heterologous						2	Neutralization	Live virus replication assay	CPE	Delta	B.1.617.2	B.1.617.2		Neutralization IC50	1/dilution		days post booster1			8	7-9 days post booster	854		15.25																												
5170		9	Moderna	Omicron Booster Strategy Update	https://s29.q4cdn.com/745959723/files/doc_presentations/2021/12/20/MASTER-Omicron-Booster-Update-Call-(12.20)_7am-(1).pdf	Other	12/20/2021	human		mRNA-1273	100	?g	mRNA-1273	50	?g		Homologous						3	Neutralization	Pseudotyped virus assay		Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	ID50 GMT			days post booster1	0	150.22	28		1951.73	12.99	1.00																												
5171		9	Moderna	Omicron Booster Strategy Update	https://s29.q4cdn.com/745959723/files/doc_presentations/2021/12/20/MASTER-Omicron-Booster-Update-Call-(12.20)_7am-(1).pdf	Other	12/20/2021	human		mRNA-1273	100	?g	mRNA-1273	100	?g		Homologous						3	Neutralization	Pseudotyped virus assay		Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	ID50 GMT			days post booster1	0	89.7	28		4039.49	45.03	3.47																												
5172		9	Moderna	Omicron Booster Strategy Update	https://s29.q4cdn.com/745959723/files/doc_presentations/2021/12/20/MASTER-Omicron-Booster-Update-Call-(12.20)_7am-(1).pdf	Other	12/20/2021	human		mRNA-1273	100	?g	mRNA-1273.211	50	?g		Variant						3	Neutralization	Pseudotyped virus assay		Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	ID50 GMT			days post booster1	0	102.97	28		2171.67	21.09	1.62																												
5173		9	Moderna	Omicron Booster Strategy Update	https://s29.q4cdn.com/745959723/files/doc_presentations/2021/12/20/MASTER-Omicron-Booster-Update-Call-(12.20)_7am-(1).pdf	Other	12/20/2021	human		mRNA-1273	100	?g	mRNA-1273.211	100	?g		Variant						3	Neutralization	Pseudotyped virus assay		Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	ID50 GMT			days post booster1	0	99.92	28		4475.34	44.79	0.99																												
5174		9	Moderna	Omicron Booster Strategy Update	https://s29.q4cdn.com/745959723/files/doc_presentations/2021/12/20/MASTER-Omicron-Booster-Update-Call-(12.20)_7am-(1).pdf	Other	12/20/2021	human		mRNA-1273	100	?g	mRNA-1273	50	?g		Homologous						3	Neutralization	Pseudotyped virus assay		Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	ID50 GMT			days post booster1	0	193	28		2423	12.55	1.00																												
5175		9	Moderna	Omicron Booster Strategy Update	https://s29.q4cdn.com/745959723/files/doc_presentations/2021/12/20/MASTER-Omicron-Booster-Update-Call-(12.20)_7am-(1).pdf	Other	12/20/2021	human		mRNA-1273	100	?g	mRNA-1273	100	?g		Homologous						3	Neutralization	Pseudotyped virus assay		Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	ID50 GMT			days post booster1	0	91	28		6690	73.52	5.86																												
5176		9	Moderna	Omicron Booster Strategy Update	https://s29.q4cdn.com/745959723/files/doc_presentations/2021/12/20/MASTER-Omicron-Booster-Update-Call-(12.20)_7am-(1).pdf	Other	12/20/2021	human		mRNA-1273	100	?g	mRNA-1273.211	50	?g		Variant						3	Neutralization	Pseudotyped virus assay		Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	ID50 GMT			days post booster1	0	101	28		1799	17.81	1.42																												
5177		9	Moderna	Omicron Booster Strategy Update	https://s29.q4cdn.com/745959723/files/doc_presentations/2021/12/20/MASTER-Omicron-Booster-Update-Call-(12.20)_7am-(1).pdf	Other	12/20/2021	human		mRNA-1273	100	?g	mRNA-1273.211	100	?g		Variant						3	Neutralization	Pseudotyped virus assay		Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	ID50 GMT			days post booster1	0	86	28		4760	55.35	0.75																												
5178		9	Moderna	Omicron Booster Strategy Update	https://s29.q4cdn.com/745959723/files/doc_presentations/2021/12/20/MASTER-Omicron-Booster-Update-Call-(12.20)_7am-(1).pdf	Other	12/20/2021	human		mRNA-1273	100	?g	mRNA-1273	50	?g		Homologous						3	Neutralization	Pseudotyped virus assay		Omicron	B.1.1.529	B.1.1.529		ID50 GMT			days post booster1	0	23	28		850	36.96	1.00																												
5179		9	Moderna	Omicron Booster Strategy Update	https://s29.q4cdn.com/745959723/files/doc_presentations/2021/12/20/MASTER-Omicron-Booster-Update-Call-(12.20)_7am-(1).pdf	Other	12/20/2021	human		mRNA-1273	100	?g	mRNA-1273	100	?g		Homologous						3	Neutralization	Pseudotyped virus assay		Omicron	B.1.1.529	B.1.1.529		ID50 GMT			days post booster1	0	27	28		2228	82.52	2.23																												
5180		9	Moderna	Omicron Booster Strategy Update	https://s29.q4cdn.com/745959723/files/doc_presentations/2021/12/20/MASTER-Omicron-Booster-Update-Call-(12.20)_7am-(1).pdf	Other	12/20/2021	human		mRNA-1273	100	?g	mRNA-1273.211	50	?g		Variant						3	Neutralization	Pseudotyped virus assay		Omicron	B.1.1.529	B.1.1.529		ID50 GMT			days post booster1	0	21	28		822	39.14	1.06																												
5181		9	Moderna	Omicron Booster Strategy Update	https://s29.q4cdn.com/745959723/files/doc_presentations/2021/12/20/MASTER-Omicron-Booster-Update-Call-(12.20)_7am-(1).pdf	Other	12/20/2021	human		mRNA-1273	100	?g	mRNA-1273.211	100	?g		Variant						3	Neutralization	Pseudotyped virus assay		Omicron	B.1.1.529	B.1.1.529		ID50 GMT			days post booster1	0	15	28		2115	141.00	1.71																												
5182		9	Moderna	Omicron Booster Strategy Update	https://s29.q4cdn.com/745959723/files/doc_presentations/2021/12/20/MASTER-Omicron-Booster-Update-Call-(12.20)_7am-(1).pdf	Other	12/20/2021	human		mRNA-1273	100	?g	mRNA-1273.213	100	?g		Variant						3	Neutralization	Pseudotyped virus assay		Omicron	B.1.1.529	B.1.1.529		ID50 GMT			days post booster1	0	28	28		2163	77.25	0.94																												
5183		10	Helmholtz Centre for Infection Research	Diminished neutralization responses towards SARS-CoV-2 Omicron VoC after mRNA or vector-based COVID-19 vaccinations	https://doi.org/10.1101/2021.12.21.21267898	Pre-print	12/21/2021	human		ChAdOx1 nCoV-19			ChAdOx1 nCoV-19			77.6 days	Homologous						1	Neutralization	Pseudotyped virus assay	Fluorescence	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	FRNT50 GMT			days post booster1			28		186.4		1.00																												
5200		12	Duke University Medical Center	SARS-CoV-2 Omicron Neutralization After Heterologous Vaccine Boosting	https://doi.org/10.1101/2022.01.13.22268861	Pre-print	01/14/2022	human		Ad26.COV2.S			BNT162b2			3.5-6 months interval	Heterologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	ID50 GMT			days post booster1	0	40.89	28		1044.9	25.55	7.08																												
5184		10	Helmholtz Centre for Infection Research	Diminished neutralization responses towards SARS-CoV-2 Omicron VoC after mRNA or vector-based COVID-19 vaccinations	https://doi.org/10.1101/2021.12.21.21267898	Pre-print	12/21/2021	human		ChAdOx1 nCoV-19			mRNA-1273			65.4 days	Heterologous						1	Neutralization	Pseudotyped virus assay	Fluorescence	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	FRNT50 GMT			days post booster1			28		1323		7.10																												
5185		10	Helmholtz Centre for Infection Research	Diminished neutralization responses towards SARS-CoV-2 Omicron VoC after mRNA or vector-based COVID-19 vaccinations	https://doi.org/10.1101/2021.12.21.21267898	Pre-print	12/21/2021	human		ChAdOx1 nCoV-19			BNT162b2			76.2 days	Heterologous						1	Neutralization	Pseudotyped virus assay	Fluorescence	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	FRNT50 GMT			days post booster1			28		902.8		4.84																												
5186		10	Helmholtz Centre for Infection Research	Diminished neutralization responses towards SARS-CoV-2 Omicron VoC after mRNA or vector-based COVID-19 vaccinations	https://doi.org/10.1101/2021.12.21.21267898	Pre-print	12/21/2021	human		ChAdOx1 nCoV-19			ChAdOx1 nCoV-19			77.6 days	Homologous						1	Neutralization	Pseudotyped virus assay	Fluorescence	Beta	B.1.351	B.1.351		FRNT50 GMT			days post booster1			28		46.4		1.00																												
5187		10	Helmholtz Centre for Infection Research	Diminished neutralization responses towards SARS-CoV-2 Omicron VoC after mRNA or vector-based COVID-19 vaccinations	https://doi.org/10.1101/2021.12.21.21267898	Pre-print	12/21/2021	human		ChAdOx1 nCoV-19			mRNA-1273			65.4 days	Heterologous						1	Neutralization	Pseudotyped virus assay	Fluorescence	Beta	B.1.351	B.1.351		FRNT50 GMT			days post booster1			28		368.9		7.95																												
5188		10	Helmholtz Centre for Infection Research	Diminished neutralization responses towards SARS-CoV-2 Omicron VoC after mRNA or vector-based COVID-19 vaccinations	https://doi.org/10.1101/2021.12.21.21267898	Pre-print	12/21/2021	human		ChAdOx1 nCoV-19			BNT162b2			76.2 days	Heterologous						1	Neutralization	Pseudotyped virus assay	Fluorescence	Beta	B.1.351	B.1.351		FRNT50 GMT			days post booster1			28		173.9		3.75																												
5189		10	Helmholtz Centre for Infection Research	Diminished neutralization responses towards SARS-CoV-2 Omicron VoC after mRNA or vector-based COVID-19 vaccinations	https://doi.org/10.1101/2021.12.21.21267898	Pre-print	12/21/2021	human		ChAdOx1 nCoV-19			ChAdOx1 nCoV-19			77.6 days	Homologous						1	Neutralization	Pseudotyped virus assay	Fluorescence	Delta	B.1.617.2	B.1.617.2		FRNT50 GMT			days post booster1			28		95.3		1.00																												
5190		10	Helmholtz Centre for Infection Research	Diminished neutralization responses towards SARS-CoV-2 Omicron VoC after mRNA or vector-based COVID-19 vaccinations	https://doi.org/10.1101/2021.12.21.21267898	Pre-print	12/21/2021	human		ChAdOx1 nCoV-19			mRNA-1273			65.4 days	Heterologous						1	Neutralization	Pseudotyped virus assay	Fluorescence	Delta	B.1.617.2	B.1.617.2		FRNT50 GMT			days post booster1			28		923.8		9.69																												
5191		10	Helmholtz Centre for Infection Research	Diminished neutralization responses towards SARS-CoV-2 Omicron VoC after mRNA or vector-based COVID-19 vaccinations	https://doi.org/10.1101/2021.12.21.21267898	Pre-print	12/21/2021	human		ChAdOx1 nCoV-19			BNT162b2			76.2 days	Heterologous						1	Neutralization	Pseudotyped virus assay	Fluorescence	Delta	B.1.617.2	B.1.617.2		FRNT50 GMT			days post booster1			28		173.9		1.82																												
5192		10	Helmholtz Centre for Infection Research	Diminished neutralization responses towards SARS-CoV-2 Omicron VoC after mRNA or vector-based COVID-19 vaccinations	https://doi.org/10.1101/2021.12.21.21267898	Pre-print	12/21/2021	human		ChAdOx1 nCoV-19			ChAdOx1 nCoV-19			77.6 days	Homologous						1	Neutralization	Pseudotyped virus assay	Fluorescence	Omicron	B.1.1.529	B.1.1.529		FRNT50 GMT			days post booster1			28		14.6		1.00																												
5193		10	Helmholtz Centre for Infection Research	Diminished neutralization responses towards SARS-CoV-2 Omicron VoC after mRNA or vector-based COVID-19 vaccinations	https://doi.org/10.1101/2021.12.21.21267898	Pre-print	12/21/2021	human		ChAdOx1 nCoV-19			mRNA-1273			65.4 days	Heterologous						1	Neutralization	Pseudotyped virus assay	Fluorescence	Omicron	B.1.1.529	B.1.1.529		FRNT50 GMT			days post booster1			28		75.6		5.18																												
5194		10	Helmholtz Centre for Infection Research	Diminished neutralization responses towards SARS-CoV-2 Omicron VoC after mRNA or vector-based COVID-19 vaccinations	https://doi.org/10.1101/2021.12.21.21267898	Pre-print	12/21/2021	human		ChAdOx1 nCoV-19			BNT162b2			76.2 days	Heterologous						1	Neutralization	Pseudotyped virus assay	Fluorescence	Omicron	B.1.1.529	B.1.1.529		FRNT50 GMT			days post booster1			28		61.5		4.21																												
5195		11	Fudan University	Homologous or Heterologous Booster of Inactivated Vaccine Reduces SARS-CoV-2 Omicron Variant Escape from Neutralizing Antibodies	https://doi.org/10.1080/22221751.2022.2030200	Peer-reviewed publication	01/15/2022	human		BBIBP-CorV			BBIBP-CorV				Homologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	ID50 GMT			days post booster1	0	53	14		574	10.83	1.00																												
5196		11	Fudan University	Homologous or Heterologous Booster of Inactivated Vaccine Reduces SARS-CoV-2 Omicron Variant Escape from Neutralizing Antibodies	https://doi.org/10.1080/22221751.2022.2030200	Peer-reviewed publication	01/15/2022	human		BBIBP-CorV			ZF2001				Heterologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	ID50 GMT			days post booster1	0	53	14		1619	30.55	2.82																												
5197		11	Fudan University	Homologous or Heterologous Booster of Inactivated Vaccine Reduces SARS-CoV-2 Omicron Variant Escape from Neutralizing Antibodies	https://doi.org/10.1080/22221751.2022.2030200	Peer-reviewed publication	01/15/2022	human		BBIBP-CorV			BBIBP-CorV				Homologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	B.1.1.529		ID50 GMT			days post booster1	0	57	14		84	1.47	1.00																												
5198		11	Fudan University	Homologous or Heterologous Booster of Inactivated Vaccine Reduces SARS-CoV-2 Omicron Variant Escape from Neutralizing Antibodies	https://doi.org/10.1080/22221751.2022.2030200	Peer-reviewed publication	01/15/2022	human		BBIBP-CorV			ZF2001				Heterologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	B.1.1.529		ID50 GMT			days post booster1	0	57	14		172	3.02	2.05																												
5199		12	Duke University Medical Center	SARS-CoV-2 Omicron Neutralization After Heterologous Vaccine Boosting	https://doi.org/10.1101/2022.01.13.22268861	Pre-print	01/14/2022	human		Ad26.COV2.S			Ad26.COV2.S			3.5-6 months interval	Homologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	ID50 GMT			days post booster1	0	35.28	28		127.28	3.61	1.00																												
5892																																																																					
5893																																																																					
5894																																																																					
5201		12	Duke University Medical Center	SARS-CoV-2 Omicron Neutralization After Heterologous Vaccine Boosting	https://doi.org/10.1101/2022.01.13.22268861	Pre-print	01/14/2022	human		BNT162b2			BNT162b2			3.5-6 months interval	Homologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	ID50 GMT			days post booster1	0	94.25	28		1315.53	13.96	1.00																												
5202		12	Duke University Medical Center	SARS-CoV-2 Omicron Neutralization After Heterologous Vaccine Boosting	https://doi.org/10.1101/2022.01.13.22268861	Pre-print	01/14/2022	human		BNT162b2			Ad26.COV2.S			3.5-6 months interval	Heterologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	ID50 GMT			days post booster1	0	71.46	28		1017.78	14.24	1.02																												
5203		12	Duke University Medical Center	SARS-CoV-2 Omicron Neutralization After Heterologous Vaccine Boosting	https://doi.org/10.1101/2022.01.13.22268861	Pre-print	01/14/2022	human		Ad26.COV2.S			Ad26.COV2.S			3.5-6 months interval	Homologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	B.1.1.529		ID50 GMT			days post booster1	0	7.16	28		45.04	6.29	1.00																												
5204		12	Duke University Medical Center	SARS-CoV-2 Omicron Neutralization After Heterologous Vaccine Boosting	https://doi.org/10.1101/2022.01.13.22268861	Pre-print	01/14/2022	human		Ad26.COV2.S			BNT162b2			3.5-6 months interval	Heterologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	B.1.1.529		ID50 GMT			days post booster1	0	7.64	28		266.18	34.84	5.54																												
5205		12	Duke University Medical Center	SARS-CoV-2 Omicron Neutralization After Heterologous Vaccine Boosting	https://doi.org/10.1101/2022.01.13.22268861	Pre-print	01/14/2022	human		BNT162b2			BNT162b2			3.5-6 months interval	Homologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	B.1.1.529		ID50 GMT			days post booster1	0	17.31	28		571.05	32.99	1.00																												
5206		12	Duke University Medical Center	SARS-CoV-2 Omicron Neutralization After Heterologous Vaccine Boosting	https://doi.org/10.1101/2022.01.13.22268861	Pre-print	01/14/2022	human		BNT162b2			Ad26.COV2.S			3.5-6 months interval	Heterologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	B.1.1.529		ID50 GMT			days post booster1	0	12.75	28		348.03	27.30	0.83																												
5207		13	NIH	mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits comparable B cell expansion, neutralizing antibodies and protection against Omicron	https://doi.org/10.1101/2022.02.03.479037	Pre-print	02/04/2022	nonhuman primate		mRNA-1273	100	?g	mRNA-1273	50	?g	5 montns	Homologous						1	Neutralization	Live virus replication assay	Fluorescence	USA-WA1/2020 D614G	USA-WA1/2020	USA-WA1/2020	D614G	Reciprocal ID50 GMT			weeks post booster1			39		9088		1.00																												
5208		13	NIH	mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits comparable B cell expansion, neutralizing antibodies and protection against Omicron	https://doi.org/10.1101/2022.02.03.479037	Pre-print	02/04/2022	nonhuman primate		mRNA-1273	100	?g	mRNA-1273.529	50	?g	5 montns	Variant						1	Neutralization	Live virus replication assay	Fluorescence	USA-WA1/2020 D614G	USA-WA1/2020	USA-WA1/2020	D614G	Reciprocal ID50 GMT			weeks post booster1			39		6069		0.67																												
5209		13	NIH	mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits comparable B cell expansion, neutralizing antibodies and protection against Omicron	https://doi.org/10.1101/2022.02.03.479037	Pre-print	02/04/2022	nonhuman primate		mRNA-1273	100	?g	mRNA-1273	50	?g	5 montns	Homologous						1	Neutralization	Live virus replication assay	Fluorescence	Delta	B.1.617.2	B.1.617.2		Reciprocal ID50 GMT			weeks post booster1			39		6297		1.00																												
5210		13	NIH	mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits comparable B cell expansion, neutralizing antibodies and protection against Omicron	https://doi.org/10.1101/2022.02.03.479037	Pre-print	02/04/2022	nonhuman primate		mRNA-1273	100	?g	mRNA-1273.529	50	?g	5 montns	Variant						1	Neutralization	Live virus replication assay	Fluorescence	Delta	B.1.617.2	B.1.617.2		Reciprocal ID50 GMT			weeks post booster1			39		4380		0.70																												
5211		13	NIH	mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits comparable B cell expansion, neutralizing antibodies and protection against Omicron	https://doi.org/10.1101/2022.02.03.479037	Pre-print	02/04/2022	nonhuman primate		mRNA-1273	100	?g	mRNA-1273	50	?g	5 montns	Homologous						1	Neutralization	Live virus replication assay	Fluorescence	Beta	B.1.351	B.1.351		Reciprocal ID50 GMT			weeks post booster1			39		3122		1.00																												
5212		13	NIH	mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits comparable B cell expansion, neutralizing antibodies and protection against Omicron	https://doi.org/10.1101/2022.02.03.479037	Pre-print	02/04/2022	nonhuman primate		mRNA-1273	100	?g	mRNA-1273.529	50	?g	5 montns	Variant						1	Neutralization	Live virus replication assay	Fluorescence	Beta	B.1.351	B.1.351		Reciprocal ID50 GMT			weeks post booster1			39		1197		0.38																												
5213		13	NIH	mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits comparable B cell expansion, neutralizing antibodies and protection against Omicron	https://doi.org/10.1101/2022.02.03.479037	Pre-print	02/04/2022	nonhuman primate		mRNA-1273	100	?g	mRNA-1273	50	?g	5 montns	Homologous						1	Neutralization	Live virus replication assay	Fluorescence	Omicron	B.1.1.529	B.1.1.529		Reciprocal ID50 GMT			weeks post booster1			39		1050		1.00																												
5214		13	NIH	mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits comparable B cell expansion, neutralizing antibodies and protection against Omicron	https://doi.org/10.1101/2022.02.03.479037	Pre-print	02/04/2022	nonhuman primate		mRNA-1273	100	?g	mRNA-1273.529	50	?g	5 montns	Variant						1	Neutralization	Live virus replication assay	Fluorescence	Omicron	B.1.1.529	B.1.1.529		Reciprocal ID50 GMT			weeks post booster1			39		718		0.68																												
5215		13	NIH	mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits comparable B cell expansion, neutralizing antibodies and protection against Omicron	https://doi.org/10.1101/2022.02.03.479037	Pre-print	02/04/2022	nonhuman primate		mRNA-1273	100	?g	mRNA-1273	50	?g	5 montns	Homologous						2	Neutralization	Pseudotyped virus assay	Luciferase	USA-WA1/2020 D614G	USA-WA1/2020	USA-WA1/2020	614G	Reciprocal ID50 GMT			weeks post booster1			39		6670		1.00																												
5216		13	NIH	mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits comparable B cell expansion, neutralizing antibodies and protection against Omicron	https://doi.org/10.1101/2022.02.03.479037	Pre-print	02/04/2022	nonhuman primate		mRNA-1273	100	?g	mRNA-1273.529	50	?g	5 montns	Variant						2	Neutralization	Pseudotyped virus assay	Luciferase	USA-WA1/2020 D614G	USA-WA1/2020	USA-WA1/2020	614G	Reciprocal ID50 GMT			weeks post booster1			39		3322		0.50																												
5895																																																																					
5896																																																																					
5897																																																																					
5217		13	NIH	mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits comparable B cell expansion, neutralizing antibodies and protection against Omicron	https://doi.org/10.1101/2022.02.03.479037	Pre-print	02/04/2022	nonhuman primate		mRNA-1273	100	?g	mRNA-1273	50	?g	5 montns	Homologous						2	Neutralization	Pseudotyped virus assay	Luciferase	Delta	B.1.617.2	B.1.617.2		Reciprocal ID50 GMT			weeks post booster1			39		3973		1.00																												
5218		13	NIH	mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits comparable B cell expansion, neutralizing antibodies and protection against Omicron	https://doi.org/10.1101/2022.02.03.479037	Pre-print	02/04/2022	nonhuman primate		mRNA-1273	100	?g	mRNA-1273.529	50	?g	5 montns	Variant						2	Neutralization	Pseudotyped virus assay	Luciferase	Delta	B.1.617.2	B.1.617.2		Reciprocal ID50 GMT			weeks post booster1			39		2244		0.56																												
5219		13	NIH	mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits comparable B cell expansion, neutralizing antibodies and protection against Omicron	https://doi.org/10.1101/2022.02.03.479037	Pre-print	02/04/2022	nonhuman primate		mRNA-1273	100	?g	mRNA-1273	50	?g	5 montns	Homologous						2	Neutralization	Pseudotyped virus assay	Luciferase	Beta	B.1.351	B.1.351		Reciprocal ID50 GMT			weeks post booster1			39		3595		1.00																												
5220		13	NIH	mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits comparable B cell expansion, neutralizing antibodies and protection against Omicron	https://doi.org/10.1101/2022.02.03.479037	Pre-print	02/04/2022	nonhuman primate		mRNA-1273	100	?g	mRNA-1273.529	50	?g	5 montns	Variant						2	Neutralization	Pseudotyped virus assay	Luciferase	Beta	B.1.351	B.1.351		Reciprocal ID50 GMT			weeks post booster1			39		1458		0.41																												
5221		13	NIH	mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits comparable B cell expansion, neutralizing antibodies and protection against Omicron	https://doi.org/10.1101/2022.02.03.479037	Pre-print	02/04/2022	nonhuman primate		mRNA-1273	100	?g	mRNA-1273	50	?g	5 montns	Homologous						2	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	B.1.1.529		Reciprocal ID50 GMT			weeks post booster1			39		4282		1.00																												
5222		13	NIH	mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits comparable B cell expansion, neutralizing antibodies and protection against Omicron	https://doi.org/10.1101/2022.02.03.479037	Pre-print	02/04/2022	nonhuman primate		mRNA-1273	100	?g	mRNA-1273.529	50	?g	5 montns	Variant						2	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	B.1.1.529		Reciprocal ID50 GMT			weeks post booster1			39		2039		0.48																												
5223		14	Sheba Medical Center	Fourth Dose COVID mRNA Vaccines' Immunogenicity & Efficacy Against Omicron VOC	https://doi.org/10.1101/2022.02.15.22270948	Pre-print	02/15/2022	human		BNT162b2	30	?g	BNT162b2	30	?g		Homologous	BNT162b2	30	?g	Homologous	at least 4 months	1	Binding	ELISA						Anti-RBD IgG GM	BAU/mL		weeks post booster1			4		2102		1.00	18	16-20 weeks post booster1	383		1.00									1	1 week post boost2	1476		1.00	2	2 weeks post boost2	2975		1.00	3	3 weeks post boost2	2684		1.00
5224		14	Sheba Medical Center	Fourth Dose COVID mRNA Vaccines' Immunogenicity & Efficacy Against Omicron VOC	https://doi.org/10.1101/2022.02.15.22270948	Pre-print	02/15/2022	human		BNT162b2	30	?g	BNT162b2	30	?g		Homologous	mRNA-1273	50	?g	Heterologous	at least 4 months	1	Binding	ELISA						Anti-RBD IgG GM	BAU/mL		weeks post booster1			4		2102		1.00	18	16-20 weeks post booster1	383		1.00									1	1 week post boost2	2341		1.59	2	2 weeks post boost2	3502		1.18	3	3 weeks post boost2	3729		1.39
5225		14	Sheba Medical Center	Fourth Dose COVID mRNA Vaccines' Immunogenicity & Efficacy Against Omicron VOC	https://doi.org/10.1101/2022.02.15.22270948	Pre-print	02/15/2022	human		BNT162b2	30	?g	BNT162b2	30	?g		Homologous	BNT162b2	30	?g	Homologous	at least 4 months	2	Binding	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		FRNT50 GMT			weeks post booster1			4		2629		1.00	18	16-20 weeks post booster1	480		1.00									1	1 week post boost2	2801		1.00	2	2 weeks post boost2	3788		1.00	3	3 weeks post boost2	3501		1.00
5226		14	Sheba Medical Center	Fourth Dose COVID mRNA Vaccines' Immunogenicity & Efficacy Against Omicron VOC	https://doi.org/10.1101/2022.02.15.22270948	Pre-print	02/15/2022	human		BNT162b2	30	?g	BNT162b2	30	?g		Homologous	mRNA-1273	50	?g	Heterologous	at least 4 months	2	Binding	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		FRNT50 GMT			weeks post booster1			4		2629		1.00	18	16-20 weeks post booster1	480		1.00									1	1 week post boost2	3424		1.22	2	2 weeks post boost2	5192		1.37	3	3 weeks post boost2	3510		1.00
5227		14	Sheba Medical Center	Fourth Dose COVID mRNA Vaccines' Immunogenicity & Efficacy Against Omicron VOC	https://doi.org/10.1101/2022.02.15.22270948	Pre-print	02/15/2022	human		BNT162b2	30	?g	BNT162b2	30	?g		Homologous	BNT162b2	30	?g	Homologous	at least 4 months	3	Binding	Live virus replication assay	CPE	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		NT/log2 GMT		Neutrialization titer/log2	months post booster 1			5		135.6																1	1 week post boost2	1407	10.38	1.00	2	2 weeks post boost2	1542	11.37	1.00					
5228		14	Sheba Medical Center	Fourth Dose COVID mRNA Vaccines' Immunogenicity & Efficacy Against Omicron VOC	https://doi.org/10.1101/2022.02.15.22270948	Pre-print	02/15/2022	human		BNT162b2	30	?g	BNT162b2	30	?g		Homologous	mRNA-1273	50	?g	Heterologous	at least 4 months	3	Binding	Live virus replication assay	CPE	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		NT/log2 GMT		Neutrialization titer/log2	months post booster 1			5		101.6																1	1 week post boost2	966.5	9.51	0.92	2	2 weeks post boost2	1162	11.44	1.01					
5229		14	Sheba Medical Center	Fourth Dose COVID mRNA Vaccines' Immunogenicity & Efficacy Against Omicron VOC	https://doi.org/10.1101/2022.02.15.22270948	Pre-print	02/15/2022	human		BNT162b2	30	?g	BNT162b2	30	?g		Homologous	BNT162b2	30	?g	Homologous	at least 4 months	3	Binding	Live virus replication assay	CPE	Delta	B.1.617.2	B.1.617.2		NT/log2 GMT		Neutrialization titer/log2	months post booster 1			5		57.02																1	1 week post boost2	645.1	11.31	1.00	2	2 weeks post boost2	638.3	11.19	1.00					
5230		14	Sheba Medical Center	Fourth Dose COVID mRNA Vaccines' Immunogenicity & Efficacy Against Omicron VOC	https://doi.org/10.1101/2022.02.15.22270948	Pre-print	02/15/2022	human		BNT162b2	30	?g	BNT162b2	30	?g		Homologous	mRNA-1273	50	?g	Heterologous	at least 4 months	3	Binding	Live virus replication assay	CPE	Delta	B.1.617.2	B.1.617.2		NT/log2 GMT		Neutrialization titer/log2	months post booster 1			5		49.3																1	1 week post boost2	497.4	10.09	0.89	2	2 weeks post boost2	771	15.64	1.40					
5231		14	Sheba Medical Center	Fourth Dose COVID mRNA Vaccines' Immunogenicity & Efficacy Against Omicron VOC	https://doi.org/10.1101/2022.02.15.22270948	Pre-print	02/15/2022	human		BNT162b2	30	?g	BNT162b2	30	?g		Homologous	BNT162b2	30	?g	Homologous	at least 4 months	3	Binding	Live virus replication assay	CPE	Omicron	B.1.1.529	B.1.1.529		NT/log2 GMT		Neutrialization titer/log2	months post booster 1			5		12.7																1	1 week post boost2	107.6	8.47	1.00	2	2 weeks post boost2	136.3	10.73	1.00					
5898																																																																					
5899																																																																					
5232		14	Sheba Medical Center	Fourth Dose COVID mRNA Vaccines' Immunogenicity & Efficacy Against Omicron VOC	https://doi.org/10.1101/2022.02.15.22270948	Pre-print	02/15/2022	human		BNT162b2	30	?g	BNT162b2	30	?g		Homologous	mRNA-1273	50	?g	Heterologous	at least 4 months	3	Binding	Live virus replication assay	CPE	Omicron	B.1.1.529	B.1.1.529		NT/log2 GMT		Neutrialization titer/log2	months post booster 1			5		14.2																1	1 week post boost2	98.7	6.95	0.82	2	2 weeks post boost2	102.7	7.23	0.67					
5233		15	Beijing Institute of Biotechnology	Aerosolized Ad5-nCoV booster vaccination elicited potent immune response against the SARS-CoV-2 Omicron variant after inactivated COVID-19 vaccine priming	https://doi.org/10.1101/2022.03.08.22271816	Pre-print	03/10/2022	human		CoronaVac			CoronaVac				Homologous						1	Binding	ELISA						Anti-RBD IgG GM	EU/mL		days post booster1	0	161	7		1506	9.35	1.00	14		10591	65.78	1.00	28		7860	48.82	1.00																		
5234		15	Beijing Institute of Biotechnology	Aerosolized Ad5-nCoV booster vaccination elicited potent immune response against the SARS-CoV-2 Omicron variant after inactivated COVID-19 vaccine priming	https://doi.org/10.1101/2022.03.08.22271816	Pre-print	03/10/2022	human		CoronaVac			Ad5-nCoV	5.00E+10	virus  particles	intramuscular delivery	Heterologous						1	Binding	ELISA						Anti-RBD IgG GM	EU/mL		days post booster1	0	169	7		4518	26.73	2.86	14		75721	448.05	6.81	28		49029	290.11	5.94																		
5235		15	Beijing Institute of Biotechnology	Aerosolized Ad5-nCoV booster vaccination elicited potent immune response against the SARS-CoV-2 Omicron variant after inactivated COVID-19 vaccine priming	https://doi.org/10.1101/2022.03.08.22271816	Pre-print	03/10/2022	human		CoronaVac			Ad5-nCoV	1.00E+10	virus  particles	aerosolized delivery	Heterologous						1	Binding	ELISA						Anti-RBD IgG GM	EU/mL		days post booster1	0	170	7		186	1.09	0.12	14		64892	381.72	5.80	28		55716	327.74	6.71																		
5236		15	Beijing Institute of Biotechnology	Aerosolized Ad5-nCoV booster vaccination elicited potent immune response against the SARS-CoV-2 Omicron variant after inactivated COVID-19 vaccine priming	https://doi.org/10.1101/2022.03.08.22271816	Pre-print	03/10/2022	human		CoronaVac			ZF2001				Heterologous						1	Binding	ELISA						Anti-RBD IgG GM	EU/mL		days post booster1	0	147	7		403	2.74	0.29	14		23836	162.15	2.47	28		17211	117.08	2.40																		
5237		15	Beijing Institute of Biotechnology	Aerosolized Ad5-nCoV booster vaccination elicited potent immune response against the SARS-CoV-2 Omicron variant after inactivated COVID-19 vaccine priming	https://doi.org/10.1101/2022.03.08.22271816	Pre-print	03/10/2022	human		CoronaVac			CoronaVac				Homologous						2	Binding	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		EC50 GM			days post booster1	0	17	14		139	8.18	1.00	28		69	4.06	1.00																							
5238		15	Beijing Institute of Biotechnology	Aerosolized Ad5-nCoV booster vaccination elicited potent immune response against the SARS-CoV-2 Omicron variant after inactivated COVID-19 vaccine priming	https://doi.org/10.1101/2022.03.08.22271816	Pre-print	03/10/2022	human		CoronaVac			Ad5-nCoV	5.00E+10	virus  particles	intramuscular delivery	Heterologous						2	Binding	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		EC50 GM			days post booster1	0	16	14		970	60.63	7.41	28		628	39.25	9.67																							
5239		15	Beijing Institute of Biotechnology	Aerosolized Ad5-nCoV booster vaccination elicited potent immune response against the SARS-CoV-2 Omicron variant after inactivated COVID-19 vaccine priming	https://doi.org/10.1101/2022.03.08.22271816	Pre-print	03/10/2022	human		CoronaVac			Ad5-nCoV	1.00E+10	virus  particles	aerosolized delivery	Heterologous						2	Binding	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		EC50 GM			days post booster1	0	16	14		567	35.44	4.33	28		874	54.63	13.45																							
5240		15	Beijing Institute of Biotechnology	Aerosolized Ad5-nCoV booster vaccination elicited potent immune response against the SARS-CoV-2 Omicron variant after inactivated COVID-19 vaccine priming	https://doi.org/10.1101/2022.03.08.22271816	Pre-print	03/10/2022	human		CoronaVac			ZF2001				Heterologous						2	Binding	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		EC50 GM			days post booster1	0	17	14		308	18.12	2.21	28		210	12.35	3.04																							
5241		15	Beijing Institute of Biotechnology	Aerosolized Ad5-nCoV booster vaccination elicited potent immune response against the SARS-CoV-2 Omicron variant after inactivated COVID-19 vaccine priming	https://doi.org/10.1101/2022.03.08.22271816	Pre-print	03/10/2022	human		CoronaVac			CoronaVac				Homologous						2	Binding	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.1		EC50 GM			days post booster1	0	15	14		54	3.60	1.00	28		25	1.67	1.00																							
5242		15	Beijing Institute of Biotechnology	Aerosolized Ad5-nCoV booster vaccination elicited potent immune response against the SARS-CoV-2 Omicron variant after inactivated COVID-19 vaccine priming	https://doi.org/10.1101/2022.03.08.22271816	Pre-print	03/10/2022	human		CoronaVac			Ad5-nCoV	5.00E+10	virus  particles	intramuscular delivery	Heterologous						2	Binding	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.1		EC50 GM			days post booster1	0	15	14		261	17.40	4.83	28		180	12.00	7.19																							
5243		15	Beijing Institute of Biotechnology	Aerosolized Ad5-nCoV booster vaccination elicited potent immune response against the SARS-CoV-2 Omicron variant after inactivated COVID-19 vaccine priming	https://doi.org/10.1101/2022.03.08.22271816	Pre-print	03/10/2022	human		CoronaVac			Ad5-nCoV	1.00E+10	virus  particles	aerosolized delivery	Heterologous						2	Binding	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.1		EC50 GM			days post booster1	0	15	14		320	21.33	5.93	28		353	23.53	14.09																							
5244		15	Beijing Institute of Biotechnology	Aerosolized Ad5-nCoV booster vaccination elicited potent immune response against the SARS-CoV-2 Omicron variant after inactivated COVID-19 vaccine priming	https://doi.org/10.1101/2022.03.08.22271816	Pre-print	03/10/2022	human		CoronaVac			ZF2001				Heterologous						2	Binding	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.1		EC50 GM			days post booster1	0	15	14		86	5.73	1.59	28		63	4.20	2.51																							
5245		16	Technical University of Munich	Dynamics of humoral and cellular immune responses after homologous and heterologous SARS-CoV-2 vaccination with ChAdOx1 nCoV-19 and BNT162b2	https://doi.org/10.1101/2022.03.23.22272771	Pre-print	03/27/2022	human		ChAdOx1 nCoV-19			ChAdOx1 nCoV-19			63 days interval	Homologous						1	Neutralization	Pseudotyped virus assay	Surrogate Virus Neutralization	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	614G	sVNT GMT	AU/mL		days post booster1			13		31.69		1.00	142		9.32		1.00																							
5246		16	Technical University of Munich	Dynamics of humoral and cellular immune responses after homologous and heterologous SARS-CoV-2 vaccination with ChAdOx1 nCoV-19 and BNT162b2	https://doi.org/10.1101/2022.03.23.22272771	Pre-print	03/27/2022	human		ChAdOx1 nCoV-19			BNT162b2			63 days interval	Heterologous						1	Neutralization	Pseudotyped virus assay	Surrogate Virus Neutralization	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	614G	sVNT GMT	AU/mL		days post booster1			14		762.78		24.07	142		41.72		4.48																							
5900																																																																					
5247		16	Technical University of Munich	Dynamics of humoral and cellular immune responses after homologous and heterologous SARS-CoV-2 vaccination with ChAdOx1 nCoV-19 and BNT162b2	https://doi.org/10.1101/2022.03.23.22272771	Pre-print	03/27/2022	human		ChAdOx1 nCoV-19			ChAdOx1 nCoV-19			63 days interval	Homologous						1	Neutralization	Pseudotyped virus assay	Surrogate Virus Neutralization	Delta	B.1.617.2	B.1.617.2		IC50	1/dilution		days post booster1			142		20		1.00																												
5248		16	Technical University of Munich	Dynamics of humoral and cellular immune responses after homologous and heterologous SARS-CoV-2 vaccination with ChAdOx1 nCoV-19 and BNT162b2	https://doi.org/10.1101/2022.03.23.22272771	Pre-print	03/27/2022	human		ChAdOx1 nCoV-19			BNT162b2			63 days interval	Heterologous						1	Neutralization	Pseudotyped virus assay	Surrogate Virus Neutralization	Delta	B.1.617.2	B.1.617.2		IC50	1/dilution		days post booster1			142		107.8		5.39																												
5249		17	NIHR Oxford Biomedical Research Centre	Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study	https://doi.org/10.1016/S0140-6736(22)00094-0	Peer-reviewed publication	01/21/2022	human		CoronaVac	600	SU inactivated virus	CoronaVac	600	SU inactivated virus		Homologous						1	Binding	ELISA						Anti-spike IgG GM	AU/mL		days post booster1	0	3899	28		48405	12.41	1.00																												
5250		17	NIHR Oxford Biomedical Research Centre	Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study	https://doi.org/10.1016/S0140-6736(22)00094-0	Peer-reviewed publication	01/21/2022	human		CoronaVac	600	SU inactivated virus	Ad26.COV2.S	5.00E+10	virus  particles		Heterologous						1	Binding	ELISA						Anti-spike IgG GM	AU/mL		days post booster1	0	4379	28		336851	76.92	6.20																												
5251		17	NIHR Oxford Biomedical Research Centre	Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study	https://doi.org/10.1016/S0140-6736(22)00094-0	Peer-reviewed publication	01/21/2022	human		CoronaVac	600	SU inactivated virus	BNT162b2	30	?g		Heterologous						1	Binding	ELISA						Anti-spike IgG GM	AU/mL		days post booster1	0	4433	28		674267	152.10	12.26																												
5252		17	NIHR Oxford Biomedical Research Centre	Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study	https://doi.org/10.1016/S0140-6736(22)00094-0	Peer-reviewed publication	01/21/2022	human		CoronaVac	600	SU inactivated virus	ChAdOx1 nCoV-19	5.00E+10	virus  particles		Heterologous						1	Binding	ELISA						Anti-spike IgG GM	AU/mL		days post booster1	0	3745	28		335213	89.51	7.21																												
5253		17	NIHR Oxford Biomedical Research Centre	Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study	https://doi.org/10.1016/S0140-6736(22)00094-0	Peer-reviewed publication	01/21/2022	human		CoronaVac	600	SU inactivated virus	CoronaVac	600	SU inactivated virus		Homologous						2	Binding	ELISA						Anti-N IgG GM	AU/mL		days post booster1	0	505.6	28		10619.7	21.00	1.00																												
5254		17	NIHR Oxford Biomedical Research Centre	Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study	https://doi.org/10.1016/S0140-6736(22)00094-0	Peer-reviewed publication	01/21/2022	human		CoronaVac	600	SU inactivated virus	Ad26.COV2.S	5.00E+10	virus  particles		Heterologous						2	Binding	ELISA						Anti-N IgG GM	AU/mL		days post booster1	0	536.7	28		522.6	0.97	0.05																												
5255		17	NIHR Oxford Biomedical Research Centre	Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study	https://doi.org/10.1016/S0140-6736(22)00094-0	Peer-reviewed publication	01/21/2022	human		CoronaVac	600	SU inactivated virus	BNT162b2	30	?g		Heterologous						2	Binding	ELISA						Anti-N IgG GM	AU/mL		days post booster1	0	583.7	28		567.1	0.97	0.05																												
5256		17	NIHR Oxford Biomedical Research Centre	Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study	https://doi.org/10.1016/S0140-6736(22)00094-0	Peer-reviewed publication	01/21/2022	human		CoronaVac	600	SU inactivated virus	ChAdOx1 nCoV-19	5.00E+10	virus  particles		Heterologous						2	Binding	ELISA						Anti-N IgG GM	AU/mL		days post booster1	0	498.4	28		469.1	0.94	0.04																												
5257		17	NIHR Oxford Biomedical Research Centre	Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study	https://doi.org/10.1016/S0140-6736(22)00094-0	Peer-reviewed publication	01/21/2022	human		CoronaVac	600	SU inactivated virus	CoronaVac	600	SU inactivated virus		Homologous						3	Binding	ELISA						Anti-RBD IgG GM	AU/mL		days post booster1	0	3897.7	28		59445.8	15.25	1.00																												
5258		17	NIHR Oxford Biomedical Research Centre	Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study	https://doi.org/10.1016/S0140-6736(22)00094-0	Peer-reviewed publication	01/21/2022	human		CoronaVac	600	SU inactivated virus	Ad26.COV2.S	5.00E+10	virus  particles		Heterologous						3	Binding	ELISA						Anti-RBD IgG GM	AU/mL		days post booster1	0	4558.7	28		430521.6	94.44	6.19																												
5259		17	NIHR Oxford Biomedical Research Centre	Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study	https://doi.org/10.1016/S0140-6736(22)00094-0	Peer-reviewed publication	01/21/2022	human		CoronaVac	600	SU inactivated virus	BNT162b2	30	?g		Heterologous						3	Binding	ELISA						Anti-RBD IgG GM	AU/mL		days post booster1	0	4780.1	28		827704.7	173.16	11.35																												
5260		17	NIHR Oxford Biomedical Research Centre	Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study	https://doi.org/10.1016/S0140-6736(22)00094-0	Peer-reviewed publication	01/21/2022	human		CoronaVac	600	SU inactivated virus	ChAdOx1 nCoV-19	5.00E+10	virus  particles		Heterologous						3	Binding	ELISA						Anti-RBD IgG GM	AU/mL		days post booster1	0	3957.3	28		447510.2	113.08	7.42																												
5261		17	NIHR Oxford Biomedical Research Centre	Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study	https://doi.org/10.1016/S0140-6736(22)00094-0	Peer-reviewed publication	01/21/2022	human		CoronaVac	600	SU inactivated virus	CoronaVac	600	SU inactivated virus		Homologous						4	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	614G	IC50 GMT			days post booster1	0	30.1	28		211.1	7.01	1.00																												
5262		17	NIHR Oxford Biomedical Research Centre	Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study	https://doi.org/10.1016/S0140-6736(22)00094-0	Peer-reviewed publication	01/21/2022	human		CoronaVac	600	SU inactivated virus	Ad26.COV2.S	5.00E+10	virus  particles		Heterologous						4	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	614G	IC50 GMT			days post booster1	0	30.5	28		1843.6	60.45	8.62																												
5263		17	NIHR Oxford Biomedical Research Centre	Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study	https://doi.org/10.1016/S0140-6736(22)00094-0	Peer-reviewed publication	01/21/2022	human		CoronaVac	600	SU inactivated virus	BNT162b2	30	?g		Heterologous						4	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	614G	IC50 GMT			days post booster1	0	24.7	28		4325.8	175.13	24.98																												
5264		17	NIHR Oxford Biomedical Research Centre	Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study	https://doi.org/10.1016/S0140-6736(22)00094-0	Peer-reviewed publication	01/21/2022	human		CoronaVac	600	SU inactivated virus	ChAdOx1 nCoV-19	5.00E+10	virus  particles		Heterologous						4	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	614G	IC50 GMT			days post booster1	0	25.2	28		2136.9	84.80	12.10																												
5265		17	NIHR Oxford Biomedical Research Centre	Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study	https://doi.org/10.1016/S0140-6736(22)00094-0	Peer-reviewed publication	01/21/2022	human		CoronaVac	600	SU inactivated virus	CoronaVac	600	SU inactivated virus		Homologous						5	Neutralization	Live virus replication assay	CPE	Delta	B.1.617.2	B.1.617.2		FRNT50 GMT	1/dilution		days post booster1	0	13	28		61	4.69	1.00																												
5266		17	NIHR Oxford Biomedical Research Centre	Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study	https://doi.org/10.1016/S0140-6736(22)00094-0	Peer-reviewed publication	01/21/2022	human		CoronaVac	600	SU inactivated virus	Ad26.COV2.S	5.00E+10	virus  particles		Heterologous						5	Neutralization	Live virus replication assay	CPE	Delta	B.1.617.2	B.1.617.2		FRNT50 GMT	1/dilution		days post booster1	0	12	28		677	56.42	12.03																												
5267		17	NIHR Oxford Biomedical Research Centre	Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study	https://doi.org/10.1016/S0140-6736(22)00094-0	Peer-reviewed publication	01/21/2022	human		CoronaVac	600	SU inactivated virus	BNT162b2	30	?g		Heterologous						5	Neutralization	Live virus replication assay	CPE	Delta	B.1.617.2	B.1.617.2		FRNT50 GMT	1/dilution		days post booster1	0	12	28		1653	137.75	29.37																												
5268		17	NIHR Oxford Biomedical Research Centre	Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study	https://doi.org/10.1016/S0140-6736(22)00094-0	Peer-reviewed publication	01/21/2022	human		CoronaVac	600	SU inactivated virus	ChAdOx1 nCoV-19	5.00E+10	virus  particles		Heterologous						5	Neutralization	Live virus replication assay	CPE	Delta	B.1.617.2	B.1.617.2		FRNT50 GMT	1/dilution		days post booster1	0	12	28		710	59.17	12.62																												
5269		17	NIHR Oxford Biomedical Research Centre	Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study	https://doi.org/10.1016/S0140-6736(22)00094-0	Peer-reviewed publication	01/21/2022	human		CoronaVac	600	SU inactivated virus	CoronaVac	600	SU inactivated virus		Homologous						5	Neutralization	Live virus replication assay	CPE	Omicron	B.1.1.529	B.1.1.529		FRNT50 GMT	1/dilution		days post booster1	0	11	28		17	1.55	1.00																												
5270		17	NIHR Oxford Biomedical Research Centre	Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study	https://doi.org/10.1016/S0140-6736(22)00094-0	Peer-reviewed publication	01/21/2022	human		CoronaVac	600	SU inactivated virus	Ad26.COV2.S	5.00E+10	virus  particles		Heterologous						5	Neutralization	Live virus replication assay	CPE	Omicron	B.1.1.529	B.1.1.529		FRNT50 GMT	1/dilution		days post booster1	0	10	28		138	13.80	8.90																												
5271		17	NIHR Oxford Biomedical Research Centre	Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study	https://doi.org/10.1016/S0140-6736(22)00094-0	Peer-reviewed publication	01/21/2022	human		CoronaVac	600	SU inactivated virus	BNT162b2	30	?g		Heterologous						5	Neutralization	Live virus replication assay	CPE	Omicron	B.1.1.529	B.1.1.529		FRNT50 GMT	1/dilution		days post booster1	0	10	28		223	22.30	14.39																												
5272		17	NIHR Oxford Biomedical Research Centre	Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study	https://doi.org/10.1016/S0140-6736(22)00094-0	Peer-reviewed publication	01/21/2022	human		CoronaVac	600	SU inactivated virus	ChAdOx1 nCoV-19	5.00E+10	virus  particles		Heterologous						5	Neutralization	Live virus replication assay	CPE	Omicron	B.1.1.529	B.1.1.529		FRNT50 GMT	1/dilution		days post booster1	0	10	28		102	10.20	6.58																												
5273		18	Harvard Medical School	Vaccine Protection Against the SARS-CoV-2 Omicron Variant in Macaques	https://doi.org/10.1016/j.cell.2022.03.024	Peer-reviewed publication	03/14/2022	macque		BNT162b2	30	?g	BNT162b2	30	?g	14 weeks interval since dose 1	Homologous						1	Neutralization	Pseudotyped virus assay	Luciferase	USA-WA1/2020	USA-WA1/2020	USA-WA1/2020		NT50 Median			weeks post booster1			18		19901		1.00																												
5274		18	Harvard Medical School	Vaccine Protection Against the SARS-CoV-2 Omicron Variant in Macaques	https://doi.org/10.1016/j.cell.2022.03.024	Peer-reviewed publication	03/14/2022	macque		BNT162b2	30	?g	Ad26.COV2.S	5.00E+10	virus  particles	14 weeks interval since dose 1	Heterologous						1	Neutralization	Pseudotyped virus assay	Luciferase	USA-WA1/2020	USA-WA1/2020	USA-WA1/2020		NT50 Median			weeks post booster1			18		15451		0.78																												
5275		18	Harvard Medical School	Vaccine Protection Against the SARS-CoV-2 Omicron Variant in Macaques	https://doi.org/10.1016/j.cell.2022.03.024	Peer-reviewed publication	03/14/2022	macque		Ad26.COV2.S	5.00E+10	virus  particles	Ad26.COV2.S	5.00E+10	virus  particles	14 weeks interval since dose 1	Homologous						1	Neutralization	Pseudotyped virus assay	Luciferase	USA-WA1/2020	USA-WA1/2020	USA-WA1/2020		NT50 Median			weeks post booster1			18		2215		1.00																												
5276		18	Harvard Medical School	Vaccine Protection Against the SARS-CoV-2 Omicron Variant in Macaques	https://doi.org/10.1016/j.cell.2022.03.024	Peer-reviewed publication	03/14/2022	macque		Ad26.COV2.S	5.00E+10	virus  particles	BNT162b2	30	?g	14 weeks interval since dose 1	Heterologous						1	Neutralization	Pseudotyped virus assay	Luciferase	USA-WA1/2020	USA-WA1/2020	USA-WA1/2020		NT50 Median			weeks post booster1			18		7461		3.37																												
5277		18	Harvard Medical School	Vaccine Protection Against the SARS-CoV-2 Omicron Variant in Macaques	https://doi.org/10.1016/j.cell.2022.03.024	Peer-reviewed publication	03/14/2022	macque		BNT162b2	30	?g	BNT162b2	30	?g	14 weeks interval since dose 1	Homologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	B.1.1.529		NT50 Median			weeks post booster1			18		1901		1.00																												
5278		18	Harvard Medical School	Vaccine Protection Against the SARS-CoV-2 Omicron Variant in Macaques	https://doi.org/10.1016/j.cell.2022.03.024	Peer-reviewed publication	03/14/2022	macque		BNT162b2	30	?g	Ad26.COV2.S	5.00E+10	virus  particles	14 weeks interval since dose 1	Heterologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	B.1.1.529		NT50 Median			weeks post booster1			18		650		0.34																												
5279		18	Harvard Medical School	Vaccine Protection Against the SARS-CoV-2 Omicron Variant in Macaques	https://doi.org/10.1016/j.cell.2022.03.024	Peer-reviewed publication	03/14/2022	macque		Ad26.COV2.S	5.00E+10	virus  particles	Ad26.COV2.S	5.00E+10	virus  particles	14 weeks interval since dose 1	Homologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	B.1.1.529		NT50 Median			weeks post booster1			18		168		1.00																												
5280		18	Harvard Medical School	Vaccine Protection Against the SARS-CoV-2 Omicron Variant in Macaques	https://doi.org/10.1016/j.cell.2022.03.024	Peer-reviewed publication	03/14/2022	macque		Ad26.COV2.S	5.00E+10	virus  particles	BNT162b2	30	?g	14 weeks interval since dose 1	Heterologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	B.1.1.529		NT50 Median			weeks post booster1			18		810		4.82																												
5281		18	Harvard Medical School	Vaccine Protection Against the SARS-CoV-2 Omicron Variant in Macaques	https://doi.org/10.1016/j.cell.2022.03.024	Peer-reviewed publication	03/14/2022	macque		BNT162b2	30	?g	BNT162b2	30	?g	14 weeks interval since dose 1	Homologous						2	Binding	ELISA		USA-WA1/2020	USA-WA1/2020	USA-WA1/2020		Anti-RBD IgG ELISA Titer		reciprocal serum dilution that yields an absorbance value of 0.2	weeks post booster1			18		107705		1.00																												
5282		18	Harvard Medical School	Vaccine Protection Against the SARS-CoV-2 Omicron Variant in Macaques	https://doi.org/10.1016/j.cell.2022.03.024	Peer-reviewed publication	03/14/2022	macque		BNT162b2	30	?g	Ad26.COV2.S	5.00E+10	virus  particles	14 weeks interval since dose 1	Heterologous						2	Binding	ELISA		USA-WA1/2020	USA-WA1/2020	USA-WA1/2020		Anti-RBD IgG ELISA Titer		reciprocal serum dilution that yields an absorbance value of 0.3	weeks post booster1			18		125694		1.17																												
5283		18	Harvard Medical School	Vaccine Protection Against the SARS-CoV-2 Omicron Variant in Macaques	https://doi.org/10.1016/j.cell.2022.03.024	Peer-reviewed publication	03/14/2022	macque		Ad26.COV2.S	5.00E+10	virus  particles	Ad26.COV2.S	5.00E+10	virus  particles	14 weeks interval since dose 1	Homologous						2	Binding	ELISA		USA-WA1/2020	USA-WA1/2020	USA-WA1/2020		Anti-RBD IgG ELISA Titer		reciprocal serum dilution that yields an absorbance value of 0.4	weeks post booster1			18		14193		1.00																												
5284		18	Harvard Medical School	Vaccine Protection Against the SARS-CoV-2 Omicron Variant in Macaques	https://doi.org/10.1016/j.cell.2022.03.024	Peer-reviewed publication	03/14/2022	macque		Ad26.COV2.S	5.00E+10	virus  particles	BNT162b2	30	?g	14 weeks interval since dose 1	Heterologous						2	Binding	ELISA		USA-WA1/2020	USA-WA1/2020	USA-WA1/2020		Anti-RBD IgG ELISA Titer		reciprocal serum dilution that yields an absorbance value of 0.5	weeks post booster1			18		60634		4.27																												
5285		18	Harvard Medical School	Vaccine Protection Against the SARS-CoV-2 Omicron Variant in Macaques	https://doi.org/10.1016/j.cell.2022.03.024	Peer-reviewed publication	03/14/2022	macque		BNT162b2	30	?g	BNT162b2	30	?g	14 weeks interval since dose 1	Homologous						2	Binding	ELISA		Omicron	B.1.1.529	B.1.1.529		Anti-RBD IgG ELISA Titer		reciprocal serum dilution that yields an absorbance value of 0.6	weeks post booster1			18		11333		1.00																												
5286		18	Harvard Medical School	Vaccine Protection Against the SARS-CoV-2 Omicron Variant in Macaques	https://doi.org/10.1016/j.cell.2022.03.024	Peer-reviewed publication	03/14/2022	macque		BNT162b2	30	?g	Ad26.COV2.S	5.00E+10	virus  particles	14 weeks interval since dose 1	Heterologous						2	Binding	ELISA		Omicron	B.1.1.529	B.1.1.529		Anti-RBD IgG ELISA Titer		reciprocal serum dilution that yields an absorbance value of 0.7	weeks post booster1			18		7452		0.66																												
5287		18	Harvard Medical School	Vaccine Protection Against the SARS-CoV-2 Omicron Variant in Macaques	https://doi.org/10.1016/j.cell.2022.03.024	Peer-reviewed publication	03/14/2022	macque		Ad26.COV2.S	5.00E+10	virus  particles	Ad26.COV2.S	5.00E+10	virus  particles	14 weeks interval since dose 1	Homologous						2	Binding	ELISA		Omicron	B.1.1.529	B.1.1.529		Anti-RBD IgG ELISA Titer		reciprocal serum dilution that yields an absorbance value of 0.8	weeks post booster1			18		1783		1.00																												
5288		18	Harvard Medical School	Vaccine Protection Against the SARS-CoV-2 Omicron Variant in Macaques	https://doi.org/10.1016/j.cell.2022.03.024	Peer-reviewed publication	03/14/2022	macque		Ad26.COV2.S	5.00E+10	virus  particles	BNT162b2	30	?g	14 weeks interval since dose 1	Heterologous						2	Binding	ELISA		Omicron	B.1.1.529	B.1.1.529		Anti-RBD IgG ELISA Titer		reciprocal serum dilution that yields an absorbance value of 0.9	weeks post booster1			18		5805		3.26																												
5426		24	University of Hong Kong	Three-dose vaccination-induced immune responses protect against SARS-CoV-2 2 Omicron-BA.2	https://doi.org/10.1101/2022.05.09.491254	Pre-print	10/06/2022	human		CoronaVac			CoronaVac			236 (191-288) days interval	Homologous						1	Neutralization	Pseudotyped virus assay	Luciferase	delta	B.1.617.2	B.1.617.2		IC50 GMT			weeks post booster1			2	0-4	46		1.00	4		41		1.00																							
5289		19	Harvard Medical School	A homologous or variant booster vaccine after Ad26.COV2.S immunization enhances SARS-CoV-2specific immune responses in rhesus macaques	https://doi.org/10.1126/scitranslmed.abm4996	Peer-reviewed publication	02/22/2022	macque		Ad26.COV2.S	5.00E+10	virus  particles	Ad26.COV2.S	5.00E+10	virus  particles	8-10 months interval	Homologous						1	Binding	ELISA		USA-WA1/2020	USA-WA1/2020	USA-WA1/2020		Anti-RBD IgG ELISA Titer		reciprocal serum dilution that yields an absorbance value of 0.10	days post booster1	0	795	14		52874	66.51	1.00	28		19436	24.45	1.00																							
5290		19	Harvard Medical School	A homologous or variant booster vaccine after Ad26.COV2.S immunization enhances SARS-CoV-2specific immune responses in rhesus macaques	https://doi.org/10.1126/scitranslmed.abm4996	Peer-reviewed publication	02/22/2022	macque		Ad26.COV2.S	5.00E+10	virus  particles	Ad26.COV2.S.351	5.00E+10	virus  particles	8-10 months interval	Variant						1	Binding	ELISA		USA-WA1/2020	USA-WA1/2020	USA-WA1/2020		Anti-RBD IgG ELISA Titer		reciprocal serum dilution that yields an absorbance value of 0.11	days post booster1	0	1155	14		51870	44.91	0.68	28		14190	12.29	0.50																							
5291		19	Harvard Medical School	A homologous or variant booster vaccine after Ad26.COV2.S immunization enhances SARS-CoV-2specific immune responses in rhesus macaques	https://doi.org/10.1126/scitranslmed.abm4996	Peer-reviewed publication	02/22/2022	macque		Ad26.COV2.S	5.00E+10	virus  particles	Ad26.COV2.S	5.00E+10	virus  particles	8-10 months interval	Homologous						1	Binding	ELISA		alpha	B.1.1.7	B.1.1.7		Anti-RBD IgG ELISA Titer		reciprocal serum dilution that yields an absorbance value of 0.12	days post booster1	0	470	14		27404	58.31	1.00	28		16485	35.07	1.00																							
5292		19	Harvard Medical School	A homologous or variant booster vaccine after Ad26.COV2.S immunization enhances SARS-CoV-2specific immune responses in rhesus macaques	https://doi.org/10.1126/scitranslmed.abm4996	Peer-reviewed publication	02/22/2022	macque		Ad26.COV2.S	5.00E+10	virus  particles	Ad26.COV2.S.351	5.00E+10	virus  particles	8-10 months interval	Variant						1	Binding	ELISA		alpha	B.1.1.7	B.1.1.7		Anti-RBD IgG ELISA Titer		reciprocal serum dilution that yields an absorbance value of 0.13	days post booster1	0	722	14		51455	71.27	1.22	28		11478	15.90	0.45																							
5293		19	Harvard Medical School	A homologous or variant booster vaccine after Ad26.COV2.S immunization enhances SARS-CoV-2specific immune responses in rhesus macaques	https://doi.org/10.1126/scitranslmed.abm4996	Peer-reviewed publication	02/22/2022	macque		Ad26.COV2.S	5.00E+10	virus  particles	Ad26.COV2.S	5.00E+10	virus  particles	8-10 months interval	Homologous						1	Binding	ELISA		beta	B.1.351	B.1.351		Anti-RBD IgG ELISA Titer		reciprocal serum dilution that yields an absorbance value of 0.14	days post booster1	0	504	14		24244	48.10	1.00	28		9693	19.23	1.00																							
5294		19	Harvard Medical School	A homologous or variant booster vaccine after Ad26.COV2.S immunization enhances SARS-CoV-2specific immune responses in rhesus macaques	https://doi.org/10.1126/scitranslmed.abm4996	Peer-reviewed publication	02/22/2022	macque		Ad26.COV2.S	5.00E+10	virus  particles	Ad26.COV2.S.351	5.00E+10	virus  particles	8-10 months interval	Variant						1	Binding	ELISA		beta	B.1.351	B.1.351		Anti-RBD IgG ELISA Titer		reciprocal serum dilution that yields an absorbance value of 0.15	days post booster1	0	823	14		46912	57.00	1.19	28		9677	11.76	0.61																							
5295		19	Harvard Medical School	A homologous or variant booster vaccine after Ad26.COV2.S immunization enhances SARS-CoV-2specific immune responses in rhesus macaques	https://doi.org/10.1126/scitranslmed.abm4996	Peer-reviewed publication	02/22/2022	macque		Ad26.COV2.S	5.00E+10	virus  particles	Ad26.COV2.S	5.00E+10	virus  particles	8-10 months interval	Homologous						1	Binding	ELISA		kappa	B.1.617.1	B.1.617.1		Anti-RBD IgG ELISA Titer		reciprocal serum dilution that yields an absorbance value of 0.18	days post booster1	0	204	14		10336	50.67	1.00	28		5982	29.32	1.00																							
5296		19	Harvard Medical School	A homologous or variant booster vaccine after Ad26.COV2.S immunization enhances SARS-CoV-2specific immune responses in rhesus macaques	https://doi.org/10.1126/scitranslmed.abm4996	Peer-reviewed publication	02/22/2022	macque		Ad26.COV2.S	5.00E+10	virus  particles	Ad26.COV2.S.351	5.00E+10	virus  particles	8-10 months interval	Variant						1	Binding	ELISA		kappa	B.1.617.1	B.1.617.1		Anti-RBD IgG ELISA Titer		reciprocal serum dilution that yields an absorbance value of 0.19	days post booster1	0	414	14		34142	82.47	1.63	28		14944	36.10	1.23																							
5297		19	Harvard Medical School	A homologous or variant booster vaccine after Ad26.COV2.S immunization enhances SARS-CoV-2specific immune responses in rhesus macaques	https://doi.org/10.1126/scitranslmed.abm4996	Peer-reviewed publication	02/22/2022	macque		Ad26.COV2.S	5.00E+10	virus  particles	Ad26.COV2.S	5.00E+10	virus  particles	8-10 months interval	Homologous						1	Binding	ELISA		delta	B.1.617.2	B.1.617.2		Anti-RBD IgG ELISA Titer		reciprocal serum dilution that yields an absorbance value of 0.20	days post booster1	0	597	14		18560	31.09	1.00	28		11779	19.73	1.00																							
5298		19	Harvard Medical School	A homologous or variant booster vaccine after Ad26.COV2.S immunization enhances SARS-CoV-2specific immune responses in rhesus macaques	https://doi.org/10.1126/scitranslmed.abm4996	Peer-reviewed publication	02/22/2022	macque		Ad26.COV2.S	5.00E+10	virus  particles	Ad26.COV2.S.351	5.00E+10	virus  particles	8-10 months interval	Variant						1	Binding	ELISA		delta	B.1.617.2	B.1.617.2		Anti-RBD IgG ELISA Titer		reciprocal serum dilution that yields an absorbance value of 0.21	days post booster1	0	818	14		63541	77.68	2.50	28		22569	27.59	1.40																							
5299		19	Harvard Medical School	A homologous or variant booster vaccine after Ad26.COV2.S immunization enhances SARS-CoV-2specific immune responses in rhesus macaques	https://doi.org/10.1126/scitranslmed.abm4996	Peer-reviewed publication	02/22/2022	macque		Ad26.COV2.S	5.00E+10	virus  particles	Ad26.COV2.S	5.00E+10	virus  particles	8-10 months interval	Homologous						1	Binding	ELISA		Omicron	B.1.1.529	B.1.1.529		Anti-RBD IgG ELISA Titer		reciprocal serum dilution that yields an absorbance value of 0.22	days post booster1			28		2517		1.00																												
5300		19	Harvard Medical School	A homologous or variant booster vaccine after Ad26.COV2.S immunization enhances SARS-CoV-2specific immune responses in rhesus macaques	https://doi.org/10.1126/scitranslmed.abm4996	Peer-reviewed publication	02/22/2022	macque		Ad26.COV2.S	5.00E+10	virus  particles	Ad26.COV2.S.351	5.00E+10	virus  particles	8-10 months interval	Variant						1	Binding	ELISA		Omicron	B.1.1.529	B.1.1.529		Anti-RBD IgG ELISA Titer		reciprocal serum dilution that yields an absorbance value of 0.23	days post booster1			28		4648		1.85																												
5328		20	Harvard Medical School	Homologous and Heterologous Vaccine Boost Strategies for Humoral and Cellular Immunologic Coverage of the SARS-CoV-2 Omicron Variant	https://doi.org/10.1101/2021.12.02.21267198	Pre-print	12/30/2021	human		BNT162b2	30	?g	Ad26.COV2.S	5.00E+10	virus  particles	6 months interval	Heterologous						2	Binding	ELISA		beta	B.1.351	B.1.351		Anti-RBD IgG ELISA Titer			weeks post booster1	0	266	2		5375	20.21	0.29	4		13095	49.23	1.29																							
5301		19	Harvard Medical School	A homologous or variant booster vaccine after Ad26.COV2.S immunization enhances SARS-CoV-2specific immune responses in rhesus macaques	https://doi.org/10.1126/scitranslmed.abm4996	Peer-reviewed publication	02/22/2022	macque		Ad26.COV2.S	5.00E+10	virus  particles	Ad26.COV2.S	5.00E+10	virus  particles	8-10 months interval	Homologous						2	Neutralization	Pseudotyped virus assay	Luciferase	USA-WA1/2020	USA-WA1/2020	USA-WA1/2020		NT50 Median		reciprocal serum dilution that yields an absorbance value of 0.10	days post booster1	0	62	14		2690	43.39	1.00	28		1421	22.92	1.00																							
5302		19	Harvard Medical School	A homologous or variant booster vaccine after Ad26.COV2.S immunization enhances SARS-CoV-2specific immune responses in rhesus macaques	https://doi.org/10.1126/scitranslmed.abm4996	Peer-reviewed publication	02/22/2022	macque		Ad26.COV2.S	5.00E+10	virus  particles	Ad26.COV2.S.351	5.00E+10	virus  particles	8-10 months interval	Variant						2	Neutralization	Pseudotyped virus assay	Luciferase	USA-WA1/2020	USA-WA1/2020	USA-WA1/2020		NT50 Median		reciprocal serum dilution that yields an absorbance value of 0.11	days post booster1	0	61	14		2522	41.34	0.95	28		1641	26.90	1.17																							
5303		19	Harvard Medical School	A homologous or variant booster vaccine after Ad26.COV2.S immunization enhances SARS-CoV-2specific immune responses in rhesus macaques	https://doi.org/10.1126/scitranslmed.abm4996	Peer-reviewed publication	02/22/2022	macque		Ad26.COV2.S	5.00E+10	virus  particles	Ad26.COV2.S	5.00E+10	virus  particles	8-10 months interval	Homologous						2	Neutralization	Pseudotyped virus assay	Luciferase	alpha	B.1.1.7	B.1.1.7		NT50 Median		reciprocal serum dilution that yields an absorbance value of 0.12	days post booster1	0	72	14		1674	23.25	1.00	28		1487	20.65	1.00																							
5304		19	Harvard Medical School	A homologous or variant booster vaccine after Ad26.COV2.S immunization enhances SARS-CoV-2specific immune responses in rhesus macaques	https://doi.org/10.1126/scitranslmed.abm4996	Peer-reviewed publication	02/22/2022	macque		Ad26.COV2.S	5.00E+10	virus  particles	Ad26.COV2.S.351	5.00E+10	virus  particles	8-10 months interval	Variant						2	Neutralization	Pseudotyped virus assay	Luciferase	alpha	B.1.1.7	B.1.1.7		NT50 Median		reciprocal serum dilution that yields an absorbance value of 0.13	days post booster1	0	64	14		1526	23.84	1.03	28		1511	23.61	1.14																							
5305		19	Harvard Medical School	A homologous or variant booster vaccine after Ad26.COV2.S immunization enhances SARS-CoV-2specific immune responses in rhesus macaques	https://doi.org/10.1126/scitranslmed.abm4996	Peer-reviewed publication	02/22/2022	macque		Ad26.COV2.S	5.00E+10	virus  particles	Ad26.COV2.S	5.00E+10	virus  particles	8-10 months interval	Homologous						2	Neutralization	Pseudotyped virus assay	Luciferase	beta	B.1.351	B.1.351		NT50 Median		reciprocal serum dilution that yields an absorbance value of 0.14	days post booster1	0	34	14		1414	41.59	1.00	28		1202	35.35	1.00																							
5306		19	Harvard Medical School	A homologous or variant booster vaccine after Ad26.COV2.S immunization enhances SARS-CoV-2specific immune responses in rhesus macaques	https://doi.org/10.1126/scitranslmed.abm4996	Peer-reviewed publication	02/22/2022	macque		Ad26.COV2.S	5.00E+10	virus  particles	Ad26.COV2.S.351	5.00E+10	virus  particles	8-10 months interval	Variant						2	Neutralization	Pseudotyped virus assay	Luciferase	beta	B.1.351	B.1.351		NT50 Median		reciprocal serum dilution that yields an absorbance value of 0.15	days post booster1	0	38	14		4038	106.26	2.56	28		2296	60.42	1.71																							
5307		19	Harvard Medical School	A homologous or variant booster vaccine after Ad26.COV2.S immunization enhances SARS-CoV-2specific immune responses in rhesus macaques	https://doi.org/10.1126/scitranslmed.abm4996	Peer-reviewed publication	02/22/2022	macque		Ad26.COV2.S	5.00E+10	virus  particles	Ad26.COV2.S	5.00E+10	virus  particles	8-10 months interval	Homologous						2	Neutralization	Pseudotyped virus assay	Luciferase	gamma	P.1	P.1		NT50 Median		reciprocal serum dilution that yields an absorbance value of 0.16	days post booster1	0	59	14		1538	26.07	1.00	28		1385	23.47	1.00																							
5308		19	Harvard Medical School	A homologous or variant booster vaccine after Ad26.COV2.S immunization enhances SARS-CoV-2specific immune responses in rhesus macaques	https://doi.org/10.1126/scitranslmed.abm4996	Peer-reviewed publication	02/22/2022	macque		Ad26.COV2.S	5.00E+10	virus  particles	Ad26.COV2.S.351	5.00E+10	virus  particles	8-10 months interval	Variant						2	Neutralization	Pseudotyped virus assay	Luciferase	gamma	P.1	P.1		NT50 Median		reciprocal serum dilution that yields an absorbance value of 0.17	days post booster1	0	47	14		2083	44.32	1.70	28		1221	25.98	1.11																							
5309		19	Harvard Medical School	A homologous or variant booster vaccine after Ad26.COV2.S immunization enhances SARS-CoV-2specific immune responses in rhesus macaques	https://doi.org/10.1126/scitranslmed.abm4996	Peer-reviewed publication	02/22/2022	macque		Ad26.COV2.S	5.00E+10	virus  particles	Ad26.COV2.S	5.00E+10	virus  particles	8-10 months interval	Homologous						2	Neutralization	Pseudotyped virus assay	Luciferase	kappa	B.1.617.1	B.1.617.1		NT50 Median		reciprocal serum dilution that yields an absorbance value of 0.18	days post booster1	0	40	14		1461	36.53	1.00	28		1256	31.40	1.00																							
5310		19	Harvard Medical School	A homologous or variant booster vaccine after Ad26.COV2.S immunization enhances SARS-CoV-2specific immune responses in rhesus macaques	https://doi.org/10.1126/scitranslmed.abm4996	Peer-reviewed publication	02/22/2022	macque		Ad26.COV2.S	5.00E+10	virus  particles	Ad26.COV2.S.351	5.00E+10	virus  particles	8-10 months interval	Variant						2	Neutralization	Pseudotyped virus assay	Luciferase	kappa	B.1.617.1	B.1.617.1		NT50 Median		reciprocal serum dilution that yields an absorbance value of 0.19	days post booster1	0	36	14		1771	49.19	1.35	28		1259	34.97	1.11																							
5311		19	Harvard Medical School	A homologous or variant booster vaccine after Ad26.COV2.S immunization enhances SARS-CoV-2specific immune responses in rhesus macaques	https://doi.org/10.1126/scitranslmed.abm4996	Peer-reviewed publication	02/22/2022	macque		Ad26.COV2.S	5.00E+10	virus  particles	Ad26.COV2.S	5.00E+10	virus  particles	8-10 months interval	Homologous						2	Neutralization	Pseudotyped virus assay	Luciferase	delta	B.1.617.2	B.1.617.2		NT50 Median		reciprocal serum dilution that yields an absorbance value of 0.20	days post booster1	0	37	14		1532	41.41	1.00	28		1448	39.14	1.00																							
5312		19	Harvard Medical School	A homologous or variant booster vaccine after Ad26.COV2.S immunization enhances SARS-CoV-2specific immune responses in rhesus macaques	https://doi.org/10.1126/scitranslmed.abm4996	Peer-reviewed publication	02/22/2022	macque		Ad26.COV2.S	5.00E+10	virus  particles	Ad26.COV2.S.351	5.00E+10	virus  particles	8-10 months interval	Variant						2	Neutralization	Pseudotyped virus assay	Luciferase	delta	B.1.617.2	B.1.617.2		NT50 Median		reciprocal serum dilution that yields an absorbance value of 0.21	days post booster1	0	38	14		1541	40.55	0.98	28		1050	27.63	0.71																							
5901																																																																					
5902																																																																					
5903																																																																					
5313		19	Harvard Medical School	A homologous or variant booster vaccine after Ad26.COV2.S immunization enhances SARS-CoV-2specific immune responses in rhesus macaques	https://doi.org/10.1126/scitranslmed.abm4996	Peer-reviewed publication	02/22/2022	macque		Ad26.COV2.S	5.00E+10	virus  particles	Ad26.COV2.S	5.00E+10	virus  particles	8-10 months interval	Homologous						2	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	B.1.1.529		NT50 Median		reciprocal serum dilution that yields an absorbance value of 0.22	days post booster1			28		415																														
5314		19	Harvard Medical School	A homologous or variant booster vaccine after Ad26.COV2.S immunization enhances SARS-CoV-2specific immune responses in rhesus macaques	https://doi.org/10.1126/scitranslmed.abm4996	Peer-reviewed publication	02/22/2022	macque		Ad26.COV2.S	5.00E+10	virus  particles	Ad26.COV2.S.351	5.00E+10	virus  particles	8-10 months interval	Variant						2	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	B.1.1.529		NT50 Median		reciprocal serum dilution that yields an absorbance value of 0.23	days post booster1			28		701																														
5315		20	Harvard Medical School	Homologous and Heterologous Vaccine Boost Strategies for Humoral and Cellular Immunologic Coverage of the SARS-CoV-2 Omicron Variant	https://doi.org/10.1101/2021.12.02.21267198	Pre-print	12/30/2021	human		BNT162b2	30	?g	BNT162b2	30	?g	6 months interval	Homologous						1	Neutralization	Pseudotyped virus assay	Luciferase	USA-WA1/2020	USA-WA1/2020	USA-WA1/2020		NT50 Median			weeks post booster1	0	129	2		7554	58.56	1.00	4		3986	30.90	1.00																							
5316		20	Harvard Medical School	Homologous and Heterologous Vaccine Boost Strategies for Humoral and Cellular Immunologic Coverage of the SARS-CoV-2 Omicron Variant	https://doi.org/10.1101/2021.12.02.21267198	Pre-print	12/30/2021	human		BNT162b2	30	?g	Ad26.COV2.S	5.00E+10	virus  particles	6 months interval	Heterologous						1	Neutralization	Pseudotyped virus assay	Luciferase	USA-WA1/2020	USA-WA1/2020	USA-WA1/2020		NT50 Median			weeks post booster1	0	281	2		1462	5.20	0.09	4		3597	12.80	0.41																							
5317		20	Harvard Medical School	Homologous and Heterologous Vaccine Boost Strategies for Humoral and Cellular Immunologic Coverage of the SARS-CoV-2 Omicron Variant	https://doi.org/10.1101/2021.12.02.21267198	Pre-print	12/30/2021	human		BNT162b2	30	?g	BNT162b2	30	?g	6 months interval	Homologous						1	Neutralization	Pseudotyped virus assay	Luciferase	delta	B.1.617.2	B.1.617.2		NT50 Median			weeks post booster1	0	56	2		3040	54.29	1.00	4		1541	27.52	1.00																							
5318		20	Harvard Medical School	Homologous and Heterologous Vaccine Boost Strategies for Humoral and Cellular Immunologic Coverage of the SARS-CoV-2 Omicron Variant	https://doi.org/10.1101/2021.12.02.21267198	Pre-print	12/30/2021	human		BNT162b2	30	?g	Ad26.COV2.S	5.00E+10	virus  particles	6 months interval	Heterologous						1	Neutralization	Pseudotyped virus assay	Luciferase	delta	B.1.617.2	B.1.617.2		NT50 Median			weeks post booster1	0	66	2		1009	15.29	0.28	4		2148	32.55	1.18																							
5319		20	Harvard Medical School	Homologous and Heterologous Vaccine Boost Strategies for Humoral and Cellular Immunologic Coverage of the SARS-CoV-2 Omicron Variant	https://doi.org/10.1101/2021.12.02.21267198	Pre-print	12/30/2021	human		BNT162b2	30	?g	BNT162b2	30	?g	6 months interval	Homologous						1	Neutralization	Pseudotyped virus assay	Luciferase	beta	B.1.351	B.1.351		NT50 Median			weeks post booster1	0	34	2		1865	54.85	1.00	4		1472	43.29	1.00																							
5320		20	Harvard Medical School	Homologous and Heterologous Vaccine Boost Strategies for Humoral and Cellular Immunologic Coverage of the SARS-CoV-2 Omicron Variant	https://doi.org/10.1101/2021.12.02.21267198	Pre-print	12/30/2021	human		BNT162b2	30	?g	Ad26.COV2.S	5.00E+10	virus  particles	6 months interval	Heterologous						1	Neutralization	Pseudotyped virus assay	Luciferase	beta	B.1.351	B.1.351		NT50 Median			weeks post booster1	0	57	2		899	15.77	0.29	4		1924	33.75	0.78																							
5321		20	Harvard Medical School	Homologous and Heterologous Vaccine Boost Strategies for Humoral and Cellular Immunologic Coverage of the SARS-CoV-2 Omicron Variant	https://doi.org/10.1101/2021.12.02.21267198	Pre-print	12/30/2021	human		BNT162b2	30	?g	BNT162b2	30	?g	6 months interval	Homologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	B.1.1.529		NT50 Median			weeks post booster1	0	20	2		1018	50.90	1.00	4		345	17.25	1.00																							
5322		20	Harvard Medical School	Homologous and Heterologous Vaccine Boost Strategies for Humoral and Cellular Immunologic Coverage of the SARS-CoV-2 Omicron Variant	https://doi.org/10.1101/2021.12.02.21267198	Pre-print	12/30/2021	human		BNT162b2	30	?g	Ad26.COV2.S	5.00E+10	virus  particles	6 months interval	Heterologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	B.1.1.529		NT50 Median			weeks post booster1	0	21	2		591	28.14	0.55	4		859	40.90	2.37																							
5323		20	Harvard Medical School	Homologous and Heterologous Vaccine Boost Strategies for Humoral and Cellular Immunologic Coverage of the SARS-CoV-2 Omicron Variant	https://doi.org/10.1101/2021.12.02.21267198	Pre-print	12/30/2021	human		BNT162b2	30	?g	BNT162b2	30	?g	6 months interval	Homologous						2	Binding	ELISA		USA-WA1/2020	USA-WA1/2020	USA-WA1/2020		Anti-RBD IgG ELISA Titer			weeks post booster1	0	502	2		27416	54.61	1.00	4		14747	29.38	1.00																							
5324		20	Harvard Medical School	Homologous and Heterologous Vaccine Boost Strategies for Humoral and Cellular Immunologic Coverage of the SARS-CoV-2 Omicron Variant	https://doi.org/10.1101/2021.12.02.21267198	Pre-print	12/30/2021	human		BNT162b2	30	?g	Ad26.COV2.S	5.00E+10	virus  particles	6 months interval	Heterologous						2	Binding	ELISA		USA-WA1/2020	USA-WA1/2020	USA-WA1/2020		Anti-RBD IgG ELISA Titer			weeks post booster1	0	629	2		11264	17.91	0.33	4		16311	25.93	0.88																							
5325		20	Harvard Medical School	Homologous and Heterologous Vaccine Boost Strategies for Humoral and Cellular Immunologic Coverage of the SARS-CoV-2 Omicron Variant	https://doi.org/10.1101/2021.12.02.21267198	Pre-print	12/30/2021	human		BNT162b2	30	?g	BNT162b2	30	?g	6 months interval	Homologous						2	Binding	ELISA		delta	B.1.617.2	B.1.617.2		Anti-RBD IgG ELISA Titer			weeks post booster1	0	587	2		25040	42.66	1.00	4		13037	22.21	1.00																							
5326		20	Harvard Medical School	Homologous and Heterologous Vaccine Boost Strategies for Humoral and Cellular Immunologic Coverage of the SARS-CoV-2 Omicron Variant	https://doi.org/10.1101/2021.12.02.21267198	Pre-print	12/30/2021	human		BNT162b2	30	?g	Ad26.COV2.S	5.00E+10	virus  particles	6 months interval	Heterologous						2	Binding	ELISA		delta	B.1.617.2	B.1.617.2		Anti-RBD IgG ELISA Titer			weeks post booster1	0	577	2		10817	18.75	0.44	4		14842	25.72	1.16																							
5327		20	Harvard Medical School	Homologous and Heterologous Vaccine Boost Strategies for Humoral and Cellular Immunologic Coverage of the SARS-CoV-2 Omicron Variant	https://doi.org/10.1101/2021.12.02.21267198	Pre-print	12/30/2021	human		BNT162b2	30	?g	BNT162b2	30	?g	6 months interval	Homologous						2	Binding	ELISA		beta	B.1.351	B.1.351		Anti-RBD IgG ELISA Titer			weeks post booster1	0	189	2		13342	70.59	1.00	4		7230	38.25	1.00																							
5329		20	Harvard Medical School	Homologous and Heterologous Vaccine Boost Strategies for Humoral and Cellular Immunologic Coverage of the SARS-CoV-2 Omicron Variant	https://doi.org/10.1101/2021.12.02.21267198	Pre-print	12/30/2021	human		BNT162b2	30	?g	BNT162b2	30	?g	6 months interval	Homologous						2	Binding	ELISA		Omicron	B.1.1.529	B.1.1.529		Anti-RBD IgG ELISA Titer			weeks post booster1	0	77	2		4301	55.86	1.00	4		1554	20.18	1.00																							
5330		20	Harvard Medical School	Homologous and Heterologous Vaccine Boost Strategies for Humoral and Cellular Immunologic Coverage of the SARS-CoV-2 Omicron Variant	https://doi.org/10.1101/2021.12.02.21267198	Pre-print	12/30/2021	human		BNT162b2	30	?g	Ad26.COV2.S	5.00E+10	virus  particles	6 months interval	Heterologous						2	Binding	ELISA		Omicron	B.1.1.529	B.1.1.529		Anti-RBD IgG ELISA Titer			weeks post booster1	0	88	2		994	11.30	0.20	4		1883	21.40	1.06																							
5331		20	Harvard Medical School	Homologous and Heterologous Vaccine Boost Strategies for Humoral and Cellular Immunologic Coverage of the SARS-CoV-2 Omicron Variant	https://doi.org/10.1101/2021.12.02.21267198	Pre-print	12/30/2021	human		BNT162b2	30	?g	BNT162b2	30	?g	6 months interval	Homologous						3	Neutralization	Live virus replication assay	Luciferase	USA-WA1/2020	USA-WA1/2020	USA-WA1/2020		NT50 GMT			weeks post booster1	0	439	2		20675	47.10	1.00	4		13731	31.28	1.00																							
5332		20	Harvard Medical School	Homologous and Heterologous Vaccine Boost Strategies for Humoral and Cellular Immunologic Coverage of the SARS-CoV-2 Omicron Variant	https://doi.org/10.1101/2021.12.02.21267198	Pre-print	12/30/2021	human		BNT162b2	30	?g	Ad26.COV2.S	5.00E+10	virus  particles	6 months interval	Heterologous						3	Neutralization	Live virus replication assay	Luciferase	USA-WA1/2020	USA-WA1/2020	USA-WA1/2020		NT50 GMT			weeks post booster1	0	437	2		7962	18.22	0.39	4		11556	26.44	0.85																							
5333		20	Harvard Medical School	Homologous and Heterologous Vaccine Boost Strategies for Humoral and Cellular Immunologic Coverage of the SARS-CoV-2 Omicron Variant	https://doi.org/10.1101/2021.12.02.21267198	Pre-print	12/30/2021	human		BNT162b2	30	?g	BNT162b2	30	?g	6 months interval	Homologous						3	Neutralization	Live virus replication assay	Luciferase	beta	B.1.351	B.1.351		NT50 GMT			weeks post booster1	0	358	2		19904	55.60	1.00	4		5815	16.24	1.00																							
5334		20	Harvard Medical School	Homologous and Heterologous Vaccine Boost Strategies for Humoral and Cellular Immunologic Coverage of the SARS-CoV-2 Omicron Variant	https://doi.org/10.1101/2021.12.02.21267198	Pre-print	12/30/2021	human		BNT162b2	30	?g	Ad26.COV2.S	5.00E+10	virus  particles	6 months interval	Heterologous						3	Neutralization	Live virus replication assay	Luciferase	beta	B.1.351	B.1.351		NT50 GMT			weeks post booster1	0	277	2		3023	10.91	0.20	4		4508	16.27	1.00																							
5335		21	University of Southampton	Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial	https://doi.org/10.1016/j.jinf.2022.04.018	Peer-reviewed publication	04/09/2022	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	ChAdOx1 nCoV-19	5.00E+10	virus  particles	6 months interval	Homologous						1	Binding	ELISA						Anti-spike IgG GM	ELU/mL		days post booster1			28		2388		1.00	84		1411		1.00																							
5336		21	University of Southampton	Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial	https://doi.org/10.1016/j.jinf.2022.04.018	Peer-reviewed publication	04/09/2022	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	BNT162b2	30	?g	6 months interval	Heterologous						1	Binding	ELISA						Anti-spike IgG GM	ELU/mL		days post booster1			28		20556		8.61	84		8674		6.15																							
5337		21	University of Southampton	Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial	https://doi.org/10.1016/j.jinf.2022.04.018	Peer-reviewed publication	04/09/2022	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	CVnCoV	12	?g	6 months interval	Heterologous						1	Binding	ELISA						Anti-spike IgG GM	ELU/mL		days post booster1			28		3880		1.62	84		2068		1.47																							
5338		21	University of Southampton	Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial	https://doi.org/10.1016/j.jinf.2022.04.018	Peer-reviewed publication	04/09/2022	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	BNT162b2	15	?g	6 months interval	Heterologous						1	Binding	ELISA						Anti-spike IgG GM	ELU/mL		days post booster1			28		15492		6.49	84		7308		5.18																							
5339		21	University of Southampton	Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial	https://doi.org/10.1016/j.jinf.2022.04.018	Peer-reviewed publication	04/09/2022	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	mRNA-1273	100	?g	6 months interval	Heterologous						1	Binding	ELISA						Anti-spike IgG GM	ELU/mL		days post booster1			28		31387		13.14	84		14489		10.27																							
5340		21	University of Southampton	Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial	https://doi.org/10.1016/j.jinf.2022.04.018	Peer-reviewed publication	04/09/2022	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	Ad26.COV2.S	5.00E+10	virus  particles	6 months interval	Heterologous						1	Binding	ELISA						Anti-spike IgG GM	ELU/mL		days post booster1			28		5780		2.42	84		4105		2.91																							
5341		21	University of Southampton	Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial	https://doi.org/10.1016/j.jinf.2022.04.018	Peer-reviewed publication	04/09/2022	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	NVX-CoV2373	5	?g	6 months interval	Heterologous						1	Binding	ELISA						Anti-spike IgG GM	ELU/mL		days post booster1			28		6883		2.88	84		3407		2.41																							
5342		21	University of Southampton	Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial	https://doi.org/10.1016/j.jinf.2022.04.018	Peer-reviewed publication	04/09/2022	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	NVX-CoV2373	2.5	?g	6 months interval	Heterologous						1	Binding	ELISA						Anti-spike IgG GM	ELU/mL		days post booster1			28		4571		1.91	84		2143		1.52																							
5904																																																																					
5905																																																																					
5906																																																																					
5343		21	University of Southampton	Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial	https://doi.org/10.1016/j.jinf.2022.04.018	Peer-reviewed publication	04/09/2022	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	VLA2001	33	antigen units	6 months interval	Heterologous						1	Binding	ELISA						Anti-spike IgG GM	ELU/mL		days post booster1			28		1745		0.73	84		1156		0.82																							
5344		21	University of Southampton	Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial	https://doi.org/10.1016/j.jinf.2022.04.018	Peer-reviewed publication	04/09/2022	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	VLA2001	16.5	antigen units	6 months interval	Heterologous						1	Binding	ELISA						Anti-spike IgG GM	ELU/mL		days post booster1			28		1423		0.60	84		893		0.63																							
5345		21	University of Southampton	Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial	https://doi.org/10.1016/j.jinf.2022.04.018	Peer-reviewed publication	04/09/2022	human		BNT162b2	30	?g	BNT162b2	30	?g	6 months interval	Homologous						1	Binding	ELISA						Anti-spike IgG GM	ELU/mL		days post booster1			28		27307		1.00	84		13025		1.00																							
5346		21	University of Southampton	Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial	https://doi.org/10.1016/j.jinf.2022.04.018	Peer-reviewed publication	04/09/2022	human		BNT162b2	30	?g	CVnCoV	12	?g	6 months interval	Heterologous						1	Binding	ELISA						Anti-spike IgG GM	ELU/mL		days post booster1			28		7602		0.28	84		4649		0.36																							
5347		21	University of Southampton	Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial	https://doi.org/10.1016/j.jinf.2022.04.018	Peer-reviewed publication	04/09/2022	human		BNT162b2	30	?g	BNT162b2	15	?g	6 months interval	Heterologous						1	Binding	ELISA						Anti-spike IgG GM	ELU/mL		days post booster1			28		23337		0.85	84		11488		0.88																							
5348		21	University of Southampton	Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial	https://doi.org/10.1016/j.jinf.2022.04.018	Peer-reviewed publication	04/09/2022	human		BNT162b2	30	?g	mRNA-1273	100	?g	6 months interval	Heterologous						1	Binding	ELISA						Anti-spike IgG GM	ELU/mL		days post booster1			28		33690		1.23	84		17718		1.36																							
5349		21	University of Southampton	Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial	https://doi.org/10.1016/j.jinf.2022.04.018	Peer-reviewed publication	04/09/2022	human		BNT162b2	30	?g	ChAdOx1 nCoV-19	5.00E+10	virus  particles	6 months interval	Heterologous						1	Binding	ELISA						Anti-spike IgG GM	ELU/mL		days post booster1			28		13361		0.49	84		9685		0.74																							
5350		21	University of Southampton	Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial	https://doi.org/10.1016/j.jinf.2022.04.018	Peer-reviewed publication	04/09/2022	human		BNT162b2	30	?g	Ad26.COV2.S	5.00E+10	virus  particles	6 months interval	Heterologous						1	Binding	ELISA						Anti-spike IgG GM	ELU/mL		days post booster1			28		17816		0.65	84		14212		1.09																							
5351		21	University of Southampton	Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial	https://doi.org/10.1016/j.jinf.2022.04.018	Peer-reviewed publication	04/09/2022	human		BNT162b2	30	?g	NVX-CoV2373	5	?g	6 months interval	Heterologous						1	Binding	ELISA						Anti-spike IgG GM	ELU/mL		days post booster1			28		10511		0.38	84		5850		0.45																							
5352		21	University of Southampton	Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial	https://doi.org/10.1016/j.jinf.2022.04.018	Peer-reviewed publication	04/09/2022	human		BNT162b2	30	?g	NVX-CoV2373	2.5	?g	6 months interval	Heterologous						1	Binding	ELISA						Anti-spike IgG GM	ELU/mL		days post booster1			28		8449		0.31	84		5051		0.39																							
5353		21	University of Southampton	Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial	https://doi.org/10.1016/j.jinf.2022.04.018	Peer-reviewed publication	04/09/2022	human		BNT162b2	30	?g	VLA2001	33	antigen units	6 months interval	Heterologous						1	Binding	ELISA						Anti-spike IgG GM	ELU/mL		days post booster1			28		4176		0.15	84		2703		0.21																							
5354		21	University of Southampton	Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial	https://doi.org/10.1016/j.jinf.2022.04.018	Peer-reviewed publication	04/09/2022	human		BNT162b2	30	?g	VLA2001	16.5	antigen units	6 months interval	Heterologous						1	Binding	ELISA						Anti-spike IgG GM	ELU/mL		days post booster1			28		3687		0.14	84		2229		0.17																							
5355		21	University of Southampton	Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial	https://doi.org/10.1016/j.jinf.2022.04.018	Peer-reviewed publication	04/09/2022	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	ChAdOx1 nCoV-19	5.00E+10	virus  particles	6 months interval	Homologous						2	Neutralization	Pseudotyped virus assay	Chemiluminescence	VIC	VIC	VIC		NT50 GMT			days post booster1			28		191		1.00	84		127		1.00																							
5356		21	University of Southampton	Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial	https://doi.org/10.1016/j.jinf.2022.04.018	Peer-reviewed publication	04/09/2022	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	BNT162b2	30	?g	6 months interval	Heterologous						2	Neutralization	Pseudotyped virus assay	Chemiluminescence	VIC	VIC	VIC		NT50 GMT			days post booster1			28		1623		8.50	84		639		5.03																							
5907																																																																					
5908																																																																					
5357		21	University of Southampton	Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial	https://doi.org/10.1016/j.jinf.2022.04.018	Peer-reviewed publication	04/09/2022	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	CVnCoV	12	?g	6 months interval	Heterologous						2	Neutralization	Pseudotyped virus assay	Chemiluminescence	VIC	VIC	VIC		NT50 GMT			days post booster1			28		372		1.95	84		188		1.48																							
5358		21	University of Southampton	Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial	https://doi.org/10.1016/j.jinf.2022.04.018	Peer-reviewed publication	04/09/2022	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	BNT162b2	15	?g	6 months interval	Heterologous						2	Neutralization	Pseudotyped virus assay	Chemiluminescence	VIC	VIC	VIC		NT50 GMT			days post booster1			28		1304		6.83	84		585		4.61																							
5359		21	University of Southampton	Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial	https://doi.org/10.1016/j.jinf.2022.04.018	Peer-reviewed publication	04/09/2022	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	mRNA-1273	100	?g	6 months interval	Heterologous						2	Neutralization	Pseudotyped virus assay	Chemiluminescence	VIC	VIC	VIC		NT50 GMT			days post booster1			28		2334		12.22	84		1061		8.35																							
5360		21	University of Southampton	Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial	https://doi.org/10.1016/j.jinf.2022.04.018	Peer-reviewed publication	04/09/2022	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	Ad26.COV2.S	5.00E+10	virus  particles	6 months interval	Heterologous						2	Neutralization	Pseudotyped virus assay	Chemiluminescence	VIC	VIC	VIC		NT50 GMT			days post booster1			28		605		3.17	84		410		3.23																							
5361		21	University of Southampton	Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial	https://doi.org/10.1016/j.jinf.2022.04.018	Peer-reviewed publication	04/09/2022	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	NVX-CoV2373	5	?g	6 months interval	Heterologous						2	Neutralization	Pseudotyped virus assay	Chemiluminescence	VIC	VIC	VIC		NT50 GMT			days post booster1			28		718		3.76	84		346		2.72																							
5362		21	University of Southampton	Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial	https://doi.org/10.1016/j.jinf.2022.04.018	Peer-reviewed publication	04/09/2022	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	NVX-CoV2373	2.5	?g	6 months interval	Heterologous						2	Neutralization	Pseudotyped virus assay	Chemiluminescence	VIC	VIC	VIC		NT50 GMT			days post booster1			28		465		2.43	84		182		1.43																							
5363		21	University of Southampton	Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial	https://doi.org/10.1016/j.jinf.2022.04.018	Peer-reviewed publication	04/09/2022	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	VLA2001	33	antigen units	6 months interval	Heterologous						2	Neutralization	Pseudotyped virus assay	Chemiluminescence	VIC	VIC	VIC		NT50 GMT			days post booster1			28		196		1.03	84		110		0.87																							
5364		21	University of Southampton	Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial	https://doi.org/10.1016/j.jinf.2022.04.018	Peer-reviewed publication	04/09/2022	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	VLA2001	16.5	antigen units	6 months interval	Heterologous						2	Neutralization	Pseudotyped virus assay	Chemiluminescence	VIC	VIC	VIC		NT50 GMT			days post booster1			28		151		0.79	84		84		0.66																							
5365		21	University of Southampton	Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial	https://doi.org/10.1016/j.jinf.2022.04.018	Peer-reviewed publication	04/09/2022	human		BNT162b2	30	?g	BNT162b2	30	?g	6 months interval	Homologous						2	Neutralization	Pseudotyped virus assay	Chemiluminescence	VIC	VIC	VIC		NT50 GMT			days post booster1			28		1767		1.00	84		789		1.00																							
5366		21	University of Southampton	Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial	https://doi.org/10.1016/j.jinf.2022.04.018	Peer-reviewed publication	04/09/2022	human		BNT162b2	30	?g	CVnCoV	12	?g	6 months interval	Heterologous						2	Neutralization	Pseudotyped virus assay	Chemiluminescence	VIC	VIC	VIC		NT50 GMT			days post booster1			28		479		0.27	84		277		0.35																							
5367		21	University of Southampton	Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial	https://doi.org/10.1016/j.jinf.2022.04.018	Peer-reviewed publication	04/09/2022	human		BNT162b2	30	?g	BNT162b2	15	?g	6 months interval	Heterologous						2	Neutralization	Pseudotyped virus assay	Chemiluminescence	VIC	VIC	VIC		NT50 GMT			days post booster1			28		1370		0.78	84		691		0.88																							
5368		21	University of Southampton	Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial	https://doi.org/10.1016/j.jinf.2022.04.018	Peer-reviewed publication	04/09/2022	human		BNT162b2	30	?g	mRNA-1273	100	?g	6 months interval	Heterologous						2	Neutralization	Pseudotyped virus assay	Chemiluminescence	VIC	VIC	VIC		NT50 GMT			days post booster1			28		2022		1.15	84		971		1.23																							
5369		21	University of Southampton	Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial	https://doi.org/10.1016/j.jinf.2022.04.018	Peer-reviewed publication	04/09/2022	human		BNT162b2	30	?g	ChAdOx1 nCoV-19	5.00E+10	virus  particles	6 months interval	Heterologous						2	Neutralization	Pseudotyped virus assay	Chemiluminescence	VIC	VIC	VIC		NT50 GMT			days post booster1			28		956		0.54	84		718		0.91																							
5909																																																																					
5910																																																																					
5911																																																																					
5370		21	University of Southampton	Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial	https://doi.org/10.1016/j.jinf.2022.04.018	Peer-reviewed publication	04/09/2022	human		BNT162b2	30	?g	Ad26.COV2.S	5.00E+10	virus  particles	6 months interval	Heterologous						2	Neutralization	Pseudotyped virus assay	Chemiluminescence	VIC	VIC	VIC		NT50 GMT			days post booster1			28		1521		0.86	84		1252		1.59																							
5371		21	University of Southampton	Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial	https://doi.org/10.1016/j.jinf.2022.04.018	Peer-reviewed publication	04/09/2022	human		BNT162b2	30	?g	NVX-CoV2373	5	?g	6 months interval	Heterologous						2	Neutralization	Pseudotyped virus assay	Chemiluminescence	VIC	VIC	VIC		NT50 GMT			days post booster1			28		738		0.42	84		406		0.51																							
5372		21	University of Southampton	Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial	https://doi.org/10.1016/j.jinf.2022.04.018	Peer-reviewed publication	04/09/2022	human		BNT162b2	30	?g	NVX-CoV2373	2.5	?g	6 months interval	Heterologous						2	Neutralization	Pseudotyped virus assay	Chemiluminescence	VIC	VIC	VIC		NT50 GMT			days post booster1			28		591		0.34	84		290		0.37																							
5373		21	University of Southampton	Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial	https://doi.org/10.1016/j.jinf.2022.04.018	Peer-reviewed publication	04/09/2022	human		BNT162b2	30	?g	VLA2001	33	antigen units	6 months interval	Heterologous						2	Neutralization	Pseudotyped virus assay	Chemiluminescence	VIC	VIC	VIC		NT50 GMT			days post booster1			28		285		0.16	84		161		0.20																							
5374		21	University of Southampton	Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial	https://doi.org/10.1016/j.jinf.2022.04.018	Peer-reviewed publication	04/09/2022	human		BNT162b2	30	?g	VLA2001	16.5	antigen units	6 months interval	Heterologous						2	Neutralization	Pseudotyped virus assay	Chemiluminescence	VIC	VIC	VIC		NT50 GMT			days post booster1			28		230		0.13	84		135		0.17																							
5375		21	University of Southampton	Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial	https://doi.org/10.1016/j.jinf.2022.04.018	Peer-reviewed publication	04/09/2022	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	ChAdOx1 nCoV-19	5.00E+10	virus  particles	6 months interval	Homologous						3	Neutralization	Live virus replication assay	Microneutralization	VIC	VIC	VIC		NT80 GMT			days post booster1			28		338		1.00	84		178		1.00																							
5376		21	University of Southampton	Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial	https://doi.org/10.1016/j.jinf.2022.04.018	Peer-reviewed publication	04/09/2022	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	BNT162b2	30	?g	6 months interval	Heterologous						3	Neutralization	Live virus replication assay	Microneutralization	VIC	VIC	VIC		NT80 GMT			days post booster1			28		4816		14.25	84		1767		9.93																							
5377		21	University of Southampton	Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial	https://doi.org/10.1016/j.jinf.2022.04.018	Peer-reviewed publication	04/09/2022	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	CVnCoV	12	?g	6 months interval	Heterologous						3	Neutralization	Live virus replication assay	Microneutralization	VIC	VIC	VIC		NT80 GMT			days post booster1			28		830		2.46	84		447		2.51																							
5378		21	University of Southampton	Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial	https://doi.org/10.1016/j.jinf.2022.04.018	Peer-reviewed publication	04/09/2022	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	BNT162b2	15	?g	6 months interval	Heterologous						3	Neutralization	Live virus replication assay	Microneutralization	VIC	VIC	VIC		NT80 GMT			days post booster1			28		2521		7.46	84		1379		7.75																							
5379		21	University of Southampton	Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial	https://doi.org/10.1016/j.jinf.2022.04.018	Peer-reviewed publication	04/09/2022	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	mRNA-1273	100	?g	6 months interval	Heterologous						3	Neutralization	Live virus replication assay	Microneutralization	VIC	VIC	VIC		NT80 GMT			days post booster1			28		5276		15.61	84		2076		11.66																							
5380		21	University of Southampton	Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial	https://doi.org/10.1016/j.jinf.2022.04.018	Peer-reviewed publication	04/09/2022	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	Ad26.COV2.S	5.00E+10	virus  particles	6 months interval	Heterologous						3	Neutralization	Live virus replication assay	Microneutralization	VIC	VIC	VIC		NT80 GMT			days post booster1			28		1061		3.14	84		867		4.87																							
5381		21	University of Southampton	Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial	https://doi.org/10.1016/j.jinf.2022.04.018	Peer-reviewed publication	04/09/2022	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	NVX-CoV2373	5	?g	6 months interval	Heterologous						3	Neutralization	Live virus replication assay	Microneutralization	VIC	VIC	VIC		NT80 GMT			days post booster1			28		837		2.48	84		546		3.07																							
5382		21	University of Southampton	Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial	https://doi.org/10.1016/j.jinf.2022.04.018	Peer-reviewed publication	04/09/2022	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	NVX-CoV2373	2.5	?g	6 months interval	Heterologous						3	Neutralization	Live virus replication assay	Microneutralization	VIC	VIC	VIC		NT80 GMT			days post booster1			28		731		2.16	84		356		2.00																							
5912																																																																					
5913																																																																					
5383		21	University of Southampton	Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial	https://doi.org/10.1016/j.jinf.2022.04.018	Peer-reviewed publication	04/09/2022	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	VLA2001	33	antigen units	6 months interval	Heterologous						3	Neutralization	Live virus replication assay	Microneutralization	VIC	VIC	VIC		NT80 GMT			days post booster1			28		319		0.94	84		244		1.37																							
5384		21	University of Southampton	Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial	https://doi.org/10.1016/j.jinf.2022.04.018	Peer-reviewed publication	04/09/2022	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	VLA2001	16.5	antigen units	6 months interval	Heterologous						3	Neutralization	Live virus replication assay	Microneutralization	VIC	VIC	VIC		NT80 GMT			days post booster1			28		299		0.88	84		264		1.48																							
5385		21	University of Southampton	Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial	https://doi.org/10.1016/j.jinf.2022.04.018	Peer-reviewed publication	04/09/2022	human		BNT162b2	30	?g	BNT162b2	30	?g	6 months interval	Homologous						3	Neutralization	Live virus replication assay	Microneutralization	VIC	VIC	VIC		NT80 GMT			days post booster1			28		4644		1.00	84		1958		11.00																							
5386		21	University of Southampton	Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial	https://doi.org/10.1016/j.jinf.2022.04.018	Peer-reviewed publication	04/09/2022	human		BNT162b2	30	?g	CVnCoV	12	?g	6 months interval	Heterologous						3	Neutralization	Live virus replication assay	Microneutralization	VIC	VIC	VIC		NT80 GMT			days post booster1			28		1994		0.43	84		906		5.09																							
5387		21	University of Southampton	Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial	https://doi.org/10.1016/j.jinf.2022.04.018	Peer-reviewed publication	04/09/2022	human		BNT162b2	30	?g	BNT162b2	15	?g	6 months interval	Heterologous						3	Neutralization	Live virus replication assay	Microneutralization	VIC	VIC	VIC		NT80 GMT			days post booster1			28		3264		0.70	84		2300		12.92																							
5388		21	University of Southampton	Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial	https://doi.org/10.1016/j.jinf.2022.04.018	Peer-reviewed publication	04/09/2022	human		BNT162b2	30	?g	mRNA-1273	100	?g	6 months interval	Heterologous						3	Neutralization	Live virus replication assay	Microneutralization	VIC	VIC	VIC		NT80 GMT			days post booster1			28		5356		1.15	84		3009		16.90																							
5389		21	University of Southampton	Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial	https://doi.org/10.1016/j.jinf.2022.04.018	Peer-reviewed publication	04/09/2022	human		BNT162b2	30	?g	ChAdOx1 nCoV-19	5.00E+10	virus  particles	6 months interval	Heterologous						3	Neutralization	Live virus replication assay	Microneutralization	VIC	VIC	VIC		NT80 GMT			days post booster1			28		2575		0.55	84		1366		7.67																							
5390		21	University of Southampton	Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial	https://doi.org/10.1016/j.jinf.2022.04.018	Peer-reviewed publication	04/09/2022	human		BNT162b2	30	?g	Ad26.COV2.S	5.00E+10	virus  particles	6 months interval	Heterologous						3	Neutralization	Live virus replication assay	Microneutralization	VIC	VIC	VIC		NT80 GMT			days post booster1			28		4045		0.87	84		3439		19.32																							
5391		21	University of Southampton	Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial	https://doi.org/10.1016/j.jinf.2022.04.018	Peer-reviewed publication	04/09/2022	human		BNT162b2	30	?g	NVX-CoV2373	5	?g	6 months interval	Heterologous						3	Neutralization	Live virus replication assay	Microneutralization	VIC	VIC	VIC		NT80 GMT			days post booster1			28		1374		0.30	84		799		4.49																							
5392		21	University of Southampton	Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial	https://doi.org/10.1016/j.jinf.2022.04.018	Peer-reviewed publication	04/09/2022	human		BNT162b2	30	?g	NVX-CoV2373	2.5	?g	6 months interval	Heterologous						3	Neutralization	Live virus replication assay	Microneutralization	VIC	VIC	VIC		NT80 GMT			days post booster1			28		1850		0.40	84		848		4.76																							
5393		21	University of Southampton	Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial	https://doi.org/10.1016/j.jinf.2022.04.018	Peer-reviewed publication	04/09/2022	human		BNT162b2	30	?g	VLA2001	33	antigen units	6 months interval	Heterologous						3	Neutralization	Live virus replication assay	Microneutralization	VIC	VIC	VIC		NT80 GMT			days post booster1			28		794		0.17	84		596		3.35																							
5394		21	University of Southampton	Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial	https://doi.org/10.1016/j.jinf.2022.04.018	Peer-reviewed publication	04/09/2022	human		BNT162b2	30	?g	VLA2001	16.5	antigen units	6 months interval	Heterologous						3	Neutralization	Live virus replication assay	Microneutralization	VIC	VIC	VIC		NT80 GMT			days post booster1			28		555		0.12	84		419		2.35																							
5395		21	University of Southampton	Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial	https://doi.org/10.1016/j.jinf.2022.04.018	Peer-reviewed publication	04/09/2022	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	ChAdOx1 nCoV-19	5.00E+10	virus  particles	6 months interval	Homologous						4	Neutralization	Live virus replication assay	Microneutralization	VIC	VIC	VIC		FRNT50 GMT			days post booster1			28		62		1.00																												
5914																																																																					
5915																																																																					
5916																																																																					
5396		21	University of Southampton	Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial	https://doi.org/10.1016/j.jinf.2022.04.018	Peer-reviewed publication	04/09/2022	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	BNT162b2	30	?g	6 months interval	Heterologous						4	Neutralization	Live virus replication assay	Microneutralization	VIC	VIC	VIC		FRNT50 GMT			days post booster1			28		1771		28.56																												
5397		21	University of Southampton	Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial	https://doi.org/10.1016/j.jinf.2022.04.018	Peer-reviewed publication	04/09/2022	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	mRNA-1273	50	?g	6 months interval	Heterologous						4	Neutralization	Live virus replication assay	Microneutralization	VIC	VIC	VIC		FRNT50 GMT			days post booster1			28		4017		64.79																												
5398		21	University of Southampton	Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial	https://doi.org/10.1016/j.jinf.2022.04.018	Peer-reviewed publication	04/09/2022	human		BNT162b2	30	?g	BNT162b2	30	?g	6 months interval	Homologous						4	Neutralization	Live virus replication assay	Microneutralization	VIC	VIC	VIC		FRNT50 GMT			days post booster1			28		1908		1.00																												
5399		21	University of Southampton	Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial	https://doi.org/10.1016/j.jinf.2022.04.018	Peer-reviewed publication	04/09/2022	human		BNT162b2	30	?g	mRNA-1273	50	?g	6 months interval	Heterologous						4	Neutralization	Live virus replication assay	Microneutralization	VIC	VIC	VIC		FRNT50 GMT			days post booster1			28		6420		3.36																												
5400		21	University of Southampton	Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial	https://doi.org/10.1016/j.jinf.2022.04.018	Peer-reviewed publication	04/09/2022	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	ChAdOx1 nCoV-19	5.00E+10	virus  particles	6 months interval	Homologous						4	Neutralization	Live virus replication assay	Microneutralization	delta	B.1.617.2	B.1.617.2		FRNT50 GMT			days post booster1			28		22		1.00																												
5401		21	University of Southampton	Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial	https://doi.org/10.1016/j.jinf.2022.04.018	Peer-reviewed publication	04/09/2022	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	BNT162b2	30	?g	6 months interval	Heterologous						4	Neutralization	Live virus replication assay	Microneutralization	delta	B.1.617.2	B.1.617.2		FRNT50 GMT			days post booster1			28		666		30.27																												
5402		21	University of Southampton	Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial	https://doi.org/10.1016/j.jinf.2022.04.018	Peer-reviewed publication	04/09/2022	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	mRNA-1273	50	?g	6 months interval	Heterologous						4	Neutralization	Live virus replication assay	Microneutralization	delta	B.1.617.2	B.1.617.2		FRNT50 GMT			days post booster1			28		1870		85.00																												
5403		21	University of Southampton	Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial	https://doi.org/10.1016/j.jinf.2022.04.018	Peer-reviewed publication	04/09/2022	human		BNT162b2	30	?g	BNT162b2	30	?g	6 months interval	Homologous						4	Neutralization	Live virus replication assay	Microneutralization	delta	B.1.617.2	B.1.617.2		FRNT50 GMT			days post booster1			28		755		1.00																												
5404		21	University of Southampton	Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial	https://doi.org/10.1016/j.jinf.2022.04.018	Peer-reviewed publication	04/09/2022	human		BNT162b2	30	?g	mRNA-1273	50	?g	6 months interval	Heterologous						4	Neutralization	Live virus replication assay	Microneutralization	delta	B.1.617.2	B.1.617.2		FRNT50 GMT			days post booster1			28		2580		3.42																												
5405		21	University of Southampton	Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial	https://doi.org/10.1016/j.jinf.2022.04.018	Peer-reviewed publication	04/09/2022	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	ChAdOx1 nCoV-19	5.00E+10	virus  particles	6 months interval	Homologous						4	Neutralization	Live virus replication assay	Microneutralization	Omicron	B.1.1.529	B.1.1.529		FRNT50 GMT			days post booster1			28		10		1.00																												
5406		21	University of Southampton	Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial	https://doi.org/10.1016/j.jinf.2022.04.018	Peer-reviewed publication	04/09/2022	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	BNT162b2	30	?g	6 months interval	Heterologous						4	Neutralization	Live virus replication assay	Microneutralization	Omicron	B.1.1.529	B.1.1.529		FRNT50 GMT			days post booster1			28		117		11.70																												
5407		21	University of Southampton	Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial	https://doi.org/10.1016/j.jinf.2022.04.018	Peer-reviewed publication	04/09/2022	human		ChAdOx1 nCoV-19	5.00E+10	virus  particles	mRNA-1273	50	?g	6 months interval	Heterologous						4	Neutralization	Live virus replication assay	Microneutralization	Omicron	B.1.1.529	B.1.1.529		FRNT50 GMT			days post booster1			28		375		37.50																												
5408		21	University of Southampton	Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial	https://doi.org/10.1016/j.jinf.2022.04.018	Peer-reviewed publication	04/09/2022	human		BNT162b2	30	?g	BNT162b2	30	?g	6 months interval	Homologous						4	Neutralization	Live virus replication assay	Microneutralization	Omicron	B.1.1.529	B.1.1.529		FRNT50 GMT			days post booster1			28		125		1.00																												
5917																																																																					
5918																																																																					
5409		21	University of Southampton	Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial	https://doi.org/10.1016/j.jinf.2022.04.018	Peer-reviewed publication	04/09/2022	human		BNT162b2	30	?g	mRNA-1273	50	?g	6 months interval	Heterologous						4	Neutralization	Live virus replication assay	Microneutralization	Omicron	B.1.1.529	B.1.1.529		FRNT50 GMT			days post booster1			28		756		6.05																												
5410		22	Hong Kong Sanatorium and Hospital	Safety and Immunogenicity of a Booster Vaccination by CoronaVac or BNT162b2 in Previously Two-Dose Inactivated Virus Vaccinated Individuals with Negative Neutralizing Antibody	https://doi.org/10.3390/vaccines10040556	Peer-reviewed publication	04/03/2022	human		CoronaVac			CoronaVac			94-215 days interval	Homologous						1	Binding	CMIA						Anti-spike IgG GM	BAU/mL		days post booster1	0	14.2	30		149.7	10.54	1.00	90		90.6	6.38	1.00																							
5411		22	Hong Kong Sanatorium and Hospital	Safety and Immunogenicity of a Booster Vaccination by CoronaVac or BNT162b2 in Previously Two-Dose Inactivated Virus Vaccinated Individuals with Negative Neutralizing Antibody	https://doi.org/10.3390/vaccines10040556	Peer-reviewed publication	04/03/2022	human		CoronaVac			BNT162b2	30	?g	124-222 days interval	Heterologous						1	Binding	CMIA						Anti-spike IgG GM	BAU/mL		days post booster1	0	11.6	30		2323.7	200.32	19.01	90		1062.9	91.63	14.36																							
5412		23	Umeå University	Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination	https://doi.org/10.1056/NEJMc2110716	Peer-reviewed publication	07/14/2021	human		ChAdOx1 nCoV-19			ChAdOx1 nCoV-19				Homologous						1	Binding	ELISA						Anti-spike IgG GM	AUC		days post booster1	0	827.6	8.5	7-10 days post booster	4320	5.22	1.00	30		7381	8.92	1.00																							
5413		23	Umeå University	Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination	https://doi.org/10.1056/NEJMc2110716	Peer-reviewed publication	07/14/2021	human		ChAdOx1 nCoV-19			mRNA-1273				Heterologous						1	Binding	ELISA						Anti-spike IgG GM	AUC		days post booster1	0	1106	8.5	7-10 days post booster	128108	115.83	22.19	30		104083	94.11	10.55																							
5414		23	Umeå University	Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination	https://doi.org/10.1056/NEJMc2110716	Peer-reviewed publication	07/14/2021	human		ChAdOx1 nCoV-19			ChAdOx1 nCoV-19				Homologous						2	Binding	ELISA						Anti-RBD IgG GM	AUC		days post booster1	0	253	8.5	7-10 days post booster	1224	4.84	1.00																												
5415		23	Umeå University	Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination	https://doi.org/10.1056/NEJMc2110716	Peer-reviewed publication	07/14/2021	human		ChAdOx1 nCoV-19			mRNA-1273				Heterologous						2	Binding	ELISA						Anti-RBD IgG GM	AUC		days post booster1	0	326	8.5	7-10 days post booster	41680	127.85	26.42																												
5416		24	University of Hong Kong	Three-dose vaccination-induced immune responses protect against SARS-CoV-2 2 Omicron-BA.2	https://doi.org/10.1101/2022.05.09.491254	Pre-print	10/06/2022	human		BNT162b2			BNT162b2			235.5 (180-283) days interval	Homologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	IC50 GMT			weeks post booster1			2	0-4	1393		1.00	4		1106		1.00																							
5417		24	University of Hong Kong	Three-dose vaccination-induced immune responses protect against SARS-CoV-2 2 Omicron-BA.2	https://doi.org/10.1101/2022.05.09.491254	Pre-print	10/06/2022	human		CoronaVac			CoronaVac			236 (191-288) days interval	Homologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	IC50 GMT			weeks post booster1			2	0-4	181		1.00	4		122		1.00																							
5418		24	University of Hong Kong	Three-dose vaccination-induced immune responses protect against SARS-CoV-2 2 Omicron-BA.2	https://doi.org/10.1101/2022.05.09.491254	Pre-print	10/06/2022	human		CoronaVac			BNT162b2			240 (189-284) days interval	Heterologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	IC50 GMT			weeks post booster1			2	0-4	1242		6.86	4		1443		11.83																							
5419		24	University of Hong Kong	Three-dose vaccination-induced immune responses protect against SARS-CoV-2 2 Omicron-BA.2	https://doi.org/10.1101/2022.05.09.491254	Pre-print	10/06/2022	human		BNT162b2			BNT162b2			235.5 (180-283) days interval	Homologous						1	Neutralization	Pseudotyped virus assay	Luciferase	alpha	B.1.1.7	B.1.1.7		IC50 GMT			weeks post booster1			2	0-4	1545		1.00	4		1140		1.00																							
5420		24	University of Hong Kong	Three-dose vaccination-induced immune responses protect against SARS-CoV-2 2 Omicron-BA.2	https://doi.org/10.1101/2022.05.09.491254	Pre-print	10/06/2022	human		CoronaVac			CoronaVac			236 (191-288) days interval	Homologous						1	Neutralization	Pseudotyped virus assay	Luciferase	alpha	B.1.1.7	B.1.1.7		IC50 GMT			weeks post booster1			2	0-4	90		1.00	4		121		1.00																							
5421		24	University of Hong Kong	Three-dose vaccination-induced immune responses protect against SARS-CoV-2 2 Omicron-BA.2	https://doi.org/10.1101/2022.05.09.491254	Pre-print	10/06/2022	human		CoronaVac			BNT162b2			240 (189-284) days interval	Heterologous						1	Neutralization	Pseudotyped virus assay	Luciferase	alpha	B.1.1.7	B.1.1.7		IC50 GMT			weeks post booster1			2	0-4	1000		11.11	4		1044		8.63																							
5422		24	University of Hong Kong	Three-dose vaccination-induced immune responses protect against SARS-CoV-2 2 Omicron-BA.2	https://doi.org/10.1101/2022.05.09.491254	Pre-print	10/06/2022	human		BNT162b2			BNT162b2			235.5 (180-283) days interval	Homologous						1	Neutralization	Pseudotyped virus assay	Luciferase	beta	B.1.351	B.1.351		IC50 GMT			weeks post booster1			2	0-4	923		1.00	4		762		1.00																							
5423		24	University of Hong Kong	Three-dose vaccination-induced immune responses protect against SARS-CoV-2 2 Omicron-BA.2	https://doi.org/10.1101/2022.05.09.491254	Pre-print	10/06/2022	human		CoronaVac			CoronaVac			236 (191-288) days interval	Homologous						1	Neutralization	Pseudotyped virus assay	Luciferase	beta	B.1.351	B.1.351		IC50 GMT			weeks post booster1			2	0-4	109		1.00	4		64		1.00																							
5424		24	University of Hong Kong	Three-dose vaccination-induced immune responses protect against SARS-CoV-2 2 Omicron-BA.2	https://doi.org/10.1101/2022.05.09.491254	Pre-print	10/06/2022	human		CoronaVac			BNT162b2			240 (189-284) days interval	Heterologous						1	Neutralization	Pseudotyped virus assay	Luciferase	beta	B.1.351	B.1.351		IC50 GMT			weeks post booster1			2	0-4	788		7.23	4		718		11.22																							
5425		24	University of Hong Kong	Three-dose vaccination-induced immune responses protect against SARS-CoV-2 2 Omicron-BA.2	https://doi.org/10.1101/2022.05.09.491254	Pre-print	10/06/2022	human		BNT162b2			BNT162b2			235.5 (180-283) days interval	Homologous						1	Neutralization	Pseudotyped virus assay	Luciferase	delta	B.1.617.2	B.1.617.2		IC50 GMT			weeks post booster1			2	0-4	586		1.00	4		584		1.00																							
5919																																																																					
5920																																																																					
5427		24	University of Hong Kong	Three-dose vaccination-induced immune responses protect against SARS-CoV-2 2 Omicron-BA.2	https://doi.org/10.1101/2022.05.09.491254	Pre-print	10/06/2022	human		CoronaVac			BNT162b2			240 (189-284) days interval	Heterologous						1	Neutralization	Pseudotyped virus assay	Luciferase	delta	B.1.617.2	B.1.617.2		IC50 GMT			weeks post booster1			2	0-4	324		7.04	4		387		9.44																							
5428		24	University of Hong Kong	Three-dose vaccination-induced immune responses protect against SARS-CoV-2 2 Omicron-BA.2	https://doi.org/10.1101/2022.05.09.491254	Pre-print	10/06/2022	human		BNT162b2			BNT162b2			235.5 (180-283) days interval	Homologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.1		IC50 GMT			weeks post booster1			2	0-4	295		1.00	4		326		1.00																							
5429		24	University of Hong Kong	Three-dose vaccination-induced immune responses protect against SARS-CoV-2 2 Omicron-BA.2	https://doi.org/10.1101/2022.05.09.491254	Pre-print	10/06/2022	human		CoronaVac			CoronaVac			236 (191-288) days interval	Homologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.1		IC50 GMT			weeks post booster1			2	0-4	36		1.00	4		31		1.00																							
5430		24	University of Hong Kong	Three-dose vaccination-induced immune responses protect against SARS-CoV-2 2 Omicron-BA.2	https://doi.org/10.1101/2022.05.09.491254	Pre-print	10/06/2022	human		CoronaVac			BNT162b2			240 (189-284) days interval	Heterologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.1		IC50 GMT			weeks post booster1			2	0-4	238		6.61	4		310		10.00																							
5431		24	University of Hong Kong	Three-dose vaccination-induced immune responses protect against SARS-CoV-2 2 Omicron-BA.2	https://doi.org/10.1101/2022.05.09.491254	Pre-print	10/06/2022	human		BNT162b2			BNT162b2			235.5 (180-283) days interval	Homologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.1.1		IC50 GMT			weeks post booster1			2	0-4	411		1.00	4		284		1.00																							
5432		24	University of Hong Kong	Three-dose vaccination-induced immune responses protect against SARS-CoV-2 2 Omicron-BA.2	https://doi.org/10.1101/2022.05.09.491254	Pre-print	10/06/2022	human		CoronaVac			CoronaVac			236 (191-288) days interval	Homologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.1.1		IC50 GMT			weeks post booster1			2	0-4	58		1.00	4		29		1.00																							
5433		24	University of Hong Kong	Three-dose vaccination-induced immune responses protect against SARS-CoV-2 2 Omicron-BA.2	https://doi.org/10.1101/2022.05.09.491254	Pre-print	10/06/2022	human		CoronaVac			BNT162b2			240 (189-284) days interval	Heterologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.1.1		IC50 GMT			weeks post booster1			2	0-4	257		4.43	4		274		9.45																							
5434		24	University of Hong Kong	Three-dose vaccination-induced immune responses protect against SARS-CoV-2 2 Omicron-BA.2	https://doi.org/10.1101/2022.05.09.491254	Pre-print	10/06/2022	human		BNT162b2			BNT162b2			235.5 (180-283) days interval	Homologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.2		IC50 GMT			weeks post booster1			2	0-4	273		1.00	4		284		1.00																							
5435		24	University of Hong Kong	Three-dose vaccination-induced immune responses protect against SARS-CoV-2 2 Omicron-BA.2	https://doi.org/10.1101/2022.05.09.491254	Pre-print	10/06/2022	human		CoronaVac			CoronaVac			236 (191-288) days interval	Homologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.2		IC50 GMT			weeks post booster1			2	0-4	28		1.00	4		27		1.00																							
5436		24	University of Hong Kong	Three-dose vaccination-induced immune responses protect against SARS-CoV-2 2 Omicron-BA.2	https://doi.org/10.1101/2022.05.09.491254	Pre-print	10/06/2022	human		CoronaVac			BNT162b2			240 (189-284) days interval	Heterologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.2		IC50 GMT			weeks post booster1			2	0-4	202		7.21	4		218		8.07																							
5437		24	University of Hong Kong	Three-dose vaccination-induced immune responses protect against SARS-CoV-2 2 Omicron-BA.2	https://doi.org/10.1101/2022.05.09.491254	Pre-print	10/06/2022	human		CoronaVac			BNT162b2			240 (189-284) days interval	Heterologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.2.12.1		IC50 GMT			weeks post booster1			2	0-4	707		1.00	4		488		1.00																							
5438		24	University of Hong Kong	Three-dose vaccination-induced immune responses protect against SARS-CoV-2 2 Omicron-BA.2	https://doi.org/10.1101/2022.05.09.491254	Pre-print	10/06/2022	human		CoronaVac			BNT162b2			240 (189-284) days interval	Heterologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.2.12.1		IC50 GMT			weeks post booster1			2	0-4	65		1.00	4		47		1.00																							
5439		24	University of Hong Kong	Three-dose vaccination-induced immune responses protect against SARS-CoV-2 2 Omicron-BA.2	https://doi.org/10.1101/2022.05.09.491254	Pre-print	10/06/2022	human		CoronaVac			BNT162b2			240 (189-284) days interval	Heterologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.2.12.1		IC50 GMT			weeks post booster1			2	0-4	521		8.02	4		550		11.70																							
5440		24	University of Hong Kong	Three-dose vaccination-induced immune responses protect against SARS-CoV-2 2 Omicron-BA.2	https://doi.org/10.1101/2022.05.09.491254	Pre-print	10/06/2022	human		CoronaVac			BNT162b2			240 (189-284) days interval	Heterologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.4/5		IC50 GMT			weeks post booster1			2	0-4	339		1.00	4		214		1.00																							
5441		24	University of Hong Kong	Three-dose vaccination-induced immune responses protect against SARS-CoV-2 2 Omicron-BA.2	https://doi.org/10.1101/2022.05.09.491254	Pre-print	10/06/2022	human		CoronaVac			BNT162b2			240 (189-284) days interval	Heterologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.4/5		IC50 GMT			weeks post booster1			2	0-4	37		1.00	4		25		1.00																							
5442		24	University of Hong Kong	Three-dose vaccination-induced immune responses protect against SARS-CoV-2 2 Omicron-BA.2	https://doi.org/10.1101/2022.05.09.491254	Pre-print	10/06/2022	human		CoronaVac			BNT162b2			240 (189-284) days interval	Heterologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.4/5		IC50 GMT			weeks post booster1			2	0-4	298		8.05	4		193		7.72																							
5443		25	Moderna	Safety, Immunogenicity and Antibody Persistence of a Bivalent Beta-Containing Booster Vaccine	https://doi.org/10.21203/rs.3.rs-1555201/v1	Pre-print	04/15/2022	human		mRNA-1273	100	?g	mRNA-1273	50	?g		Homologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	ID50 GMT			days post booster1			29		1782.7		1.00	181		617.2		1.00																							
5480		26	Fudan University	Antibody Resistance of SARS-CoV-2 Omicron BA.1, BA.1.1, BA.2 and BA.3 Sub-lineages	https://doi.org/10.1101/2022.04.06.22273503	Pre-print	04/06/2022	human		BBIBP-CorV			ZF001				Heterologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.2		Reciprocal ID50 GMT			days post booster1			14		42		0.75																												
5444		25	Moderna	Safety, Immunogenicity and Antibody Persistence of a Bivalent Beta-Containing Booster Vaccine	https://doi.org/10.21203/rs.3.rs-1555201/v1	Pre-print	04/15/2022	human		mRNA-1273	100	?g	mRNA-1273.211	50	?g		Variant						1	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	ID50 GMT			days post booster1			29		2278		1.28	181		1040		1.69																							
5445		25	Moderna	Safety, Immunogenicity and Antibody Persistence of a Bivalent Beta-Containing Booster Vaccine	https://doi.org/10.21203/rs.3.rs-1555201/v1	Pre-print	04/15/2022	human		mRNA-1273	100	?g	mRNA-1273	50	?g		Homologous						1	Neutralization	Pseudotyped virus assay	Luciferase	beta	B.1.351	B.1.351		ID50 GMT			days post booster1			29		825.6		1.00	181		125.2		1.00																							
5446		25	Moderna	Safety, Immunogenicity and Antibody Persistence of a Bivalent Beta-Containing Booster Vaccine	https://doi.org/10.21203/rs.3.rs-1555201/v1	Pre-print	04/15/2022	human		mRNA-1273	100	?g	mRNA-1273.211	50	?g		Variant						1	Neutralization	Pseudotyped virus assay	Luciferase	beta	B.1.351	B.1.351		ID50 GMT			days post booster1			29		1095.3		1.33	181		343.5		2.74																							
5447		25	Moderna	Safety, Immunogenicity and Antibody Persistence of a Bivalent Beta-Containing Booster Vaccine	https://doi.org/10.21203/rs.3.rs-1555201/v1	Pre-print	04/15/2022	human		mRNA-1273	100	?g	mRNA-1273	50	?g		Homologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	B.1.1.529		ID50 GMT			days post booster1			29		630.5		1.00	181		145.6		1.00																							
5448		25	Moderna	Safety, Immunogenicity and Antibody Persistence of a Bivalent Beta-Containing Booster Vaccine	https://doi.org/10.21203/rs.3.rs-1555201/v1	Pre-print	04/15/2022	human		mRNA-1273	100	?g	mRNA-1273.211	50	?g		Variant						1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	B.1.1.529		ID50 GMT			days post booster1			29		1389.8		2.20	181		312.9		2.15																							
5449		25	Moderna	Safety, Immunogenicity and Antibody Persistence of a Bivalent Beta-Containing Booster Vaccine	https://doi.org/10.21203/rs.3.rs-1555201/v1	Pre-print	04/15/2022	human		mRNA-1273	100	?g	mRNA-1273	50	?g		Homologous						1	Neutralization	Pseudotyped virus assay	Luciferase	delta	B.1.617.2	B.1.617.2		ID50 GMT			days post booster1			29		844.1		1.00	181		408		1.00																							
5450		25	Moderna	Safety, Immunogenicity and Antibody Persistence of a Bivalent Beta-Containing Booster Vaccine	https://doi.org/10.21203/rs.3.rs-1555201/v1	Pre-print	04/15/2022	human		mRNA-1273	100	?g	mRNA-1273.211	50	?g		Variant						1	Neutralization	Pseudotyped virus assay	Luciferase	delta	B.1.617.2	B.1.617.2		ID50 GMT			days post booster1			29		1481.2		1.75	181		491.3		1.20																							
5451		25	Moderna	Safety, Immunogenicity and Antibody Persistence of a Bivalent Beta-Containing Booster Vaccine	https://doi.org/10.21203/rs.3.rs-1555201/v1	Pre-print	04/15/2022	human		mRNA-1273	100	?g	mRNA-1273	50	?g		Homologous						2	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	ID50 GMT			days post booster1	0	150	29		1952	13.01	1.00	181		673	4.49	1.00																							
5452		25	Moderna	Safety, Immunogenicity and Antibody Persistence of a Bivalent Beta-Containing Booster Vaccine	https://doi.org/10.21203/rs.3.rs-1555201/v1	Pre-print	04/15/2022	human		mRNA-1273	100	?g	mRNA-1273.211	50	?g		Variant						2	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	ID50 GMT			days post booster1	0	103	29		2172	21.09	1.62	181		1006	9.77	2.18																							
5453		25	Moderna	Safety, Immunogenicity and Antibody Persistence of a Bivalent Beta-Containing Booster Vaccine	https://doi.org/10.21203/rs.3.rs-1555201/v1	Pre-print	04/15/2022	human		mRNA-1273	100	?g	mRNA-1273.211	100	?g		Variant						2	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	ID50 GMT			days post booster1	0	100	29		4503	45.03	3.46	181		1483	14.83	3.30																							
5454		25	Moderna	Safety, Immunogenicity and Antibody Persistence of a Bivalent Beta-Containing Booster Vaccine	https://doi.org/10.21203/rs.3.rs-1555201/v1	Pre-print	04/15/2022	human		mRNA-1273	100	?g	mRNA-1273	50	?g		Homologous						2	Neutralization	Pseudotyped virus assay	Luciferase	beta	B.1.351	B.1.351		ID50 GMT			days post booster1	0	38	29		921	24.24	1.00	181		139	3.66	1.00																							
5455		25	Moderna	Safety, Immunogenicity and Antibody Persistence of a Bivalent Beta-Containing Booster Vaccine	https://doi.org/10.21203/rs.3.rs-1555201/v1	Pre-print	04/15/2022	human		mRNA-1273	100	?g	mRNA-1273.211	50	?g		Variant						2	Neutralization	Pseudotyped virus assay	Luciferase	beta	B.1.351	B.1.351		ID50 GMT			days post booster1	0	26	29		1032	39.69	1.64	181		326	12.54	3.43																							
5456		25	Moderna	Safety, Immunogenicity and Antibody Persistence of a Bivalent Beta-Containing Booster Vaccine	https://doi.org/10.21203/rs.3.rs-1555201/v1	Pre-print	04/15/2022	human		mRNA-1273	100	?g	mRNA-1273.211	100	?g		Variant						2	Neutralization	Pseudotyped virus assay	Luciferase	beta	B.1.351	B.1.351		ID50 GMT			days post booster1	0	24	29		1642	68.42	2.82	181		414	17.25	4.71																							
5457		25	Moderna	Safety, Immunogenicity and Antibody Persistence of a Bivalent Beta-Containing Booster Vaccine	https://doi.org/10.21203/rs.3.rs-1555201/v1	Pre-print	04/15/2022	human		mRNA-1273	100	?g	mRNA-1273	50	?g		Homologous						2	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	B.1.1.529		ID50 GMT			days post booster1	0	38	29		629	16.55	1.00	181		146	3.84	1.00																							
5458		25	Moderna	Safety, Immunogenicity and Antibody Persistence of a Bivalent Beta-Containing Booster Vaccine	https://doi.org/10.21203/rs.3.rs-1555201/v1	Pre-print	04/15/2022	human		mRNA-1273	100	?g	mRNA-1273.211	50	?g		Variant						2	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	B.1.1.529		ID50 GMT			days post booster1	0	39	29		1408	36.10	2.18	181		317	8.13	2.12																							
5459		25	Moderna	Safety, Immunogenicity and Antibody Persistence of a Bivalent Beta-Containing Booster Vaccine	https://doi.org/10.21203/rs.3.rs-1555201/v1	Pre-print	04/15/2022	human		mRNA-1273	100	?g	mRNA-1273	50	?g		Homologous						2	Neutralization	Pseudotyped virus assay	Luciferase	delta	B.1.617.2	B.1.617.2		ID50 GMT			days post booster1	0	47	29		828	17.62	1.00	181		397	8.45	1.00																							
5460		25	Moderna	Safety, Immunogenicity and Antibody Persistence of a Bivalent Beta-Containing Booster Vaccine	https://doi.org/10.21203/rs.3.rs-1555201/v1	Pre-print	04/15/2022	human		mRNA-1273	100	?g	mRNA-1273.211	50	?g		Variant						2	Neutralization	Pseudotyped virus assay	Luciferase	delta	B.1.617.2	B.1.617.2		ID50 GMT			days post booster1	0	53	29		1507	28.43	1.61	181		499	9.42	1.11																							
5461		25	Moderna	Safety, Immunogenicity and Antibody Persistence of a Bivalent Beta-Containing Booster Vaccine	https://doi.org/10.21203/rs.3.rs-1555201/v1	Pre-print	04/15/2022	human		mRNA-1273	100	?g	mRNA-1273	50	?g		Homologous						3	Binding	Meso Scale Discovery assay		Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	Spike binding antibody titer gm	AU/mL		days post booster1	0	40948	29		480711	11.74	1.00																												
5921																																																																					
5922																																																																					
5462		25	Moderna	Safety, Immunogenicity and Antibody Persistence of a Bivalent Beta-Containing Booster Vaccine	https://doi.org/10.21203/rs.3.rs-1555201/v1	Pre-print	04/15/2022	human		mRNA-1273	100	?g	mRNA-1273.211	50	?g		Variant						3	Binding	Meso Scale Discovery assay		Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	Spike binding antibody titer gm	AU/mL		days post booster1	0	26992	29		592403	21.95	1.87																												
5463		25	Moderna	Safety, Immunogenicity and Antibody Persistence of a Bivalent Beta-Containing Booster Vaccine	https://doi.org/10.21203/rs.3.rs-1555201/v1	Pre-print	04/15/2022	human		mRNA-1273	100	?g	mRNA-1273.211	100	?g		Variant						3	Binding	Meso Scale Discovery assay		Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	Spike binding antibody titer gm	AU/mL		days post booster1	0	17207	29		803379	46.69	3.98																												
5464		25	Moderna	Safety, Immunogenicity and Antibody Persistence of a Bivalent Beta-Containing Booster Vaccine	https://doi.org/10.21203/rs.3.rs-1555201/v1	Pre-print	04/15/2022	human		mRNA-1273	100	?g	mRNA-1273	50	?g		Homologous						3	Binding	Meso Scale Discovery assay		gamma	P.1	P.1		Spike binding antibody titer gm	AU/mL		days post booster1	0	18391	29		231094	12.57	1.00																												
5465		25	Moderna	Safety, Immunogenicity and Antibody Persistence of a Bivalent Beta-Containing Booster Vaccine	https://doi.org/10.21203/rs.3.rs-1555201/v1	Pre-print	04/15/2022	human		mRNA-1273	100	?g	mRNA-1273.211	50	?g		Variant						3	Binding	Meso Scale Discovery assay		gamma	P.1	P.1		Spike binding antibody titer gm	AU/mL		days post booster1	0	12674	29		313177	24.71	1.97																												
5466		25	Moderna	Safety, Immunogenicity and Antibody Persistence of a Bivalent Beta-Containing Booster Vaccine	https://doi.org/10.21203/rs.3.rs-1555201/v1	Pre-print	04/15/2022	human		mRNA-1273	100	?g	mRNA-1273.211	100	?g		Variant						3	Binding	Meso Scale Discovery assay		gamma	P.1	P.1		Spike binding antibody titer gm	AU/mL		days post booster1	0	8108	29		406226	50.10	3.99																												
5467		25	Moderna	Safety, Immunogenicity and Antibody Persistence of a Bivalent Beta-Containing Booster Vaccine	https://doi.org/10.21203/rs.3.rs-1555201/v1	Pre-print	04/15/2022	human		mRNA-1273	100	?g	mRNA-1273	50	?g		Homologous						3	Binding	Meso Scale Discovery assay		alpha	B.1.1.7	B.1.1.7		Spike binding antibody titer gm	AU/mL		days post booster1	0	25644	29		368165	14.36	1.00																												
5468		25	Moderna	Safety, Immunogenicity and Antibody Persistence of a Bivalent Beta-Containing Booster Vaccine	https://doi.org/10.21203/rs.3.rs-1555201/v1	Pre-print	04/15/2022	human		mRNA-1273	100	?g	mRNA-1273.211	50	?g		Variant						3	Binding	Meso Scale Discovery assay		alpha	B.1.1.7	B.1.1.7		Spike binding antibody titer gm	AU/mL		days post booster1	0	17040	29		454210	26.66	1.86																												
5469		25	Moderna	Safety, Immunogenicity and Antibody Persistence of a Bivalent Beta-Containing Booster Vaccine	https://doi.org/10.21203/rs.3.rs-1555201/v1	Pre-print	04/15/2022	human		mRNA-1273	100	?g	mRNA-1273.211	100	?g		Variant						3	Binding	Meso Scale Discovery assay		alpha	B.1.1.7	B.1.1.7		Spike binding antibody titer gm	AU/mL		days post booster1	0	11040	29		603467	54.66	3.81																												
5470		25	Moderna	Safety, Immunogenicity and Antibody Persistence of a Bivalent Beta-Containing Booster Vaccine	https://doi.org/10.21203/rs.3.rs-1555201/v1	Pre-print	04/15/2022	human		mRNA-1273	100	?g	mRNA-1273	50	?g		Homologous						3	Binding	Meso Scale Discovery assay		beta	B.1.351	B.1.351		Spike binding antibody titer gm	AU/mL		days post booster1	0	14524	29		199067	13.71	1.00																												
5471		25	Moderna	Safety, Immunogenicity and Antibody Persistence of a Bivalent Beta-Containing Booster Vaccine	https://doi.org/10.21203/rs.3.rs-1555201/v1	Pre-print	04/15/2022	human		mRNA-1273	100	?g	mRNA-1273.211	50	?g		Variant						3	Binding	Meso Scale Discovery assay		beta	B.1.351	B.1.351		Spike binding antibody titer gm	AU/mL		days post booster1	0	10216	29		299241	29.29	2.14																												
5472		25	Moderna	Safety, Immunogenicity and Antibody Persistence of a Bivalent Beta-Containing Booster Vaccine	https://doi.org/10.21203/rs.3.rs-1555201/v1	Pre-print	04/15/2022	human		mRNA-1273	100	?g	mRNA-1273.211	100	?g		Variant						3	Binding	Meso Scale Discovery assay		beta	B.1.351	B.1.351		Spike binding antibody titer gm	AU/mL		days post booster1	0	6628	29		393776	59.41	4.33																												
5473		26	Fudan University	Antibody Resistance of SARS-CoV-2 Omicron BA.1, BA.1.1, BA.2 and BA.3 Sub-lineages	https://doi.org/10.1101/2022.04.06.22273503	Pre-print	04/06/2022	human		BBIBP-CorV			BBIBP-CorV				Homologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	Reciprocal ID50 GMT			days post booster1			14		225		1.00																												
5474		26	Fudan University	Antibody Resistance of SARS-CoV-2 Omicron BA.1, BA.1.1, BA.2 and BA.3 Sub-lineages	https://doi.org/10.1101/2022.04.06.22273503	Pre-print	04/06/2022	human		BBIBP-CorV			ZF001				Heterologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	Reciprocal ID50 GMT			days post booster1			14		537		2.39																												
5475		26	Fudan University	Antibody Resistance of SARS-CoV-2 Omicron BA.1, BA.1.1, BA.2 and BA.3 Sub-lineages	https://doi.org/10.1101/2022.04.06.22273503	Pre-print	04/06/2022	human		BBIBP-CorV			BBIBP-CorV				Homologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.1		Reciprocal ID50 GMT			days post booster1			14		63		1.00																												
5476		26	Fudan University	Antibody Resistance of SARS-CoV-2 Omicron BA.1, BA.1.1, BA.2 and BA.3 Sub-lineages	https://doi.org/10.1101/2022.04.06.22273503	Pre-print	04/06/2022	human		BBIBP-CorV			ZF001				Heterologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.1		Reciprocal ID50 GMT			days post booster1			14		108		1.71																												
5477		26	Fudan University	Antibody Resistance of SARS-CoV-2 Omicron BA.1, BA.1.1, BA.2 and BA.3 Sub-lineages	https://doi.org/10.1101/2022.04.06.22273503	Pre-print	04/06/2022	human		BBIBP-CorV			BBIBP-CorV				Homologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.1.1		Reciprocal ID50 GMT			days post booster1			14		48		1.00																												
5478		26	Fudan University	Antibody Resistance of SARS-CoV-2 Omicron BA.1, BA.1.1, BA.2 and BA.3 Sub-lineages	https://doi.org/10.1101/2022.04.06.22273503	Pre-print	04/06/2022	human		BBIBP-CorV			ZF001				Heterologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.1.1		Reciprocal ID50 GMT			days post booster1			14		81		1.69																												
5479		26	Fudan University	Antibody Resistance of SARS-CoV-2 Omicron BA.1, BA.1.1, BA.2 and BA.3 Sub-lineages	https://doi.org/10.1101/2022.04.06.22273503	Pre-print	04/06/2022	human		BBIBP-CorV			BBIBP-CorV				Homologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.2		Reciprocal ID50 GMT			days post booster1			14		56		1.00																												
5923																																																																					
5924																																																																					
5925																																																																					
5483		27	Peking University	BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection	https://doi.org/10.1101/2022.04.30.489997	Pre-print	05/02/2022	human		CoronaVac			CoronaVac				Homologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	NT50 GMT			weeks post booster1			4		632		1.00																												
5484		27	Peking University	BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection	https://doi.org/10.1101/2022.04.30.489997	Pre-print	05/02/2022	human		CoronaVac			ZF001				Heterologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	NT50 GMT			weeks post booster1			4		857		1.36																												
5485		27	Peking University	BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection	https://doi.org/10.1101/2022.04.30.489997	Pre-print	05/02/2022	human		CoronaVac			CoronaVac				Homologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.1		NT50 GMT			weeks post booster1			4		122		1.00																												
5486		27	Peking University	BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection	https://doi.org/10.1101/2022.04.30.489997	Pre-print	05/02/2022	human		CoronaVac			ZF001				Heterologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.1		NT50 GMT			weeks post booster1			4		246		2.02																												
5487		27	Peking University	BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection	https://doi.org/10.1101/2022.04.30.489997	Pre-print	05/02/2022	human		CoronaVac			CoronaVac				Homologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.1.1		NT50 GMT			weeks post booster1			4		112		1.00																												
5488		27	Peking University	BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection	https://doi.org/10.1101/2022.04.30.489997	Pre-print	05/02/2022	human		CoronaVac			ZF001				Heterologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.1.1		NT50 GMT			weeks post booster1			4		233		2.08																												
5489		27	Peking University	BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection	https://doi.org/10.1101/2022.04.30.489997	Pre-print	05/02/2022	human		CoronaVac			CoronaVac				Homologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.3		NT50 GMT			weeks post booster1			4		105		1.00																												
5490		27	Peking University	BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection	https://doi.org/10.1101/2022.04.30.489997	Pre-print	05/02/2022	human		CoronaVac			ZF001				Heterologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.3		NT50 GMT			weeks post booster1			4		214		2.04																												
5491		27	Peking University	BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection	https://doi.org/10.1101/2022.04.30.489997	Pre-print	05/02/2022	human		CoronaVac			CoronaVac				Homologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.2		NT50 GMT			weeks post booster1			4		122		1.00																												
5492		27	Peking University	BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection	https://doi.org/10.1101/2022.04.30.489997	Pre-print	05/02/2022	human		CoronaVac			ZF001				Heterologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.2		NT50 GMT			weeks post booster1			4		234		1.92																												
5493		27	Peking University	BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection	https://doi.org/10.1101/2022.04.30.489997	Pre-print	05/02/2022	human		CoronaVac			CoronaVac				Homologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.2.13		NT50 GMT			weeks post booster1			4		117		1.00																												
5494		27	Peking University	BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection	https://doi.org/10.1101/2022.04.30.489997	Pre-print	05/02/2022	human		CoronaVac			ZF001				Heterologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.2.13		NT50 GMT			weeks post booster1			4		213		1.82																												
5495		27	Peking University	BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection	https://doi.org/10.1101/2022.04.30.489997	Pre-print	05/02/2022	human		CoronaVac			CoronaVac				Homologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.2.12.1		NT50 GMT			weeks post booster1			4		100		1.00																												
5496		27	Peking University	BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection	https://doi.org/10.1101/2022.04.30.489997	Pre-print	05/02/2022	human		CoronaVac			ZF001				Heterologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.2.12.1		NT50 GMT			weeks post booster1			4		187		1.87																												
5497		27	Peking University	BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection	https://doi.org/10.1101/2022.04.30.489997	Pre-print	05/02/2022	human		CoronaVac			CoronaVac				Homologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.4/5		NT50 GMT			weeks post booster1			4		75		1.00																												
5498		27	Peking University	BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection	https://doi.org/10.1101/2022.04.30.489997	Pre-print	05/02/2022	human		CoronaVac			ZF001				Heterologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.4/5		NT50 GMT			weeks post booster1			4		103		1.37																												
5499		28	Aix Marseille University	Immunogenicity and Safety of Beta Adjuvanted Recombinant Booster Vaccine	https://doi.org/10.1101/2022.05.25.22274904	Pre-print	05/27/2022	human		BNT162b2			BNT162b2				Homologous						1	Neutralization	Live virus replication assay	Microneutralization	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	NAbT GMT			days post booster1	0	96	15		1364.4	14.21	1.00																												
5500		28	Aix Marseille University	Immunogenicity and Safety of Beta Adjuvanted Recombinant Booster Vaccine	https://doi.org/10.1101/2022.05.25.22274904	Pre-print	05/27/2022	human		BNT162b2			MV D614				Heterologous						1	Neutralization	Live virus replication assay	Microneutralization	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	NAbT GMT			days post booster1	0	86.8	15		1168.4	13.46	0.95																												
5501		28	Aix Marseille University	Immunogenicity and Safety of Beta Adjuvanted Recombinant Booster Vaccine	https://doi.org/10.1101/2022.05.25.22274904	Pre-print	05/27/2022	human		BNT162b2			MV B.1.351				Heterologous						1	Neutralization	Live virus replication assay	Microneutralization	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	NAbT GMT			days post booster1	0	84	15		1801.4	21.45	1.51																												
5502		28	Aix Marseille University	Immunogenicity and Safety of Beta Adjuvanted Recombinant Booster Vaccine	https://doi.org/10.1101/2022.05.25.22274904	Pre-print	05/27/2022	human		BNT162b2			BNT162b2				Homologous						1	Neutralization	Live virus replication assay	Microneutralization	beta	B.1.351	B.1.351		NAbT GMT			days post booster1	0	38.6	15		428.4	11.10	1.00																												
5503		28	Aix Marseille University	Immunogenicity and Safety of Beta Adjuvanted Recombinant Booster Vaccine	https://doi.org/10.1101/2022.05.25.22274904	Pre-print	05/27/2022	human		BNT162b2			MV D614				Heterologous						1	Neutralization	Live virus replication assay	Microneutralization	beta	B.1.351	B.1.351		NAbT GMT			days post booster1	0	38.6	15		416.9	10.80	0.97																												
5504		28	Aix Marseille University	Immunogenicity and Safety of Beta Adjuvanted Recombinant Booster Vaccine	https://doi.org/10.1101/2022.05.25.22274904	Pre-print	05/27/2022	human		BNT162b2			MV B.1.351				Heterologous						1	Neutralization	Live virus replication assay	Microneutralization	beta	B.1.351	B.1.351		NAbT GMT			days post booster1	0	33.2	15		1053	31.72	2.86																												
5505		28	Aix Marseille University	Immunogenicity and Safety of Beta Adjuvanted Recombinant Booster Vaccine	https://doi.org/10.1101/2022.05.25.22274904	Pre-print	05/27/2022	human		BNT162b2			BNT162b2				Homologous						1	Neutralization	Live virus replication assay	Microneutralization	delta	B.1.617.2	B.1.617.2		NAbT GMT			days post booster1	0	41.5	15		553.1	13.33	1.00																												
5506		28	Aix Marseille University	Immunogenicity and Safety of Beta Adjuvanted Recombinant Booster Vaccine	https://doi.org/10.1101/2022.05.25.22274904	Pre-print	05/27/2022	human		BNT162b2			MV D614				Heterologous						1	Neutralization	Live virus replication assay	Microneutralization	delta	B.1.617.2	B.1.617.2		NAbT GMT			days post booster1	0	45.9	15		491.3	10.70	0.80																												
5507		28	Aix Marseille University	Immunogenicity and Safety of Beta Adjuvanted Recombinant Booster Vaccine	https://doi.org/10.1101/2022.05.25.22274904	Pre-print	05/27/2022	human		BNT162b2			MV B.1.351				Heterologous						1	Neutralization	Live virus replication assay	Microneutralization	delta	B.1.617.2	B.1.617.2		NAbT GMT			days post booster1	0	39.2	15		894.4	22.82	1.71																												
5508		28	Aix Marseille University	Immunogenicity and Safety of Beta Adjuvanted Recombinant Booster Vaccine	https://doi.org/10.1101/2022.05.25.22274904	Pre-print	05/27/2022	human		BNT162b2			BNT162b2				Homologous						1	Neutralization	Live virus replication assay	Microneutralization	Omicron	B.1.1.529	BA.1		NAbT GMT			days post booster1	0	19.1	15		139.5	7.30	1.00																												
5509		28	Aix Marseille University	Immunogenicity and Safety of Beta Adjuvanted Recombinant Booster Vaccine	https://doi.org/10.1101/2022.05.25.22274904	Pre-print	05/27/2022	human		BNT162b2			MV D614				Heterologous						1	Neutralization	Live virus replication assay	Microneutralization	Omicron	B.1.1.529	BA.1		NAbT GMT			days post booster1	0	22.5	15		123.9	5.51	0.75																												
5510		28	Aix Marseille University	Immunogenicity and Safety of Beta Adjuvanted Recombinant Booster Vaccine	https://doi.org/10.1101/2022.05.25.22274904	Pre-print	05/27/2022	human		BNT162b2			MV B.1.351				Heterologous						1	Neutralization	Live virus replication assay	Microneutralization	Omicron	B.1.1.529	BA.1		NAbT GMT			days post booster1	0	17.4	15		253.2	14.55	1.99																												
5511		28	Aix Marseille University	Immunogenicity and Safety of Beta Adjuvanted Recombinant Booster Vaccine	https://doi.org/10.1101/2022.05.25.22274904	Pre-print	05/27/2022	human		BNT162b2			BNT162b2				Homologous						2	Binding	ELISA						Anti-S1 Ab GMT	BAU/mL		days post booster1	0	253.6	15		2405.4	9.49	1.00																												
5512		28	Aix Marseille University	Immunogenicity and Safety of Beta Adjuvanted Recombinant Booster Vaccine	https://doi.org/10.1101/2022.05.25.22274904	Pre-print	05/27/2022	human		BNT162b2			MV D614				Heterologous						2	Binding	ELISA						Anti-S1 Ab GMT	BAU/mL		days post booster1	0	277.1	15		1875.1	6.77	0.71																												
5513		28	Aix Marseille University	Immunogenicity and Safety of Beta Adjuvanted Recombinant Booster Vaccine	https://doi.org/10.1101/2022.05.25.22274904	Pre-print	05/27/2022	human		BNT162b2			MV B.1.351				Heterologous						2	Binding	ELISA						Anti-S1 Ab GMT	BAU/mL		days post booster1	0	206.8	15		2240.8	10.84	1.14																												
5514		29	Chinese Academy of Medical Sciences	Safety and superior immunogenicity of heterologous boosting with an RBD-based SARS-CoV-2 mRNA vaccine in Chinese adults	https://doi.org/10.1101/2022.05.30.22275753	Pre-print	05/31/2022	human		CoronaVac			CoronaVac				Homologous						1	Neutralization	Live virus replication assay	Microneutralization	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		NAbT GMT			days post booster1	0	4.5	14		89.1	19.80	1.00	28		64.3	14.29	1.00																							
5515		29	Chinese Academy of Medical Sciences	Safety and superior immunogenicity of heterologous boosting with an RBD-based SARS-CoV-2 mRNA vaccine in Chinese adults	https://doi.org/10.1101/2022.05.30.22275753	Pre-print	06/01/2022	human		CoronaVac			Awcorna				Heterologous						1	Neutralization	Live virus replication assay	Microneutralization	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		NAbT GMT			days post booster1	0	4.4	14		293.9	66.80	3.37	28		242.4	55.09	3.86																							
5516		29	Chinese Academy of Medical Sciences	Safety and superior immunogenicity of heterologous boosting with an RBD-based SARS-CoV-2 mRNA vaccine in Chinese adults	https://doi.org/10.1101/2022.05.30.22275753	Pre-print	05/31/2022	human		CoronaVac			CoronaVac				Homologous						1	Neutralization	Live virus replication assay	Microneutralization	delta	B.1.617.2	B.1.617.2		NAbT GMT			days post booster1	0	4.1	14		56.5	13.78	1.00	28		39.8	9.71	1.00																							
5517		29	Chinese Academy of Medical Sciences	Safety and superior immunogenicity of heterologous boosting with an RBD-based SARS-CoV-2 mRNA vaccine in Chinese adults	https://doi.org/10.1101/2022.05.30.22275753	Pre-print	06/01/2022	human		CoronaVac			Awcorna				Heterologous						1	Neutralization	Live virus replication assay	Microneutralization	delta	B.1.617.2	B.1.617.2		NAbT GMT			days post booster1	0	4.2	14		286.8	68.29	4.96	28		257.8	61.38	6.32																							
5518		29	Chinese Academy of Medical Sciences	Safety and superior immunogenicity of heterologous boosting with an RBD-based SARS-CoV-2 mRNA vaccine in Chinese adults	https://doi.org/10.1101/2022.05.30.22275753	Pre-print	05/31/2022	human		CoronaVac			CoronaVac				Homologous						1	Neutralization	Live virus replication assay	Microneutralization	Omicron	B.1.1.529	B.1.1.529		NAbT GMT			days post booster1			28		6.4		1.00																												
5519		29	Chinese Academy of Medical Sciences	Safety and superior immunogenicity of heterologous boosting with an RBD-based SARS-CoV-2 mRNA vaccine in Chinese adults	https://doi.org/10.1101/2022.05.30.22275753	Pre-print	06/01/2022	human		CoronaVac			Awcorna				Heterologous						1	Neutralization	Live virus replication assay	Microneutralization	Omicron	B.1.1.529	B.1.1.529		NAbT GMT			days post booster1			28		28.1		4.39																												
5520		29	Chinese Academy of Medical Sciences	Safety and superior immunogenicity of heterologous boosting with an RBD-based SARS-CoV-2 mRNA vaccine in Chinese adults	https://doi.org/10.1101/2022.05.30.22275753	Pre-print	05/31/2022	human		CoronaVac			CoronaVac				Homologous						2	Binding	ELISA						Anti-RBD IgG GMT	BAU/mL		days post booster1	0	140.8	14		4317.8	30.67	1.00	28		3102.3	22.03	1.00																							
5926																																																																					
5927																																																																					
5521		29	Chinese Academy of Medical Sciences	Safety and superior immunogenicity of heterologous boosting with an RBD-based SARS-CoV-2 mRNA vaccine in Chinese adults	https://doi.org/10.1101/2022.05.30.22275753	Pre-print	06/01/2022	human		CoronaVac			Awcorna				Heterologous						2	Binding	ELISA						Anti-RBD IgG GMT	BAU/mL		days post booster1	0	134.7	14		29270.4	217.30	7.09	28		21874.4	162.39	7.37																							
5522		30	Jiangsu Province Center for Disease Control and Prevention	Heterologous CoronaVac plus Ad5-nCOV versus homologous CoronaVac vaccination among elderly: a phase 4, non-inferiority, randomized study	https://doi.org/10.1101/2022.06.03.22275983	Pre-print	06/06/2022	human	Over 60m years old	CoronaVac			CoronaVac			3-6 months interval	Homologous						1	Neutralization	Live virus replication assay	Microneutralization	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		NAbT GMT			days post booster1			14		48.2		1.00	28		42.2		1.00																							
5523		30	Jiangsu Province Center for Disease Control and Prevention	Heterologous CoronaVac plus Ad5-nCOV versus homologous CoronaVac vaccination among elderly: a phase 4, non-inferiority, randomized study	https://doi.org/10.1101/2022.06.03.22275983	Pre-print	06/06/2022	human	Over 60m years old	CoronaVac			Ad5-nCoV			3-6 months interval	Heterologous						1	Neutralization	Live virus replication assay	Microneutralization	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		NAbT GMT			days post booster1			14		286.4		5.94	28		243.5		5.77																							
5524		30	Jiangsu Province Center for Disease Control and Prevention	Heterologous CoronaVac plus Ad5-nCOV versus homologous CoronaVac vaccination among elderly: a phase 4, non-inferiority, randomized study	https://doi.org/10.1101/2022.06.03.22275983	Pre-print	06/06/2022	human	Over 60m years old	CoronaVac			CoronaVac			3-6 months interval	Homologous						1	Neutralization	Live virus replication assay	Microneutralization	delta	B.1.617.2	B.1.617.2		NAbT GMT			days post booster1			14		7.3		1.00																												
5525		30	Jiangsu Province Center for Disease Control and Prevention	Heterologous CoronaVac plus Ad5-nCOV versus homologous CoronaVac vaccination among elderly: a phase 4, non-inferiority, randomized study	https://doi.org/10.1101/2022.06.03.22275983	Pre-print	06/06/2022	human	Over 60m years old	CoronaVac			Ad5-nCoV			3-6 months interval	Heterologous						1	Neutralization	Live virus replication assay	Microneutralization	delta	B.1.617.2	B.1.617.2		NAbT GMT			days post booster1			14		45.9		6.29																												
5526		30	Jiangsu Province Center for Disease Control and Prevention	Heterologous CoronaVac plus Ad5-nCOV versus homologous CoronaVac vaccination among elderly: a phase 4, non-inferiority, randomized study	https://doi.org/10.1101/2022.06.03.22275983	Pre-print	06/06/2022	human	Over 60m years old	CoronaVac			CoronaVac			3-6 months interval	Homologous						1	Neutralization	Live virus replication assay	Microneutralization	Omicron	B.1.1.529	BA.1		NAbT GMT			days post booster1			14		4.4		1.00																												
5527		30	Jiangsu Province Center for Disease Control and Prevention	Heterologous CoronaVac plus Ad5-nCOV versus homologous CoronaVac vaccination among elderly: a phase 4, non-inferiority, randomized study	https://doi.org/10.1101/2022.06.03.22275983	Pre-print	06/06/2022	human	Over 60m years old	CoronaVac			Ad5-nCoV			3-6 months interval	Heterologous						1	Neutralization	Live virus replication assay	Microneutralization	Omicron	B.1.1.529	BA.1		NAbT GMT			days post booster1			14		32.9		7.48																												
5528		30	Jiangsu Province Center for Disease Control and Prevention	Heterologous CoronaVac plus Ad5-nCOV versus homologous CoronaVac vaccination among elderly: a phase 4, non-inferiority, randomized study	https://doi.org/10.1101/2022.06.03.22275983	Pre-print	06/06/2022	human	Over 60m years old	CoronaVac			CoronaVac			3-6 months interval	Homologous						2	Binding	ELISA						Anti-RBD IgG GMC	BAU/mL		days post booster1	0	23.4	14		253.8	10.85	1.00	28		227	9.70	1.00																							
5529		30	Jiangsu Province Center for Disease Control and Prevention	Heterologous CoronaVac plus Ad5-nCOV versus homologous CoronaVac vaccination among elderly: a phase 4, non-inferiority, randomized study	https://doi.org/10.1101/2022.06.03.22275983	Pre-print	06/06/2022	human	Over 60m years old	CoronaVac			Ad5-nCoV			3-6 months interval	Heterologous						2	Binding	ELISA						Anti-RBD IgG GMC	BAU/mL		days post booster1	0	22.6	14		1731.9	76.63	7.07	28		1355.9	60.00	6.18																							
5530		31	Jiangsu Province Center for Disease Control and Prevention	Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial	https://doi.org/10.1038/s41591-021-01677-z	Peer-reviewed publication	01/27/2022	human	18-59 years old	CoronaVac			CoronaVac			3-6 months interval	Homologous						1	Neutralization	Live virus replication assay	Microneutralization	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		NAbT GMT			days post booster1	0	2.2	14		33.6	15.27	1.00	28		35.3	16.05	1.00																							
5531		31	Jiangsu Province Center for Disease Control and Prevention	Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial	https://doi.org/10.1038/s41591-021-01677-z	Peer-reviewed publication	01/27/2022	human	18-59 years old	CoronaVac			Ad5-nCoV			3-6 months interval	Heterologous						1	Neutralization	Live virus replication assay	Microneutralization	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		NAbT GMT			days post booster1	0	2.5	14		197.4	78.96	5.17	28		150.3	60.12	3.75																							
5532		31	Jiangsu Province Center for Disease Control and Prevention	Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial	https://doi.org/10.1038/s41591-021-01677-z	Peer-reviewed publication	01/27/2022	human	18-59 years old	CoronaVac			CoronaVac			3-6 months interval	Homologous						1	Neutralization	Live virus replication assay	Microneutralization	delta	B.1.617.2	B.1.617.2		NAbT GMT			days post booster1	0	2.1	14		8.2	3.90	1.00																												
5533		31	Jiangsu Province Center for Disease Control and Prevention	Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial	https://doi.org/10.1038/s41591-021-01677-z	Peer-reviewed publication	01/27/2022	human	18-59 years old	CoronaVac			Ad5-nCoV			3-6 months interval	Heterologous						1	Neutralization	Live virus replication assay	Microneutralization	delta	B.1.617.2	B.1.617.2		NAbT GMT			days post booster1	0	2.2	14		55	25.00	6.40																												
5534		32	Chulalongkorn University	Persistence of immunity against omicron BA.1 and BA.2 following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-doses AZD1222 vaccination	https://doi.org/10.1101/2022.06.05.22276016	Pre-print	06/06/2022	human		ChAdOx1 nCoV-19			ChAdOx1 nCoV-19				Homologous						1	Binding	Elecsys						Total RBD Ig	U/mL		days post booster1	0	298	14		2069	6.94	1.00	28		2121	7.12	1.00	90		1303	4.37	1.00																		
5535		32	Chulalongkorn University	Persistence of immunity against omicron BA.1 and BA.2 following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-doses AZD1222 vaccination	https://doi.org/10.1101/2022.06.05.22276016	Pre-print	06/06/2022	human		ChAdOx1 nCoV-19			BNT162b2				Heterologous						1	Binding	Elecsys						Total RBD Ig	U/mL		days post booster1	0	216	14		13651	63.20	9.11	28		10919	50.55	7.10	90		3974	18.40	4.21																		
5536		32	Chulalongkorn University	Persistence of immunity against omicron BA.1 and BA.2 following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-doses AZD1222 vaccination	https://doi.org/10.1101/2022.06.05.22276016	Pre-print	06/06/2022	human		ChAdOx1 nCoV-19			mRNA-1273	100	?g		Heterologous						1	Binding	Elecsys						Total RBD Ig	U/mL		days post booster1	0	200	14		28172	140.86	20.30	28		16950	84.75	11.90	90		5516	27.58	6.31																		
5537		32	Chulalongkorn University	Persistence of immunity against omicron BA.1 and BA.2 following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-doses AZD1222 vaccination	https://doi.org/10.1101/2022.06.05.22276016	Pre-print	06/06/2022	human		ChAdOx1 nCoV-19			mRNA-1273	50	?g		Heterologous						1	Binding	Elecsys						Total RBD Ig	U/mL		days post booster1	0	284	14		25824	90.93	13.10	28		16701	58.81	8.26	90		6120	21.55	4.93																		
5538		32	Chulalongkorn University	Persistence of immunity against omicron BA.1 and BA.2 following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-doses AZD1222 vaccination	https://doi.org/10.1101/2022.06.05.22276016	Pre-print	06/06/2022	human		ChAdOx1 nCoV-19			ChAdOx1 nCoV-19				Homologous						2	Binding	ELISA						Anti-RBD IgG GMT	BAU/mL		days post booster1	0	60.7	14		268	4.42	1.00	28		277	4.56	1.00	90		190	3.13	1.00																		
5539		32	Chulalongkorn University	Persistence of immunity against omicron BA.1 and BA.2 following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-doses AZD1222 vaccination	https://doi.org/10.1101/2022.06.05.22276016	Pre-print	06/06/2022	human		ChAdOx1 nCoV-19			BNT162b2				Heterologous						2	Binding	ELISA						Anti-RBD IgG GMT	BAU/mL		days post booster1	0	46.2	14		2285	49.46	11.19	28		1625	35.17	7.71	90		536	11.60	3.71																		
5540		32	Chulalongkorn University	Persistence of immunity against omicron BA.1 and BA.2 following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-doses AZD1222 vaccination	https://doi.org/10.1101/2022.06.05.22276016	Pre-print	06/06/2022	human		ChAdOx1 nCoV-19			mRNA-1273	100	?g		Heterologous						2	Binding	ELISA						Anti-RBD IgG GMT	BAU/mL		days post booster1	0	41.1	14		3864	94.01	21.27	28		2763	67.23	14.74	90		818	19.90	6.36																		
5541		32	Chulalongkorn University	Persistence of immunity against omicron BA.1 and BA.2 following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-doses AZD1222 vaccination	https://doi.org/10.1101/2022.06.05.22276016	Pre-print	06/06/2022	human		ChAdOx1 nCoV-19			mRNA-1273	50	?g		Heterologous						2	Binding	ELISA						Anti-RBD IgG GMT	BAU/mL		days post booster1	0	56.1	14		3976	70.87	16.03	28		2484	44.28	9.71	90		885	15.78	5.04																		
5542		32	Chulalongkorn University	Persistence of immunity against omicron BA.1 and BA.2 following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-doses AZD1222 vaccination	https://doi.org/10.1101/2022.06.05.22276016	Pre-print	06/06/2022	human		ChAdOx1 nCoV-19			ChAdOx1 nCoV-19				Homologous						1	Neutralization	Pseudotyped virus assay	Surrogate Virus Neutralization	delta	B.1.617.2	B.1.617.2		sVNT % Inhibition GMT			days post booster1	0	40.3	28		93.5	2.32	1.00	90		78	1.94	1.00																							
5543		32	Chulalongkorn University	Persistence of immunity against omicron BA.1 and BA.2 following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-doses AZD1222 vaccination	https://doi.org/10.1101/2022.06.05.22276016	Pre-print	06/06/2022	human		ChAdOx1 nCoV-19			BNT162b2				Heterologous						1	Neutralization	Pseudotyped virus assay	Surrogate Virus Neutralization	delta	B.1.617.2	B.1.617.2		sVNT % Inhibition GMT			days post booster1	0	20.5	28		96.9	4.73	2.04	90		96.9	4.73	2.44																							
5544		32	Chulalongkorn University	Persistence of immunity against omicron BA.1 and BA.2 following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-doses AZD1222 vaccination	https://doi.org/10.1101/2022.06.05.22276016	Pre-print	06/06/2022	human		ChAdOx1 nCoV-19			mRNA-1273	100	?g		Heterologous						1	Neutralization	Pseudotyped virus assay	Surrogate Virus Neutralization	delta	B.1.617.2	B.1.617.2		sVNT % Inhibition GMT			days post booster1	0	21	28		97.9	4.66	2.01	90		97.6	4.65	2.40																							
5545		32	Chulalongkorn University	Persistence of immunity against omicron BA.1 and BA.2 following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-doses AZD1222 vaccination	https://doi.org/10.1101/2022.06.05.22276016	Pre-print	06/06/2022	human		ChAdOx1 nCoV-19			mRNA-1273	50	?g		Heterologous						1	Neutralization	Pseudotyped virus assay	Surrogate Virus Neutralization	delta	B.1.617.2	B.1.617.2		sVNT % Inhibition GMT			days post booster1	0	28.2	28		97	3.44	1.48	90		97.7	3.46	1.79																							
5546		32	Chulalongkorn University	Persistence of immunity against omicron BA.1 and BA.2 following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-doses AZD1222 vaccination	https://doi.org/10.1101/2022.06.05.22276016	Pre-print	06/06/2022	human		ChAdOx1 nCoV-19			ChAdOx1 nCoV-19				Homologous						1	Neutralization	Pseudotyped virus assay	Surrogate Virus Neutralization	Omicron	B.1.1.529	BA.1		sVNT % Inhibition GMT			days post booster1	0	11.3	28		15	1.33	1.00	90		9	0.80	1.00																							
5547		32	Chulalongkorn University	Persistence of immunity against omicron BA.1 and BA.2 following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-doses AZD1222 vaccination	https://doi.org/10.1101/2022.06.05.22276016	Pre-print	06/06/2022	human		ChAdOx1 nCoV-19			BNT162b2				Heterologous						1	Neutralization	Pseudotyped virus assay	Surrogate Virus Neutralization	Omicron	B.1.1.529	BA.1		sVNT % Inhibition GMT			days post booster1	0	15.4	28		67.1	4.36	3.28	90		33.2	2.16	2.69																							
5548		32	Chulalongkorn University	Persistence of immunity against omicron BA.1 and BA.2 following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-doses AZD1222 vaccination	https://doi.org/10.1101/2022.06.05.22276016	Pre-print	06/06/2022	human		ChAdOx1 nCoV-19			mRNA-1273	100	?g		Heterologous						1	Neutralization	Pseudotyped virus assay	Surrogate Virus Neutralization	Omicron	B.1.1.529	BA.1		sVNT % Inhibition GMT			days post booster1	0	3.23	28		64.6	20.00	15.04	90		35.5	10.99	13.74																							
5549		32	Chulalongkorn University	Persistence of immunity against omicron BA.1 and BA.2 following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-doses AZD1222 vaccination	https://doi.org/10.1101/2022.06.05.22276016	Pre-print	06/06/2022	human		ChAdOx1 nCoV-19			mRNA-1273	50	?g		Heterologous						1	Neutralization	Pseudotyped virus assay	Surrogate Virus Neutralization	Omicron	B.1.1.529	BA.1		sVNT % Inhibition GMT			days post booster1	0	7.5	28		65.7	8.76	6.59	90		38.7	5.16	6.45																							
5740		41	Pfizer	Pfizer Quarterly Corporate Performance  Second Quarter 2022	https://s28.q4cdn.com/781576035/files/doc_financials/2022/q2/Q2-2022-Earnings-Charts-FINAL.pdf	Press release	07/28/2022	mice		BNT162b2			BNT162b2				Homologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.2		pVNT50 GMT								872		1.00																												
5550		32	Chulalongkorn University	Persistence of immunity against omicron BA.1 and BA.2 following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-doses AZD1222 vaccination	https://doi.org/10.1101/2022.06.05.22276016	Pre-print	06/06/2022	human		ChAdOx1 nCoV-19			ChAdOx1 nCoV-19				Homologous						2	Neutralization	Live virus replication assay	FRNT50	Omicron	B.1.1.529	BA.1		FRNT50 GMT			days post booster1	0	13	28		32.2	2.48	1.00	90		21.6	1.66	1.00																							
5551		32	Chulalongkorn University	Persistence of immunity against omicron BA.1 and BA.2 following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-doses AZD1222 vaccination	https://doi.org/10.1101/2022.06.05.22276016	Pre-print	06/06/2022	human		ChAdOx1 nCoV-19			BNT162b2				Heterologous						2	Neutralization	Live virus replication assay	FRNT50	Omicron	B.1.1.529	BA.1		FRNT50 GMT			days post booster1	0	10	28		166	16.60	12.48	90		78.1	7.81	9.76																							
5552		32	Chulalongkorn University	Persistence of immunity against omicron BA.1 and BA.2 following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-doses AZD1222 vaccination	https://doi.org/10.1101/2022.06.05.22276016	Pre-print	06/06/2022	human		ChAdOx1 nCoV-19			mRNA-1273	100	?g		Heterologous						2	Neutralization	Live virus replication assay	FRNT50	Omicron	B.1.1.529	BA.1		FRNT50 GMT			days post booster1	0	16.6	28		548	33.01	24.82	90		141	8.49	10.62																							
5553		32	Chulalongkorn University	Persistence of immunity against omicron BA.1 and BA.2 following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-doses AZD1222 vaccination	https://doi.org/10.1101/2022.06.05.22276016	Pre-print	06/06/2022	human		ChAdOx1 nCoV-19			mRNA-1273	50	?g		Heterologous						2	Neutralization	Live virus replication assay	FRNT50	Omicron	B.1.1.529	BA.1		FRNT50 GMT			days post booster1	0	14.6	28		396	27.12	20.39	90		119	8.15	10.19																							
5554		32	Chulalongkorn University	Persistence of immunity against omicron BA.1 and BA.2 following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-doses AZD1222 vaccination	https://doi.org/10.1101/2022.06.05.22276016	Pre-print	06/06/2022	human		ChAdOx1 nCoV-19			ChAdOx1 nCoV-19				Homologous						2	Neutralization	Live virus replication assay	FRNT50	Omicron	B.1.1.529	BA.2		FRNT50 GMT			days post booster1	0	12.5	28		45.6	3.65	1.00	90		32.6	2.61	1.00																							
5555		32	Chulalongkorn University	Persistence of immunity against omicron BA.1 and BA.2 following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-doses AZD1222 vaccination	https://doi.org/10.1101/2022.06.05.22276016	Pre-print	06/06/2022	human		ChAdOx1 nCoV-19			BNT162b2				Heterologous						2	Neutralization	Live virus replication assay	FRNT50	Omicron	B.1.1.529	BA.2		FRNT50 GMT			days post booster1	0	15	28		248	16.53	4.53	90		73.8	4.92	1.89																							
5556		32	Chulalongkorn University	Persistence of immunity against omicron BA.1 and BA.2 following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-doses AZD1222 vaccination	https://doi.org/10.1101/2022.06.05.22276016	Pre-print	06/06/2022	human		ChAdOx1 nCoV-19			mRNA-1273	100	?g		Heterologous						2	Neutralization	Live virus replication assay	FRNT50	Omicron	B.1.1.529	BA.2		FRNT50 GMT			days post booster1	0	11	28		324	29.45	8.07	90		122	11.09	4.25																							
5557		32	Chulalongkorn University	Persistence of immunity against omicron BA.1 and BA.2 following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-doses AZD1222 vaccination	https://doi.org/10.1101/2022.06.05.22276016	Pre-print	06/06/2022	human		ChAdOx1 nCoV-19			mRNA-1273	50	?g		Heterologous						2	Neutralization	Live virus replication assay	FRNT50	Omicron	B.1.1.529	BA.2		FRNT50 GMT			days post booster1	0	13	28		224	17.23	4.72	90		111	8.54	3.27																							
5558		33	Moderna	A Bivalent Omicron-containing Booster Vaccine Against Covid-19	https://doi.org/10.1056/NEJMoa2208343	Peer-reviewed publication	10/06/2022	human		mRNA-1273	100	?g	mRNA-1273	50	?g		Homologous	mRNA-1273	50	?g		Homologous	1	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	ID50 GMT			days post booster1	0	1521	28		5649.3	3.71	1.00																												
5559		33	Moderna	A Bivalent Omicron-containing Booster Vaccine Against Covid-19	https://doi.org/10.1056/NEJMoa2208343	Peer-reviewed publication	10/06/2022	human		mRNA-1273	100	?g	mRNA-1273	50	?g		Homologous	mRNA-1273.214	50	?g		Variant	1	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	ID50 GMT			days post booster1	0	1266.7	28		5977.3	4.72	1.27																												
5560		33	Moderna	A Bivalent Omicron-containing Booster Vaccine Against Covid-19	https://doi.org/10.1056/NEJMoa2208343	Peer-reviewed publication	10/06/2022	human		mRNA-1273	100	?g	mRNA-1273	50	?g		Homologous	mRNA-1273	50	?g		Homologous	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.1		ID50 GMT			days post booster1	0	332	28		1473.5	4.44	1.00																												
5561		33	Moderna	A Bivalent Omicron-containing Booster Vaccine Against Covid-19	https://doi.org/10.1056/NEJMoa2208343	Peer-reviewed publication	10/06/2022	human		mRNA-1273	100	?g	mRNA-1273	50	?g		Homologous	mRNA-1273.214	50	?g		Variant	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.1		ID50 GMT			days post booster1	0	298.1	28		2372.4	7.96	1.79																												
5562		33	Moderna	A Bivalent Omicron-containing Booster Vaccine Against Covid-19	https://doi.org/10.1056/NEJMoa2208343	Peer-reviewed publication	10/06/2022	human		mRNA-1273	100	?g	mRNA-1273	50	?g		Homologous	mRNA-1273	50	?g		Homologous	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.4/5		ID50 GMT			days post booster1	0	140	28		492	3.51	1.00																												
5563		33	Moderna	A Bivalent Omicron-containing Booster Vaccine Against Covid-19	https://doi.org/10.1056/NEJMoa2208343	Peer-reviewed publication	10/06/2022	human		mRNA-1273	100	?g	mRNA-1273	50	?g		Homologous	mRNA-1273.214	50	?g		Variant	1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.4/5		ID50 GMT			days post booster1	0	116	28		727	6.27	1.78																												
5564		33	Moderna	A Bivalent Omicron-containing Booster Vaccine Against Covid-19	https://doi.org/10.1056/NEJMoa2208343	Peer-reviewed publication	10/06/2022	human		mRNA-1273	100	?g	mRNA-1273	50	?g		Homologous	mRNA-1273	50	?g		Homologous	2	Binding	Meso Scale Discovery assay		Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	Anti-spike IgG GM	AU/mL		days post booster1	0	299028	28		753438	2.52	1.00																												
5565		33	Moderna	A Bivalent Omicron-containing Booster Vaccine Against Covid-19	https://doi.org/10.1056/NEJMoa2208343	Peer-reviewed publication	10/06/2022	human		mRNA-1273	100	?g	mRNA-1273	50	?g		Homologous	mRNA-1273.214	50	?g		Variant	2	Binding	Meso Scale Discovery assay		Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	Anti-spike IgG GM	AU/mL		days post booster1	0	282635	28		856394	3.03	1.20																												
5854																																																																					
5855																																																																					
5566		33	Moderna	A Bivalent Omicron-containing Booster Vaccine Against Covid-19	https://doi.org/10.1056/NEJMoa2208343	Peer-reviewed publication	10/06/2022	human		mRNA-1273	100	?g	mRNA-1273	50	?g		Homologous	mRNA-1273	50	?g		Homologous	2	Binding	Meso Scale Discovery assay		Omicron	B.1.1.529	BA.1		Anti-spike IgG GM	AU/mL		days post booster1	0	58640	28		163486	2.79	1.00																												
5567		33	Moderna	A Bivalent Omicron-containing Booster Vaccine Against Covid-19	https://doi.org/10.1056/NEJMoa2208343	Peer-reviewed publication	10/06/2022	human		mRNA-1273	100	?g	mRNA-1273	50	?g		Homologous	mRNA-1273.214	50	?g		Variant	2	Binding	Meso Scale Discovery assay		Omicron	B.1.1.529	BA.1		Anti-spike IgG GM	AU/mL		days post booster1	0	54956	28		201367	3.66	1.31																												
5568		33	Moderna	A Bivalent Omicron-containing Booster Vaccine Against Covid-19	https://doi.org/10.1056/NEJMoa2208343	Peer-reviewed publication	10/06/2022	human		mRNA-1273	100	?g	mRNA-1273	50	?g		Homologous	mRNA-1273	50	?g		Homologous	2	Binding	Meso Scale Discovery assay		beta				Anti-spike IgG GM	AU/mL		days post booster1	0	135259	28		352739	2.61	1.00																												
5569		33	Moderna	A Bivalent Omicron-containing Booster Vaccine Against Covid-19	https://doi.org/10.1056/NEJMoa2208343	Peer-reviewed publication	10/06/2022	human		mRNA-1273	100	?g	mRNA-1273	50	?g		Homologous	mRNA-1273.214	50	?g		Variant	2	Binding	Meso Scale Discovery assay		beta				Anti-spike IgG GM	AU/mL		days post booster1	0	127083	28		403166	3.17	1.22																												
5570		33	Moderna	A Bivalent Omicron-containing Booster Vaccine Against Covid-19	https://doi.org/10.1056/NEJMoa2208343	Peer-reviewed publication	10/06/2022	human		mRNA-1273	100	?g	mRNA-1273	50	?g		Homologous	mRNA-1273	50	?g		Homologous	2	Binding	Meso Scale Discovery assay		delta				Anti-spike IgG GM	AU/mL		days post booster1	0	193939	28		502005	2.59	1.00																												
5571		33	Moderna	A Bivalent Omicron-containing Booster Vaccine Against Covid-19	https://doi.org/10.1056/NEJMoa2208343	Peer-reviewed publication	10/06/2022	human		mRNA-1273	100	?g	mRNA-1273	50	?g		Homologous	mRNA-1273.214	50	?g		Variant	2	Binding	Meso Scale Discovery assay		delta				Anti-spike IgG GM	AU/mL		days post booster1	0	181213	28		546450	3.02	1.16																												
5572		33	Moderna	A Bivalent Omicron-containing Booster Vaccine Against Covid-19	https://doi.org/10.1056/NEJMoa2208343	Peer-reviewed publication	10/06/2022	human		mRNA-1273	100	?g	mRNA-1273	50	?g		Homologous	mRNA-1273	50	?g		Homologous	2	Binding	Meso Scale Discovery assay		gamma				Anti-spike IgG GM	AU/mL		days post booster1	0	150030	28		384401	2.56	1.00																												
5573		33	Moderna	A Bivalent Omicron-containing Booster Vaccine Against Covid-19	https://doi.org/10.1056/NEJMoa2208343	Peer-reviewed publication	10/06/2022	human		mRNA-1273	100	?g	mRNA-1273	50	?g		Homologous	mRNA-1273.214	50	?g		Variant	2	Binding	Meso Scale Discovery assay		gamma				Anti-spike IgG GM	AU/mL		days post booster1	0	138574	28		441810	3.19	1.24																												
5574		33	Moderna	A Bivalent Omicron-containing Booster Vaccine Against Covid-19	https://doi.org/10.1056/NEJMoa2208343	Peer-reviewed publication	10/06/2022	human		mRNA-1273	100	?g	mRNA-1273	50	?g		Homologous	mRNA-1273	50	?g		Homologous	2	Binding	Meso Scale Discovery assay		alpha				Anti-spike IgG GM	AU/mL		days post booster1	0	223595	28		568576	2.54	1.00																												
5575		33	Moderna	A Bivalent Omicron-containing Booster Vaccine Against Covid-19	https://doi.org/10.1056/NEJMoa2208343	Peer-reviewed publication	10/06/2022	human		mRNA-1273	100	?g	mRNA-1273	50	?g		Homologous	mRNA-1273.214	50	?g		Variant	2	Binding	Meso Scale Discovery assay		alpha				Anti-spike IgG GM	AU/mL		days post booster1	0	207587	28		652098	3.14	1.24																												
5576		34	Chulalongkorn University	Strong correlations between the binding antibodies against wild type and neutralizing antibodies against omicron BA.1 and BA.2 variants of SARS-CoV-2 in individuals following booster (third dose) vaccination	https://doi.org/10.1101/2022.06.27.22276959	Pre-print	06/27/2022	human		ChAdOx1 nCoV-19			ChAdOx1 nCoV-19				Homologous						1	Binding	Chemiluminescent microparticle immunoassay						Anti-RBD IgG GMT	BAU/mL		days post booster1	0	67.4	28		298.5	4.43	1.00																												
5577		34	Chulalongkorn University	Strong correlations between the binding antibodies against wild type and neutralizing antibodies against omicron BA.1 and BA.2 variants of SARS-CoV-2 in individuals following booster (third dose) vaccination	https://doi.org/10.1101/2022.06.27.22276959	Pre-print	06/27/2022	human		ChAdOx1 nCoV-19			mRNA-1273	50	?g		Heterologous						1	Binding	Chemiluminescent microparticle immunoassay						Anti-RBD IgG GMT	BAU/mL		days post booster1	0	46.8	28		2160	46.15	10.42	90		901.2	19.26																								
5578		34	Chulalongkorn University	Strong correlations between the binding antibodies against wild type and neutralizing antibodies against omicron BA.1 and BA.2 variants of SARS-CoV-2 in individuals following booster (third dose) vaccination	https://doi.org/10.1101/2022.06.27.22276959	Pre-print	06/27/2022	human		ChAdOx1 nCoV-19			mRNA-1273	100	?g		Heterologous						1	Binding	Chemiluminescent microparticle immunoassay						Anti-RBD IgG GMT	BAU/mL		days post booster1	0	43.6	28		3034	69.59	15.71	90		916	21.01																								
5579		34	Chulalongkorn University	Strong correlations between the binding antibodies against wild type and neutralizing antibodies against omicron BA.1 and BA.2 variants of SARS-CoV-2 in individuals following booster (third dose) vaccination	https://doi.org/10.1101/2022.06.27.22276959	Pre-print	06/27/2022	human		ChAdOx1 nCoV-19			BNT162b2				Heterologous						1	Binding	Chemiluminescent microparticle immunoassay						Anti-RBD IgG GMT	BAU/mL		days post booster1	0	43.3	28		1876	43.33	9.78	90		556	12.84																								
5580		34	Chulalongkorn University	Strong correlations between the binding antibodies against wild type and neutralizing antibodies against omicron BA.1 and BA.2 variants of SARS-CoV-2 in individuals following booster (third dose) vaccination	https://doi.org/10.1101/2022.06.27.22276959	Pre-print	06/27/2022	human		ChAdOx1 nCoV-19			ChAdOx1 nCoV-19				Homologous						2	Neutralization	Pseudotyped virus assay	Surrogate Virus Neutralization	Omicron	B.1.1.529	BA.1		sVNT GMT			days post booster1			28		15		1.00																												
5581		34	Chulalongkorn University	Strong correlations between the binding antibodies against wild type and neutralizing antibodies against omicron BA.1 and BA.2 variants of SARS-CoV-2 in individuals following booster (third dose) vaccination	https://doi.org/10.1101/2022.06.27.22276959	Pre-print	06/27/2022	human		ChAdOx1 nCoV-19			mRNA-1273	50	?g		Heterologous						2	Neutralization	Pseudotyped virus assay	Surrogate Virus Neutralization	Omicron	B.1.1.529	BA.1		sVNT GMT			days post booster1			28		65.7		4.38	90		38																									
5597		35	Fudan University	Neutralization of Omicron BA.4/BA.5 and BA.2.75 by Booster Vaccination or BA.2 Breakthrough Infection Sera	https://doi.org/10.1101/2022.08.04.502716	Pre-print	08/06/2022	human		BBIBP-CorV			ZF2001				Heterologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.1		Reciprocal ID50 GMT			days post booster1			14		155		2.98																												
5582		34	Chulalongkorn University	Strong correlations between the binding antibodies against wild type and neutralizing antibodies against omicron BA.1 and BA.2 variants of SARS-CoV-2 in individuals following booster (third dose) vaccination	https://doi.org/10.1101/2022.06.27.22276959	Pre-print	06/27/2022	human		ChAdOx1 nCoV-19			mRNA-1273	100	?g		Heterologous						2	Neutralization	Pseudotyped virus assay	Surrogate Virus Neutralization	Omicron	B.1.1.529	BA.1		sVNT GMT			days post booster1			28		67.7		4.51	90		54.4																									
5583		34	Chulalongkorn University	Strong correlations between the binding antibodies against wild type and neutralizing antibodies against omicron BA.1 and BA.2 variants of SARS-CoV-2 in individuals following booster (third dose) vaccination	https://doi.org/10.1101/2022.06.27.22276959	Pre-print	06/27/2022	human		ChAdOx1 nCoV-19			BNT162b2				Heterologous						2	Neutralization	Pseudotyped virus assay	Surrogate Virus Neutralization	Omicron	B.1.1.529	BA.1		sVNT GMT			days post booster1			28		70.3		4.69	90		32.5																									
5584		34	Chulalongkorn University	Strong correlations between the binding antibodies against wild type and neutralizing antibodies against omicron BA.1 and BA.2 variants of SARS-CoV-2 in individuals following booster (third dose) vaccination	https://doi.org/10.1101/2022.06.27.22276959	Pre-print	06/27/2022	human		ChAdOx1 nCoV-19			ChAdOx1 nCoV-19				Homologous						3	Neutralization	Live virus replication assay	FRNT50	Omicron	B.1.1.529	BA.1		FRNT50 GMT			days post booster1	0	13	28		32.2	2.48	1.00																												
5585		34	Chulalongkorn University	Strong correlations between the binding antibodies against wild type and neutralizing antibodies against omicron BA.1 and BA.2 variants of SARS-CoV-2 in individuals following booster (third dose) vaccination	https://doi.org/10.1101/2022.06.27.22276959	Pre-print	06/27/2022	human		ChAdOx1 nCoV-19			mRNA-1273	50	?g		Heterologous						3	Neutralization	Live virus replication assay	FRNT50	Omicron	B.1.1.529	BA.1		FRNT50 GMT			days post booster1	0	14.6	28		396.5	27.16	10.95	90		119.1																									
5586		34	Chulalongkorn University	Strong correlations between the binding antibodies against wild type and neutralizing antibodies against omicron BA.1 and BA.2 variants of SARS-CoV-2 in individuals following booster (third dose) vaccination	https://doi.org/10.1101/2022.06.27.22276959	Pre-print	06/27/2022	human		ChAdOx1 nCoV-19			mRNA-1273	100	?g		Heterologous						3	Neutralization	Live virus replication assay	FRNT50	Omicron	B.1.1.529	BA.1		FRNT50 GMT			days post booster1	0	16.6	28		547.8	33.00	13.31	90		141																									
5587		34	Chulalongkorn University	Strong correlations between the binding antibodies against wild type and neutralizing antibodies against omicron BA.1 and BA.2 variants of SARS-CoV-2 in individuals following booster (third dose) vaccination	https://doi.org/10.1101/2022.06.27.22276959	Pre-print	06/27/2022	human		ChAdOx1 nCoV-19			BNT162b2				Heterologous						3	Neutralization	Live virus replication assay	FRNT50	Omicron	B.1.1.529	BA.1		FRNT50 GMT			days post booster1	0	10	28		166.3	16.63	6.71	90		78.1																									
5588		34	Chulalongkorn University	Strong correlations between the binding antibodies against wild type and neutralizing antibodies against omicron BA.1 and BA.2 variants of SARS-CoV-2 in individuals following booster (third dose) vaccination	https://doi.org/10.1101/2022.06.27.22276959	Pre-print	06/27/2022	human		ChAdOx1 nCoV-19			ChAdOx1 nCoV-19				Homologous						3	Neutralization	Live virus replication assay	FRNT50	Omicron	B.1.1.529	BA.2		FRNT50 GMT			days post booster1	0	12.5	28		45.6	3.65	1.00																												
5589		34	Chulalongkorn University	Strong correlations between the binding antibodies against wild type and neutralizing antibodies against omicron BA.1 and BA.2 variants of SARS-CoV-2 in individuals following booster (third dose) vaccination	https://doi.org/10.1101/2022.06.27.22276959	Pre-print	06/27/2022	human		ChAdOx1 nCoV-19			mRNA-1273	50	?g		Heterologous						3	Neutralization	Live virus replication assay	FRNT50	Omicron	B.1.1.529	BA.2		FRNT50 GMT			days post booster1	0	13	28		224.5	17.27	4.73	90		110.5																									
5590		34	Chulalongkorn University	Strong correlations between the binding antibodies against wild type and neutralizing antibodies against omicron BA.1 and BA.2 variants of SARS-CoV-2 in individuals following booster (third dose) vaccination	https://doi.org/10.1101/2022.06.27.22276959	Pre-print	06/27/2022	human		ChAdOx1 nCoV-19			mRNA-1273	100	?g		Heterologous						3	Neutralization	Live virus replication assay	FRNT50	Omicron	B.1.1.529	BA.2		FRNT50 GMT			days post booster1	0	11	28		324.2	29.47	8.07	90		122																									
5591		34	Chulalongkorn University	Strong correlations between the binding antibodies against wild type and neutralizing antibodies against omicron BA.1 and BA.2 variants of SARS-CoV-2 in individuals following booster (third dose) vaccination	https://doi.org/10.1101/2022.06.27.22276959	Pre-print	06/27/2022	human		ChAdOx1 nCoV-19			BNT162b2				Heterologous						3	Neutralization	Live virus replication assay	FRNT50	Omicron	B.1.1.529	BA.2		FRNT50 GMT			days post booster1	0	15	28		247.7	16.51	4.52	90		73.8																									
5592		35	Fudan University	Neutralization of Omicron BA.4/BA.5 and BA.2.75 by Booster Vaccination or BA.2 Breakthrough Infection Sera	https://doi.org/10.1101/2022.08.04.502716	Pre-print	08/06/2022	human		BBIBP-CorV			BBIBP-CorV				Homologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	Reciprocal ID50 GMT			days post booster1			14		278		1.00																												
5593		35	Fudan University	Neutralization of Omicron BA.4/BA.5 and BA.2.75 by Booster Vaccination or BA.2 Breakthrough Infection Sera	https://doi.org/10.1101/2022.08.04.502716	Pre-print	08/06/2022	human		BBIBP-CorV			ZF2001				Heterologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	Reciprocal ID50 GMT			days post booster1			14		1179		4.24																												
5594		35	Fudan University	Neutralization of Omicron BA.4/BA.5 and BA.2.75 by Booster Vaccination or BA.2 Breakthrough Infection Sera	https://doi.org/10.1101/2022.08.04.502716	Pre-print	08/06/2022	human		BBIBP-CorV			BBIBP-CorV				Homologous						1	Neutralization	Pseudotyped virus assay	Luciferase	delta	B.1.617.2	B.1.617.2		Reciprocal ID50 GMT			days post booster1			14		133		1.00																												
5595		35	Fudan University	Neutralization of Omicron BA.4/BA.5 and BA.2.75 by Booster Vaccination or BA.2 Breakthrough Infection Sera	https://doi.org/10.1101/2022.08.04.502716	Pre-print	08/06/2022	human		BBIBP-CorV			ZF2001				Heterologous						1	Neutralization	Pseudotyped virus assay	Luciferase	delta	B.1.617.2	B.1.617.2		Reciprocal ID50 GMT			days post booster1			14		593		4.46																												
5596		35	Fudan University	Neutralization of Omicron BA.4/BA.5 and BA.2.75 by Booster Vaccination or BA.2 Breakthrough Infection Sera	https://doi.org/10.1101/2022.08.04.502716	Pre-print	08/06/2022	human		BBIBP-CorV			BBIBP-CorV				Homologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.1		Reciprocal ID50 GMT			days post booster1			14		52		1.00																												
5856																																																																					
5857																																																																					
5598		35	Fudan University	Neutralization of Omicron BA.4/BA.5 and BA.2.75 by Booster Vaccination or BA.2 Breakthrough Infection Sera	https://doi.org/10.1101/2022.08.04.502716	Pre-print	08/06/2022	human		BBIBP-CorV			BBIBP-CorV				Homologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.1.1		Reciprocal ID50 GMT			days post booster1			14		48		1.00																												
5599		35	Fudan University	Neutralization of Omicron BA.4/BA.5 and BA.2.75 by Booster Vaccination or BA.2 Breakthrough Infection Sera	https://doi.org/10.1101/2022.08.04.502716	Pre-print	08/06/2022	human		BBIBP-CorV			ZF2001				Heterologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.1.1		Reciprocal ID50 GMT			days post booster1			14		125		2.60																												
5600		35	Fudan University	Neutralization of Omicron BA.4/BA.5 and BA.2.75 by Booster Vaccination or BA.2 Breakthrough Infection Sera	https://doi.org/10.1101/2022.08.04.502716	Pre-print	08/06/2022	human		BBIBP-CorV			BBIBP-CorV				Homologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.3		Reciprocal ID50 GMT			days post booster1			14		50		1.00																												
5601		35	Fudan University	Neutralization of Omicron BA.4/BA.5 and BA.2.75 by Booster Vaccination or BA.2 Breakthrough Infection Sera	https://doi.org/10.1101/2022.08.04.502716	Pre-print	08/06/2022	human		BBIBP-CorV			ZF2001				Heterologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.3		Reciprocal ID50 GMT			days post booster1			14		99		1.98																												
5602		35	Fudan University	Neutralization of Omicron BA.4/BA.5 and BA.2.75 by Booster Vaccination or BA.2 Breakthrough Infection Sera	https://doi.org/10.1101/2022.08.04.502716	Pre-print	08/06/2022	human		BBIBP-CorV			BBIBP-CorV				Homologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.2		Reciprocal ID50 GMT			days post booster1			14		67		1.00																												
5603		35	Fudan University	Neutralization of Omicron BA.4/BA.5 and BA.2.75 by Booster Vaccination or BA.2 Breakthrough Infection Sera	https://doi.org/10.1101/2022.08.04.502716	Pre-print	08/06/2022	human		BBIBP-CorV			ZF2001				Heterologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.2		Reciprocal ID50 GMT			days post booster1			14		123		1.84																												
5604		35	Fudan University	Neutralization of Omicron BA.4/BA.5 and BA.2.75 by Booster Vaccination or BA.2 Breakthrough Infection Sera	https://doi.org/10.1101/2022.08.04.502716	Pre-print	08/06/2022	human		BBIBP-CorV			BBIBP-CorV				Homologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.2.3.1		Reciprocal ID50 GMT			days post booster1			14		71		1.00																												
5605		35	Fudan University	Neutralization of Omicron BA.4/BA.5 and BA.2.75 by Booster Vaccination or BA.2 Breakthrough Infection Sera	https://doi.org/10.1101/2022.08.04.502716	Pre-print	08/06/2022	human		BBIBP-CorV			ZF2001				Heterologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.2.3.1		Reciprocal ID50 GMT			days post booster1			14		117		1.65																												
5606		35	Fudan University	Neutralization of Omicron BA.4/BA.5 and BA.2.75 by Booster Vaccination or BA.2 Breakthrough Infection Sera	https://doi.org/10.1101/2022.08.04.502716	Pre-print	08/06/2022	human		BBIBP-CorV			BBIBP-CorV				Homologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.2.10.1		Reciprocal ID50 GMT			days post booster1			14		82		1.00																												
5607		35	Fudan University	Neutralization of Omicron BA.4/BA.5 and BA.2.75 by Booster Vaccination or BA.2 Breakthrough Infection Sera	https://doi.org/10.1101/2022.08.04.502716	Pre-print	08/06/2022	human		BBIBP-CorV			ZF2001				Heterologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.2.10.1		Reciprocal ID50 GMT			days post booster1			14		113		1.38																												
5608		35	Fudan University	Neutralization of Omicron BA.4/BA.5 and BA.2.75 by Booster Vaccination or BA.2 Breakthrough Infection Sera	https://doi.org/10.1101/2022.08.04.502716	Pre-print	08/06/2022	human		BBIBP-CorV			BBIBP-CorV				Homologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.2.12.1		Reciprocal ID50 GMT			days post booster1			14		59		1.00																												
5609		35	Fudan University	Neutralization of Omicron BA.4/BA.5 and BA.2.75 by Booster Vaccination or BA.2 Breakthrough Infection Sera	https://doi.org/10.1101/2022.08.04.502716	Pre-print	08/06/2022	human		BBIBP-CorV			ZF2001				Heterologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.2.12.1		Reciprocal ID50 GMT			days post booster1			14		94		1.59																												
5610		35	Fudan University	Neutralization of Omicron BA.4/BA.5 and BA.2.75 by Booster Vaccination or BA.2 Breakthrough Infection Sera	https://doi.org/10.1101/2022.08.04.502716	Pre-print	08/06/2022	human		BBIBP-CorV			BBIBP-CorV				Homologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.2.13		Reciprocal ID50 GMT			days post booster1			14		74		1.00																												
5611		35	Fudan University	Neutralization of Omicron BA.4/BA.5 and BA.2.75 by Booster Vaccination or BA.2 Breakthrough Infection Sera	https://doi.org/10.1101/2022.08.04.502716	Pre-print	08/06/2022	human		BBIBP-CorV			ZF2001				Heterologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.2.13		Reciprocal ID50 GMT			days post booster1			14		96		1.30																												
5612		35	Fudan University	Neutralization of Omicron BA.4/BA.5 and BA.2.75 by Booster Vaccination or BA.2 Breakthrough Infection Sera	https://doi.org/10.1101/2022.08.04.502716	Pre-print	08/06/2022	human		BBIBP-CorV			BBIBP-CorV				Homologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.2.75		Reciprocal ID50 GMT			days post booster1			14		58		1.00																												
5613		35	Fudan University	Neutralization of Omicron BA.4/BA.5 and BA.2.75 by Booster Vaccination or BA.2 Breakthrough Infection Sera	https://doi.org/10.1101/2022.08.04.502716	Pre-print	08/06/2022	human		BBIBP-CorV			ZF2001				Heterologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.2.75		Reciprocal ID50 GMT			days post booster1			14		93		1.60																												
5614		35	Fudan University	Neutralization of Omicron BA.4/BA.5 and BA.2.75 by Booster Vaccination or BA.2 Breakthrough Infection Sera	https://doi.org/10.1101/2022.08.04.502716	Pre-print	08/06/2022	human		BBIBP-CorV			BBIBP-CorV				Homologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.4/5		Reciprocal ID50 GMT			days post booster1			14		33		1.00																												
5615		35	Fudan University	Neutralization of Omicron BA.4/BA.5 and BA.2.75 by Booster Vaccination or BA.2 Breakthrough Infection Sera	https://doi.org/10.1101/2022.08.04.502716	Pre-print	08/06/2022	human		BBIBP-CorV			ZF2001				Heterologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.4/5		Reciprocal ID50 GMT			days post booster1			14		83		2.52																												
5858																																																																					
5859																																																																					
5616		36	Erasmus Medical Center	Ad26.COV2.S priming provides a solid immunological base for mRNA-based COVID-19 booster vaccination	https://doi.org/10.1101/2022.07.15.22277639	Pre-print	07/18/2022	human		Ad26.COV2.S			Ad26.COV2.S				Homologous						1	Neutralization	Live virus replication assay	CPE	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	PRNT50 GMT			days post booster1	0	206	28		602	2.92	1.00																												
5617		36	Erasmus Medical Center	Ad26.COV2.S priming provides a solid immunological base for mRNA-based COVID-19 booster vaccination	https://doi.org/10.1101/2022.07.15.22277639	Pre-print	07/18/2022	human		Ad26.COV2.S			mRNA-1273				Heterologous						1	Neutralization	Live virus replication assay	CPE	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	PRNT50 GMT			days post booster1	0	180	28		3983	22.13	7.58																												
5618		36	Erasmus Medical Center	Ad26.COV2.S priming provides a solid immunological base for mRNA-based COVID-19 booster vaccination	https://doi.org/10.1101/2022.07.15.22277639	Pre-print	07/18/2022	human		Ad26.COV2.S			BNT162b2				Heterologous						1	Neutralization	Live virus replication assay	CPE	Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	PRNT50 GMT			days post booster1	0	157	28		3382	21.54	7.38																												
5619		36	Erasmus Medical Center	Ad26.COV2.S priming provides a solid immunological base for mRNA-based COVID-19 booster vaccination	https://doi.org/10.1101/2022.07.15.22277639	Pre-print	07/18/2022	human		Ad26.COV2.S			Ad26.COV2.S				Homologous						1	Neutralization	Live virus replication assay	CPE	delta	B.1.617.2	B.1.617.2		PRNT50 GMT			days post booster1	0	82	28		318	3.88	1.00																												
5620		36	Erasmus Medical Center	Ad26.COV2.S priming provides a solid immunological base for mRNA-based COVID-19 booster vaccination	https://doi.org/10.1101/2022.07.15.22277639	Pre-print	07/18/2022	human		Ad26.COV2.S			mRNA-1273				Heterologous						1	Neutralization	Live virus replication assay	CPE	delta	B.1.617.2	B.1.617.2		PRNT50 GMT			days post booster1	0	78	28		2402	30.79	7.94																												
5621		36	Erasmus Medical Center	Ad26.COV2.S priming provides a solid immunological base for mRNA-based COVID-19 booster vaccination	https://doi.org/10.1101/2022.07.15.22277639	Pre-print	07/18/2022	human		Ad26.COV2.S			BNT162b2				Heterologous						1	Neutralization	Live virus replication assay	CPE	delta	B.1.617.2	B.1.617.2		PRNT50 GMT			days post booster1	0	50	28		1672	33.44	8.62																												
5622		36	Erasmus Medical Center	Ad26.COV2.S priming provides a solid immunological base for mRNA-based COVID-19 booster vaccination	https://doi.org/10.1101/2022.07.15.22277639	Pre-print	07/18/2022	human		Ad26.COV2.S			Ad26.COV2.S				Homologous						1	Neutralization	Live virus replication assay	CPE	Omicron	B.1.1.529	BA.1		PRNT50 GMT			days post booster1	0	206	28		602	2.92	1.00																												
5623		36	Erasmus Medical Center	Ad26.COV2.S priming provides a solid immunological base for mRNA-based COVID-19 booster vaccination	https://doi.org/10.1101/2022.07.15.22277639	Pre-print	07/18/2022	human		Ad26.COV2.S			mRNA-1273				Heterologous						1	Neutralization	Live virus replication assay	CPE	Omicron	B.1.1.529	BA.1		PRNT50 GMT			days post booster1	0	180	28		3983	22.13	7.58																												
5624		36	Erasmus Medical Center	Ad26.COV2.S priming provides a solid immunological base for mRNA-based COVID-19 booster vaccination	https://doi.org/10.1101/2022.07.15.22277639	Pre-print	07/18/2022	human		Ad26.COV2.S			BNT162b2				Heterologous						1	Neutralization	Live virus replication assay	CPE	Omicron	B.1.1.529	BA.1		PRNT50 GMT			days post booster1	0	157	28		3382	21.54	7.38																												
5625		36	Erasmus Medical Center	Ad26.COV2.S priming provides a solid immunological base for mRNA-based COVID-19 booster vaccination	https://doi.org/10.1101/2022.07.15.22277639	Pre-print	07/18/2022	human		Ad26.COV2.S			Ad26.COV2.S				Homologous						2	Binding	ELISA		Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	S-binding antibody GMT			days post booster1	0	999	28		3774	3.78	1.00																												
5626		36	Erasmus Medical Center	Ad26.COV2.S priming provides a solid immunological base for mRNA-based COVID-19 booster vaccination	https://doi.org/10.1101/2022.07.15.22277639	Pre-print	07/18/2022	human		Ad26.COV2.S			mRNA-1273				Heterologous						2	Binding	ELISA		Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	S-binding antibody GMT			days post booster1	0	931	28		117660	126.38	33.43																												
5627		36	Erasmus Medical Center	Ad26.COV2.S priming provides a solid immunological base for mRNA-based COVID-19 booster vaccination	https://doi.org/10.1101/2022.07.15.22277639	Pre-print	07/18/2022	human		Ad26.COV2.S			BNT162b2				Heterologous						2	Binding	ELISA		Wuhan-Hu-1 D614G	Wuhan-Hu-1	Wuhan-Hu-1	D614G	S-binding antibody GMT			days post booster1	0	1007	28		58747	58.34	15.43																												
5628		36	Erasmus Medical Center	Ad26.COV2.S priming provides a solid immunological base for mRNA-based COVID-19 booster vaccination	https://doi.org/10.1101/2022.07.15.22277639	Pre-print	07/18/2022	human		Ad26.COV2.S			Ad26.COV2.S				Homologous						2	Binding	ELISA		delta	B.1.617.2	B.1.617.2		S-binding antibody GMT			days post booster1	0	1085	28		2408	2.22	1.00																												
5629		36	Erasmus Medical Center	Ad26.COV2.S priming provides a solid immunological base for mRNA-based COVID-19 booster vaccination	https://doi.org/10.1101/2022.07.15.22277639	Pre-print	07/18/2022	human		Ad26.COV2.S			mRNA-1273				Heterologous						2	Binding	ELISA		delta	B.1.617.2	B.1.617.2		S-binding antibody GMT			days post booster1	0	855	28		113662	132.94	59.88																												
5630		36	Erasmus Medical Center	Ad26.COV2.S priming provides a solid immunological base for mRNA-based COVID-19 booster vaccination	https://doi.org/10.1101/2022.07.15.22277639	Pre-print	07/18/2022	human		Ad26.COV2.S			BNT162b2				Heterologous						2	Binding	ELISA		delta	B.1.617.2	B.1.617.2		S-binding antibody GMT			days post booster1	0	614	28		44040	71.73	32.31																												
5631		36	Erasmus Medical Center	Ad26.COV2.S priming provides a solid immunological base for mRNA-based COVID-19 booster vaccination	https://doi.org/10.1101/2022.07.15.22277639	Pre-print	07/18/2022	human		Ad26.COV2.S			Ad26.COV2.S				Homologous						2	Binding	ELISA		Omicron	B.1.1.529	BA.1		S-binding antibody GMT			days post booster1	0	239	28		997	4.17	1.00																												
5632		36	Erasmus Medical Center	Ad26.COV2.S priming provides a solid immunological base for mRNA-based COVID-19 booster vaccination	https://doi.org/10.1101/2022.07.15.22277639	Pre-print	07/18/2022	human		Ad26.COV2.S			mRNA-1273				Heterologous						2	Binding	ELISA		Omicron	B.1.1.529	BA.1		S-binding antibody GMT			days post booster1	0	268	28		33073	123.41	29.59																												
5633		36	Erasmus Medical Center	Ad26.COV2.S priming provides a solid immunological base for mRNA-based COVID-19 booster vaccination	https://doi.org/10.1101/2022.07.15.22277639	Pre-print	07/18/2022	human		Ad26.COV2.S			BNT162b2				Heterologous						2	Binding	ELISA		Omicron	B.1.1.529	BA.1		S-binding antibody GMT			days post booster1	0	183	28		11024	60.24	14.45																												
5860																																																																					
5861																																																																					
5634		37	Royal College of Surgeons in Ireland	Comparing the Safety and Immunogenicity of homologous (Sputnik V) and heterologous (BNT162B2) COVID-19 prime-boost vaccination	https://doi.org/10.1101/2022.08.24.22279160	Pre-print	08/24/2022	human		Sputnik V	0.5	mL	Sputnik V	0.5	mL		Homologous						1	Binding	ECLIA						Anti-spike IgG GMT	U/mL		days post booster1	0	1478.6	30		4578.7	3.10	1.00																												
5635		37	Royal College of Surgeons in Ireland	Comparing the Safety and Immunogenicity of homologous (Sputnik V) and heterologous (BNT162B2) COVID-19 prime-boost vaccination	https://doi.org/10.1101/2022.08.24.22279160	Pre-print	08/24/2022	human		Sputnik V	0.5	mL	BNT162b2	0.3	mL		Heterologous						1	Binding	ECLIA						Anti-spike IgG GMT	U/mL		days post booster1	0	1025.3	30		15167	14.79	4.77																												
5636		37	Royal College of Surgeons in Ireland	Comparing the Safety and Immunogenicity of homologous (Sputnik V) and heterologous (BNT162B2) COVID-19 prime-boost vaccination	https://doi.org/10.1101/2022.08.24.22279160	Pre-print	08/24/2022	human		Sputnik V	0.5	mL	Sputnik V	0.5	mL		Homologous						2	Neutralization	Pseudotyped virus assay	Surrogate Virus Neutralization					sVNT % Inhibition GMT			days post booster1	0	56.3	30		91.5	1.63	1.00																												
5637		37	Royal College of Surgeons in Ireland	Comparing the Safety and Immunogenicity of homologous (Sputnik V) and heterologous (BNT162B2) COVID-19 prime-boost vaccination	https://doi.org/10.1101/2022.08.24.22279160	Pre-print	08/24/2022	human		Sputnik V	0.5	mL	BNT162b2	0.3	mL		Heterologous						2	Neutralization	Pseudotyped virus assay	Surrogate Virus Neutralization					sVNT % Inhibition GMT			days post booster1	0	48.6	30		96.9	1.99	1.22																												
5638		38	University of Oxford	Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial	https://doi.org/10.1016/S2213-2600(22)00163-1	Peer-reviewed publication	06/08/2022	human		ChAdOx1 nCoV-19			ChAdOx1 nCoV-19			4 weeks interval	Homologous						1	Binding	ELISA						Anti-spike IgG GM	ELU/mL		weeks post booster1			4		1444		1.00	24		334		1.00																							
5639		38	University of Oxford	Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial	https://doi.org/10.1016/S2213-2600(22)00163-1	Peer-reviewed publication	06/08/2022	human		ChAdOx1 nCoV-19			BNT162b2			4 weeks interval	Heterologous						1	Binding	ELISA						Anti-spike IgG GM	ELU/mL		weeks post booster1			4		12979		8.99	24		2236		6.69																							
5640		38	University of Oxford	Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial	https://doi.org/10.1016/S2213-2600(22)00163-1	Peer-reviewed publication	06/08/2022	human		BNT162b2			BNT162b2			4 weeks interval	Homologous						1	Binding	ELISA						Anti-spike IgG GM	ELU/mL		weeks post booster1			4		14349		1.00	24		2612		1.00																							
5641		38	University of Oxford	Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial	https://doi.org/10.1016/S2213-2600(22)00163-1	Peer-reviewed publication	06/08/2022	human		BNT162b2			ChAdOx1 nCoV-19			4 weeks interval	Heterologous						1	Binding	ELISA						Anti-spike IgG GM	ELU/mL		weeks post booster1			4		7530		0.52	24		1748		0.67																							
5642		38	University of Oxford	Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial	https://doi.org/10.1016/S2213-2600(22)00163-1	Peer-reviewed publication	06/08/2022	human		ChAdOx1 nCoV-19			ChAdOx1 nCoV-19			12 weeks interval	Homologous						1	Binding	ELISA						Anti-spike IgG GM	ELU/mL		weeks post booster1			4		2622		1.00	24		661		1.00																							
5643		38	University of Oxford	Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial	https://doi.org/10.1016/S2213-2600(22)00163-1	Peer-reviewed publication	06/08/2022	human		ChAdOx1 nCoV-19			BNT162b2			12 weeks interval	Heterologous						1	Binding	ELISA						Anti-spike IgG GM	ELU/mL		weeks post booster1			4		13465		5.14	24		2437		3.69																							
5644		38	University of Oxford	Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial	https://doi.org/10.1016/S2213-2600(22)00163-1	Peer-reviewed publication	06/08/2022	human		BNT162b2			BNT162b2			12 weeks interval	Homologous						1	Binding	ELISA						Anti-spike IgG GM	ELU/mL		weeks post booster1			4		19011		1.00	24		3560		1.00																							
5645		38	University of Oxford	Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial	https://doi.org/10.1016/S2213-2600(22)00163-1	Peer-reviewed publication	06/08/2022	human		BNT162b2			ChAdOx1 nCoV-19			12 weeks interval	Heterologous						1	Binding	ELISA						Anti-spike IgG GM	ELU/mL		weeks post booster1			4		10642		0.56	24		2012		0.57																							
5646		38	University of Oxford	Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial	https://doi.org/10.1016/S2213-2600(22)00163-1	Peer-reviewed publication	06/08/2022	human		ChAdOx1 nCoV-19			ChAdOx1 nCoV-19			4 weeks interval	Homologous						2	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		NT50 GMT			weeks post booster1			4		74		1.00																												
5647		38	University of Oxford	Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial	https://doi.org/10.1016/S2213-2600(22)00163-1	Peer-reviewed publication	06/08/2022	human		ChAdOx1 nCoV-19			BNT162b2			4 weeks interval	Heterologous						2	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		NT50 GMT			weeks post booster1			4		529		7.15																												
5648		38	University of Oxford	Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial	https://doi.org/10.1016/S2213-2600(22)00163-1	Peer-reviewed publication	06/08/2022	human		BNT162b2			BNT162b2			4 weeks interval	Homologous						2	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		NT50 GMT			weeks post booster1			4		585		1.00																												
5649		38	University of Oxford	Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial	https://doi.org/10.1016/S2213-2600(22)00163-1	Peer-reviewed publication	06/08/2022	human		BNT162b2			ChAdOx1 nCoV-19			4 weeks interval	Heterologous						2	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		NT50 GMT			weeks post booster1			4		397		0.68																												
5650		38	University of Oxford	Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial	https://doi.org/10.1016/S2213-2600(22)00163-1	Peer-reviewed publication	06/08/2022	human		ChAdOx1 nCoV-19			ChAdOx1 nCoV-19			12 weeks interval	Homologous						2	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		NT50 GMT			weeks post booster1			4		188		1.00																												
5651		38	University of Oxford	Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial	https://doi.org/10.1016/S2213-2600(22)00163-1	Peer-reviewed publication	06/08/2022	human		ChAdOx1 nCoV-19			BNT162b2			12 weeks interval	Heterologous						2	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		NT50 GMT			weeks post booster1			4		781		4.15																												
5652		38	University of Oxford	Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial	https://doi.org/10.1016/S2213-2600(22)00163-1	Peer-reviewed publication	06/08/2022	human		BNT162b2			BNT162b2			12 weeks interval	Homologous						2	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		NT50 GMT			weeks post booster1			4		899		1.00																												
5653		38	University of Oxford	Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial	https://doi.org/10.1016/S2213-2600(22)00163-1	Peer-reviewed publication	06/08/2022	human		BNT162b2			ChAdOx1 nCoV-19			12 weeks interval	Heterologous						2	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		NT50 GMT			weeks post booster1			4		645		0.72																												
5654		38	University of Oxford	Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial	https://doi.org/10.1016/S2213-2600(22)00163-1	Peer-reviewed publication	06/08/2022	human		ChAdOx1 nCoV-19			ChAdOx1 nCoV-19			12 weeks interval	Homologous						3	Neutralization	Live virus replication assay	CPE	VIC	VIC	VIC		FRNT50 GMT			weeks post booster1			4		252		1.00																												
5655		38	University of Oxford	Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial	https://doi.org/10.1016/S2213-2600(22)00163-1	Peer-reviewed publication	06/08/2022	human		ChAdOx1 nCoV-19			BNT162b2			12 weeks interval	Heterologous						3	Neutralization	Live virus replication assay	CPE	VIC	VIC	VIC		FRNT50 GMT			weeks post booster1			4		1410		5.60																												
5656		38	University of Oxford	Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial	https://doi.org/10.1016/S2213-2600(22)00163-1	Peer-reviewed publication	06/08/2022	human		BNT162b2			BNT162b2			12 weeks interval	Homologous						3	Neutralization	Live virus replication assay	CPE	VIC	VIC	VIC		FRNT50 GMT			weeks post booster1			4		2392		1.00																												
5657		38	University of Oxford	Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial	https://doi.org/10.1016/S2213-2600(22)00163-1	Peer-reviewed publication	06/08/2022	human		BNT162b2			ChAdOx1 nCoV-19			12 weeks interval	Heterologous						3	Neutralization	Live virus replication assay	CPE	VIC	VIC	VIC		FRNT50 GMT			weeks post booster1			4		1273		0.53																												
5658		38	University of Oxford	Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial	https://doi.org/10.1016/S2213-2600(22)00163-1	Peer-reviewed publication	06/08/2022	human		ChAdOx1 nCoV-19			ChAdOx1 nCoV-19			12 weeks interval	Homologous						3	Neutralization	Live virus replication assay	CPE	beta	B.1.351	B.1.351		FRNT50 GMT			weeks post booster1			4		51		1.00																												
5659		38	University of Oxford	Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial	https://doi.org/10.1016/S2213-2600(22)00163-1	Peer-reviewed publication	06/08/2022	human		ChAdOx1 nCoV-19			BNT162b2			12 weeks interval	Heterologous						3	Neutralization	Live virus replication assay	CPE	beta	B.1.351	B.1.351		FRNT50 GMT			weeks post booster1			4		264		5.18																												
5660		38	University of Oxford	Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial	https://doi.org/10.1016/S2213-2600(22)00163-1	Peer-reviewed publication	06/08/2022	human		BNT162b2			BNT162b2			12 weeks interval	Homologous						3	Neutralization	Live virus replication assay	CPE	beta	B.1.351	B.1.351		FRNT50 GMT			weeks post booster1			4		690		1.00																												
5661		38	University of Oxford	Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial	https://doi.org/10.1016/S2213-2600(22)00163-1	Peer-reviewed publication	06/08/2022	human		BNT162b2			ChAdOx1 nCoV-19			12 weeks interval	Heterologous						3	Neutralization	Live virus replication assay	CPE	beta	B.1.351	B.1.351		FRNT50 GMT			weeks post booster1			4		360		0.52																												
5662		38	University of Oxford	Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial	https://doi.org/10.1016/S2213-2600(22)00163-1	Peer-reviewed publication	06/08/2022	human		ChAdOx1 nCoV-19			ChAdOx1 nCoV-19			12 weeks interval	Homologous						3	Neutralization	Live virus replication assay	CPE	delta	B.1.617.2	B.1.617.2		FRNT50 GMT			weeks post booster1			4		88		1.00																												
5663		38	University of Oxford	Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial	https://doi.org/10.1016/S2213-2600(22)00163-1	Peer-reviewed publication	06/08/2022	human		ChAdOx1 nCoV-19			BNT162b2			12 weeks interval	Heterologous						3	Neutralization	Live virus replication assay	CPE	delta	B.1.617.2	B.1.617.2		FRNT50 GMT			weeks post booster1			4		528		6.00																												
5664		38	University of Oxford	Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial	https://doi.org/10.1016/S2213-2600(22)00163-1	Peer-reviewed publication	06/08/2022	human		BNT162b2			BNT162b2			12 weeks interval	Homologous						3	Neutralization	Live virus replication assay	CPE	delta	B.1.617.2	B.1.617.2		FRNT50 GMT			weeks post booster1			4		990		1.00																												
5665		38	University of Oxford	Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial	https://doi.org/10.1016/S2213-2600(22)00163-1	Peer-reviewed publication	06/08/2022	human		BNT162b2			ChAdOx1 nCoV-19			12 weeks interval	Heterologous						3	Neutralization	Live virus replication assay	CPE	delta	B.1.617.2	B.1.617.2		FRNT50 GMT			weeks post booster1			4		498		0.50																												
5666		38	University of Oxford	Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial	https://doi.org/10.1016/S2213-2600(22)00163-1	Peer-reviewed publication	06/08/2022	human		ChAdOx1 nCoV-19			ChAdOx1 nCoV-19			4 weeks interval	Homologous						4	Cellular response	T-cell ELISpot	Interferon-?-secreting T cells (fresh cells)	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		SFC/106 PBMCs			weeks post booster1			4		48		1.00	24		32		1.00																							
5667		38	University of Oxford	Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial	https://doi.org/10.1016/S2213-2600(22)00163-1	Peer-reviewed publication	06/08/2022	human		ChAdOx1 nCoV-19			BNT162b2			4 weeks interval	Heterologous						4	Cellular response	T-cell ELISpot	Interferon-?-secreting T cells (fresh cells)	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		SFC/106 PBMCs			weeks post booster1			4		186		3.88	24		91		2.84																							
5668		38	University of Oxford	Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial	https://doi.org/10.1016/S2213-2600(22)00163-1	Peer-reviewed publication	06/08/2022	human		BNT162b2			BNT162b2			4 weeks interval	Homologous						4	Cellular response	T-cell ELISpot	Interferon-?-secreting T cells (fresh cells)	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		SFC/106 PBMCs			weeks post booster1			4		72		1.00	24		35		1.00																							
5669		38	University of Oxford	Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial	https://doi.org/10.1016/S2213-2600(22)00163-1	Peer-reviewed publication	06/08/2022	human		BNT162b2			ChAdOx1 nCoV-19			4 weeks interval	Heterologous						4	Cellular response	T-cell ELISpot	Interferon-?-secreting T cells (fresh cells)	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		SFC/106 PBMCs			weeks post booster1			4		98		1.36	24		52		1.49																							
5670		38	University of Oxford	Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial	https://doi.org/10.1016/S2213-2600(22)00163-1	Peer-reviewed publication	06/08/2022	human		ChAdOx1 nCoV-19			ChAdOx1 nCoV-19			12 weeks interval	Homologous						4	Cellular response	T-cell ELISpot	Interferon-?-secreting T cells (fresh cells)	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		SFC/106 PBMCs			weeks post booster1			4		35		1.00	24		17		1.00																							
5671		38	University of Oxford	Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial	https://doi.org/10.1016/S2213-2600(22)00163-1	Peer-reviewed publication	06/08/2022	human		ChAdOx1 nCoV-19			BNT162b2			12 weeks interval	Heterologous						4	Cellular response	T-cell ELISpot	Interferon-?-secreting T cells (fresh cells)	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		SFC/106 PBMCs			weeks post booster1			4		110		3.14	24		54		3.18																							
5672		38	University of Oxford	Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial	https://doi.org/10.1016/S2213-2600(22)00163-1	Peer-reviewed publication	06/08/2022	human		BNT162b2			BNT162b2			12 weeks interval	Homologous						4	Cellular response	T-cell ELISpot	Interferon-?-secreting T cells (fresh cells)	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		SFC/106 PBMCs			weeks post booster1			4		49		1.00	24		23		1.00																							
5673		38	University of Oxford	Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial	https://doi.org/10.1016/S2213-2600(22)00163-1	Peer-reviewed publication	06/08/2022	human		BNT162b2			ChAdOx1 nCoV-19			12 weeks interval	Heterologous						4	Cellular response	T-cell ELISpot	Interferon-?-secreting T cells (fresh cells)	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		SFC/106 PBMCs			weeks post booster1			4		37		0.76	24		21		0.91																							
5674		38	University of Oxford	Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial	https://doi.org/10.1016/S2213-2600(22)00163-1	Peer-reviewed publication	06/08/2022	human		ChAdOx1 nCoV-19			ChAdOx1 nCoV-19			12 weeks interval	Homologous						5	Cellular response	T-cell ELISpot	Interferon-?-secreting T cells (frozen cells)	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		SFC/106 PBMCs			weeks post booster1			4		24		1.00																												
5675		38	University of Oxford	Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial	https://doi.org/10.1016/S2213-2600(22)00163-1	Peer-reviewed publication	06/08/2022	human		ChAdOx1 nCoV-19			BNT162b2			12 weeks interval	Heterologous						5	Cellular response	T-cell ELISpot	Interferon-?-secreting T cells (frozen cells)	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		SFC/106 PBMCs			weeks post booster1			4		64		2.67																												
5862																																																																					
5676		38	University of Oxford	Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial	https://doi.org/10.1016/S2213-2600(22)00163-1	Peer-reviewed publication	06/08/2022	human		BNT162b2			BNT162b2			12 weeks interval	Homologous						5	Cellular response	T-cell ELISpot	Interferon-?-secreting T cells (frozen cells)	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		SFC/106 PBMCs			weeks post booster1			4		42		1.00																												
5677		38	University of Oxford	Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial	https://doi.org/10.1016/S2213-2600(22)00163-1	Peer-reviewed publication	06/08/2022	human		BNT162b2			ChAdOx1 nCoV-19			12 weeks interval	Heterologous						5	Cellular response	T-cell ELISpot	Interferon-?-secreting T cells (frozen cells)	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		SFC/106 PBMCs			weeks post booster1			4		32		0.76																												
5678		38	University of Oxford	Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial	https://doi.org/10.1016/S2213-2600(22)00163-1	Peer-reviewed publication	06/08/2022	human		ChAdOx1 nCoV-19			ChAdOx1 nCoV-19			12 weeks interval	Homologous						5	Cellular response	T-cell ELISpot	Interferon-?-secreting T cells (frozen cells)	beta	B.1.351	B.1.351		SFC/106 PBMCs			weeks post booster1			4		26		1.00																												
5679		38	University of Oxford	Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial	https://doi.org/10.1016/S2213-2600(22)00163-1	Peer-reviewed publication	06/08/2022	human		ChAdOx1 nCoV-19			BNT162b2			12 weeks interval	Heterologous						5	Cellular response	T-cell ELISpot	Interferon-?-secreting T cells (frozen cells)	beta	B.1.351	B.1.351		SFC/106 PBMCs			weeks post booster1			4		70		2.69																												
5680		38	University of Oxford	Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial	https://doi.org/10.1016/S2213-2600(22)00163-1	Peer-reviewed publication	06/08/2022	human		BNT162b2			BNT162b2			12 weeks interval	Homologous						5	Cellular response	T-cell ELISpot	Interferon-?-secreting T cells (frozen cells)	beta	B.1.351	B.1.351		SFC/106 PBMCs			weeks post booster1			4		42		1.00																												
5681		38	University of Oxford	Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial	https://doi.org/10.1016/S2213-2600(22)00163-1	Peer-reviewed publication	06/08/2022	human		BNT162b2			ChAdOx1 nCoV-19			12 weeks interval	Heterologous						5	Cellular response	T-cell ELISpot	Interferon-?-secreting T cells (frozen cells)	beta	B.1.351	B.1.351		SFC/106 PBMCs			weeks post booster1			4		29		0.69																												
5682		38	University of Oxford	Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial	https://doi.org/10.1016/S2213-2600(22)00163-1	Peer-reviewed publication	06/08/2022	human		ChAdOx1 nCoV-19			ChAdOx1 nCoV-19			12 weeks interval	Homologous						5	Cellular response	T-cell ELISpot	Interferon-?-secreting T cells (frozen cells)	delta	B.1.617.2	B.1.617.2		SFC/106 PBMCs			weeks post booster1			4		26		1.00																												
5683		38	University of Oxford	Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial	https://doi.org/10.1016/S2213-2600(22)00163-1	Peer-reviewed publication	06/08/2022	human		ChAdOx1 nCoV-19			BNT162b2			12 weeks interval	Heterologous						5	Cellular response	T-cell ELISpot	Interferon-?-secreting T cells (frozen cells)	delta	B.1.617.2	B.1.617.2		SFC/106 PBMCs			weeks post booster1			4		71		2.73																												
5684		38	University of Oxford	Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial	https://doi.org/10.1016/S2213-2600(22)00163-1	Peer-reviewed publication	06/08/2022	human		BNT162b2			BNT162b2			12 weeks interval	Homologous						5	Cellular response	T-cell ELISpot	Interferon-?-secreting T cells (frozen cells)	delta	B.1.617.2	B.1.617.2		SFC/106 PBMCs			weeks post booster1			4		44		1.00																												
5685		38	University of Oxford	Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial	https://doi.org/10.1016/S2213-2600(22)00163-1	Peer-reviewed publication	06/08/2022	human		BNT162b2			ChAdOx1 nCoV-19			12 weeks interval	Heterologous						5	Cellular response	T-cell ELISpot	Interferon-?-secreting T cells (frozen cells)	delta	B.1.617.2	B.1.617.2		SFC/106 PBMCs			weeks post booster1			4		28		0.64																												
5686		39	The University of Hong Kong	Homologous and heterologous boosting with CoronaVac and BNT162b2: a randomized trial (the Cobovax study)	https://doi.org/10.1101/2022.08.25.22279158	Pre-print	08/28/2022	human		CoronaVac			CoronaVac				Homologous						1	Neutralization	Live virus replication assay	Plaque reduction assay	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		FRNT50 GMT			days post booster1	0	8	28		109	13.63	1.00																												
5687		39	The University of Hong Kong	Homologous and heterologous boosting with CoronaVac and BNT162b2: a randomized trial (the Cobovax study)	https://doi.org/10.1101/2022.08.25.22279158	Pre-print	08/28/2022	human		CoronaVac			BNT162b2				Heterologous						1	Neutralization	Live virus replication assay	Plaque reduction assay	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		FRNT50 GMT			days post booster1	0	10	28		905	90.50	6.64																												
5688		39	The University of Hong Kong	Homologous and heterologous boosting with CoronaVac and BNT162b2: a randomized trial (the Cobovax study)	https://doi.org/10.1101/2022.08.25.22279158	Pre-print	08/28/2022	human		BNT162b2			BNT162b2				Homologous						1	Neutralization	Live virus replication assay	Plaque reduction assay	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		FRNT50 GMT			days post booster1	0	43	28		816	18.98	1.00																												
5689		39	The University of Hong Kong	Homologous and heterologous boosting with CoronaVac and BNT162b2: a randomized trial (the Cobovax study)	https://doi.org/10.1101/2022.08.25.22279158	Pre-print	08/28/2022	human		BNT162b2			CoronaVac				Heterologous						1	Neutralization	Live virus replication assay	Plaque reduction assay	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		FRNT50 GMT			days post booster1	0	34	28		92	2.71	0.14																												
5863																																																																					
5690		39	The University of Hong Kong	Homologous and heterologous boosting with CoronaVac and BNT162b2: a randomized trial (the Cobovax study)	https://doi.org/10.1101/2022.08.25.22279158	Pre-print	08/28/2022	human		CoronaVac			CoronaVac				Homologous						1	Neutralization	Live virus replication assay	Plaque reduction assay	Omicron	B.1.1.529	BA.1		FRNT50 GMT			days post booster1	0	5	28		9	1.80	1.00																												
5691		39	The University of Hong Kong	Homologous and heterologous boosting with CoronaVac and BNT162b2: a randomized trial (the Cobovax study)	https://doi.org/10.1101/2022.08.25.22279158	Pre-print	08/28/2022	human		CoronaVac			BNT162b2				Heterologous						1	Neutralization	Live virus replication assay	Plaque reduction assay	Omicron	B.1.1.529	BA.1		FRNT50 GMT			days post booster1	0	5	28		75	15.00	8.33																												
5692		39	The University of Hong Kong	Homologous and heterologous boosting with CoronaVac and BNT162b2: a randomized trial (the Cobovax study)	https://doi.org/10.1101/2022.08.25.22279158	Pre-print	08/28/2022	human		BNT162b2			BNT162b2				Homologous						1	Neutralization	Live virus replication assay	Plaque reduction assay	Omicron	B.1.1.529	BA.1		FRNT50 GMT			days post booster1	0	6	28		86	14.33	1.00																												
5693		39	The University of Hong Kong	Homologous and heterologous boosting with CoronaVac and BNT162b2: a randomized trial (the Cobovax study)	https://doi.org/10.1101/2022.08.25.22279158	Pre-print	08/28/2022	human		BNT162b2			CoronaVac				Heterologous						1	Neutralization	Live virus replication assay	Plaque reduction assay	Omicron	B.1.1.529	BA.1		FRNT50 GMT			days post booster1	0	6	28		8	1.33	0.09																												
5694		39	The University of Hong Kong	Homologous and heterologous boosting with CoronaVac and BNT162b2: a randomized trial (the Cobovax study)	https://doi.org/10.1101/2022.08.25.22279158	Pre-print	08/28/2022	human		CoronaVac			CoronaVac				Homologous						1	Neutralization	Live virus replication assay	Plaque reduction assay	Omicron	B.1.1.529	BA.2		FRNT50 GMT			days post booster1	0	6	28		6	1.00	1.00																												
5695		39	The University of Hong Kong	Homologous and heterologous boosting with CoronaVac and BNT162b2: a randomized trial (the Cobovax study)	https://doi.org/10.1101/2022.08.25.22279158	Pre-print	08/28/2022	human		CoronaVac			BNT162b2				Heterologous						1	Neutralization	Live virus replication assay	Plaque reduction assay	Omicron	B.1.1.529	BA.2		FRNT50 GMT			days post booster1	0	5	28		80	16.00	16.00																												
5696		39	The University of Hong Kong	Homologous and heterologous boosting with CoronaVac and BNT162b2: a randomized trial (the Cobovax study)	https://doi.org/10.1101/2022.08.25.22279158	Pre-print	08/28/2022	human		BNT162b2			BNT162b2				Homologous						1	Neutralization	Live virus replication assay	Plaque reduction assay	Omicron	B.1.1.529	BA.2		FRNT50 GMT			days post booster1	0	5	28		67	13.40	1.00																												
5697		39	The University of Hong Kong	Homologous and heterologous boosting with CoronaVac and BNT162b2: a randomized trial (the Cobovax study)	https://doi.org/10.1101/2022.08.25.22279158	Pre-print	08/28/2022	human		BNT162b2			CoronaVac				Heterologous						1	Neutralization	Live virus replication assay	Plaque reduction assay	Omicron	B.1.1.529	BA.2		FRNT50 GMT			days post booster1	0	5	28		6	1.20	0.09																												
5698		39	The University of Hong Kong	Homologous and heterologous boosting with CoronaVac and BNT162b2: a randomized trial (the Cobovax study)	https://doi.org/10.1101/2022.08.25.22279158	Pre-print	08/28/2022	human		CoronaVac			CoronaVac				Homologous						2	Neutralization	Pseudotyped virus assay	Surrogate Virus Neutralization	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		sVNT50 GMT	% inhibition		days post booster1	0	17	28		83	4.88	1.00																												
5699		39	The University of Hong Kong	Homologous and heterologous boosting with CoronaVac and BNT162b2: a randomized trial (the Cobovax study)	https://doi.org/10.1101/2022.08.25.22279158	Pre-print	08/28/2022	human		CoronaVac			BNT162b2				Heterologous						2	Neutralization	Pseudotyped virus assay	Surrogate Virus Neutralization	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		sVNT50 GMT	% inhibition		days post booster1	0	16	28		96	6.00	1.23																												
5700		39	The University of Hong Kong	Homologous and heterologous boosting with CoronaVac and BNT162b2: a randomized trial (the Cobovax study)	https://doi.org/10.1101/2022.08.25.22279158	Pre-print	08/28/2022	human		BNT162b2			BNT162b2				Homologous						2	Neutralization	Pseudotyped virus assay	Surrogate Virus Neutralization	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		sVNT50 GMT	% inhibition		days post booster1	0	70	28		96	1.37	1.00																												
5701		39	The University of Hong Kong	Homologous and heterologous boosting with CoronaVac and BNT162b2: a randomized trial (the Cobovax study)	https://doi.org/10.1101/2022.08.25.22279158	Pre-print	08/28/2022	human		BNT162b2			CoronaVac				Heterologous						2	Neutralization	Pseudotyped virus assay	Surrogate Virus Neutralization	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		sVNT50 GMT	% inhibition		days post booster1	0	66	28		87	1.32	0.96																												
5702		39	The University of Hong Kong	Homologous and heterologous boosting with CoronaVac and BNT162b2: a randomized trial (the Cobovax study)	https://doi.org/10.1101/2022.08.25.22279158	Pre-print	08/28/2022	human		CoronaVac			CoronaVac				Homologous						2	Neutralization	Pseudotyped virus assay	Surrogate Virus Neutralization	Omicron	B.1.1.529	BA.1		sVNT50 GMT	% inhibition		days post booster1	0	6	28		15	2.50	1.00																												
5703		39	The University of Hong Kong	Homologous and heterologous boosting with CoronaVac and BNT162b2: a randomized trial (the Cobovax study)	https://doi.org/10.1101/2022.08.25.22279158	Pre-print	08/28/2022	human		CoronaVac			BNT162b2				Heterologous						2	Neutralization	Pseudotyped virus assay	Surrogate Virus Neutralization	Omicron	B.1.1.529	BA.1		sVNT50 GMT	% inhibition		days post booster1	0	6	28		58	9.67	3.87																												
5704		39	The University of Hong Kong	Homologous and heterologous boosting with CoronaVac and BNT162b2: a randomized trial (the Cobovax study)	https://doi.org/10.1101/2022.08.25.22279158	Pre-print	08/28/2022	human		BNT162b2			BNT162b2				Homologous						2	Neutralization	Pseudotyped virus assay	Surrogate Virus Neutralization	Omicron	B.1.1.529	BA.1		sVNT50 GMT	% inhibition		days post booster1	0	7	28		69	9.86	1.00																												
5705		39	The University of Hong Kong	Homologous and heterologous boosting with CoronaVac and BNT162b2: a randomized trial (the Cobovax study)	https://doi.org/10.1101/2022.08.25.22279158	Pre-print	08/28/2022	human		BNT162b2			CoronaVac				Heterologous						2	Neutralization	Pseudotyped virus assay	Surrogate Virus Neutralization	Omicron	B.1.1.529	BA.1		sVNT50 GMT	% inhibition		days post booster1	0	8	28		19	2.38	0.24																												
5706		39	The University of Hong Kong	Homologous and heterologous boosting with CoronaVac and BNT162b2: a randomized trial (the Cobovax study)	https://doi.org/10.1101/2022.08.25.22279158	Pre-print	08/28/2022	human		CoronaVac			CoronaVac				Homologous						2	Neutralization	Pseudotyped virus assay	Surrogate Virus Neutralization	Omicron	B.1.1.529	BA.2		sVNT50 GMT	% inhibition		days post booster1	0	5	28		43	8.60	1.00																												
5864																																																																					
5707		39	The University of Hong Kong	Homologous and heterologous boosting with CoronaVac and BNT162b2: a randomized trial (the Cobovax study)	https://doi.org/10.1101/2022.08.25.22279158	Pre-print	08/28/2022	human		CoronaVac			BNT162b2				Heterologous						2	Neutralization	Pseudotyped virus assay	Surrogate Virus Neutralization	Omicron	B.1.1.529	BA.2		sVNT50 GMT	% inhibition		days post booster1	0	6	28		85	14.17	1.65																												
5708		39	The University of Hong Kong	Homologous and heterologous boosting with CoronaVac and BNT162b2: a randomized trial (the Cobovax study)	https://doi.org/10.1101/2022.08.25.22279158	Pre-print	08/28/2022	human		BNT162b2			BNT162b2				Homologous						2	Neutralization	Pseudotyped virus assay	Surrogate Virus Neutralization	Omicron	B.1.1.529	BA.2		sVNT50 GMT	% inhibition		days post booster1	0	29	28		90	3.10	1.00																												
5709		39	The University of Hong Kong	Homologous and heterologous boosting with CoronaVac and BNT162b2: a randomized trial (the Cobovax study)	https://doi.org/10.1101/2022.08.25.22279158	Pre-print	08/28/2022	human		BNT162b2			CoronaVac				Heterologous						2	Neutralization	Pseudotyped virus assay	Surrogate Virus Neutralization	Omicron	B.1.1.529	BA.2		sVNT50 GMT	% inhibition		days post booster1	0	28	28		50	1.79	0.58																												
5710		39	The University of Hong Kong	Homologous and heterologous boosting with CoronaVac and BNT162b2: a randomized trial (the Cobovax study)	https://doi.org/10.1101/2022.08.25.22279158	Pre-print	08/28/2022	human		CoronaVac			CoronaVac				Homologous						3	Cellular response	Intracellular cytokine staining (ICS)	IFN?+ CD4+ T cells					IFN?+ CD4+ T cells/106 cells			days post booster1	0	877	7		4248	4.84	1.00	28		2241	2.56	1.00																							
5711		39	The University of Hong Kong	Homologous and heterologous boosting with CoronaVac and BNT162b2: a randomized trial (the Cobovax study)	https://doi.org/10.1101/2022.08.25.22279158	Pre-print	08/28/2022	human		CoronaVac			BNT162b2				Heterologous						3	Cellular response	Intracellular cytokine staining (ICS)	IFN?+ CD4+ T cells					IFN?+ CD4+ T cells/106 cells			days post booster1	0	641	7		3203	5.00	1.03	28		1822	2.84	1.11																							
5712		39	The University of Hong Kong	Homologous and heterologous boosting with CoronaVac and BNT162b2: a randomized trial (the Cobovax study)	https://doi.org/10.1101/2022.08.25.22279158	Pre-print	08/28/2022	human		BNT162b2			BNT162b2				Homologous						3	Cellular response	Intracellular cytokine staining (ICS)	IFN?+ CD4+ T cells					IFN?+ CD4+ T cells/106 cells			days post booster1	0	2196	7		2087	0.95	1.00	28		1383	0.63	1.00																							
5713		39	The University of Hong Kong	Homologous and heterologous boosting with CoronaVac and BNT162b2: a randomized trial (the Cobovax study)	https://doi.org/10.1101/2022.08.25.22279158	Pre-print	08/28/2022	human		BNT162b2			CoronaVac				Heterologous						3	Cellular response	Intracellular cytokine staining (ICS)	IFN?+ CD4+ T cells					IFN?+ CD4+ T cells/106 cells			days post booster1	0	3034	7		2745	0.90	0.95	28		2449	0.81	1.28																							
5714		39	The University of Hong Kong	Homologous and heterologous boosting with CoronaVac and BNT162b2: a randomized trial (the Cobovax study)	https://doi.org/10.1101/2022.08.25.22279158	Pre-print	08/28/2022	human		CoronaVac			CoronaVac				Homologous						3	Cellular response	Intracellular cytokine staining (ICS)	IFN?+ CD8+ T cells					IFN?+ CD8+ T cells/106 cells			days post booster1	0	208	7		668	3.21	1.00	28		359	1.73	1.00																							
5715		39	The University of Hong Kong	Homologous and heterologous boosting with CoronaVac and BNT162b2: a randomized trial (the Cobovax study)	https://doi.org/10.1101/2022.08.25.22279158	Pre-print	08/28/2022	human		CoronaVac			BNT162b2				Heterologous						3	Cellular response	Intracellular cytokine staining (ICS)	IFN?+ CD8+ T cells					IFN?+ CD8+ T cells/106 cells			days post booster1	0	78	7		969	12.42	3.87	28		98	1.26	0.73																							
5716		39	The University of Hong Kong	Homologous and heterologous boosting with CoronaVac and BNT162b2: a randomized trial (the Cobovax study)	https://doi.org/10.1101/2022.08.25.22279158	Pre-print	08/28/2022	human		BNT162b2			BNT162b2				Homologous						3	Cellular response	Intracellular cytokine staining (ICS)	IFN?+ CD8+ T cells					IFN?+ CD8+ T cells/106 cells			days post booster1	0	146	7		173	1.18	1.00	28		164	1.12	1.00																							
5717		39	The University of Hong Kong	Homologous and heterologous boosting with CoronaVac and BNT162b2: a randomized trial (the Cobovax study)	https://doi.org/10.1101/2022.08.25.22279158	Pre-print	08/28/2022	human		BNT162b2			CoronaVac				Heterologous						3	Cellular response	Intracellular cytokine staining (ICS)	IFN?+ CD8+ T cells					IFN?+ CD8+ T cells/106 cells			days post booster1	0	213	7		122	0.57	0.48	28		218	1.02	0.91																							
5718		40	National Vaccine and Serum Institute	Safety and immunogenicity of a broad-spectrum mosaic vaccine as a booster dose against SARS-CoV-2 Omicron and other circulating variants	https://doi.org/10.1101/2022.09.05.22279589	Pre-print	09/06/2022	human		BBIBP-CorV			BBIBP-CorV				Homologous						1	Neutralization	Live virus replication assay	CPE	Prototype	Wuhan-Hu-1	Wuhan-Hu-1		TCID50 GMT			days post booster1	0	113.29	14		506.47	4.47	1.00																												
5719		40	National Vaccine and Serum Institute	Safety and immunogenicity of a broad-spectrum mosaic vaccine as a booster dose against SARS-CoV-2 Omicron and other circulating variants	https://doi.org/10.1101/2022.09.05.22279589	Pre-print	09/06/2022	human		BBIBP-CorV			NVSI-06-09				Heterologous						1	Neutralization	Live virus replication assay	CPE	Prototype	Wuhan-Hu-1	Wuhan-Hu-1		TCID50 GMT			days post booster1	0	119.42	14		2349.44	19.67	4.40																												
5720		40	National Vaccine and Serum Institute	Safety and immunogenicity of a broad-spectrum mosaic vaccine as a booster dose against SARS-CoV-2 Omicron and other circulating variants	https://doi.org/10.1101/2022.09.05.22279589	Pre-print	09/06/2022	human		BBIBP-CorV			BBIBP-CorV				Homologous						1	Neutralization	Live virus replication assay	CPE	Omicron	B.1.1.529	BA.1.1		TCID50 GMT			days post booster1	0	37.91	14		143.23	3.78	1.00																												
5721		40	National Vaccine and Serum Institute	Safety and immunogenicity of a broad-spectrum mosaic vaccine as a booster dose against SARS-CoV-2 Omicron and other circulating variants	https://doi.org/10.1101/2022.09.05.22279589	Pre-print	09/06/2022	human		BBIBP-CorV			NVSI-06-09				Heterologous						1	Neutralization	Live virus replication assay	CPE	Omicron	B.1.1.529	BA.1.1		TCID50 GMT			days post booster1	0	40.47	14		1713.71	42.35	11.21																												
5722		40	National Vaccine and Serum Institute	Safety and immunogenicity of a broad-spectrum mosaic vaccine as a booster dose against SARS-CoV-2 Omicron and other circulating variants	https://doi.org/10.1101/2022.09.05.22279589	Pre-print	09/06/2022	human		BBIBP-CorV			BBIBP-CorV				Homologous						1	Neutralization	Live virus replication assay	CPE	Omicron	B.1.1.529	BA.2		TCID50 GMT			days post booster1	0	40.35	14		117.33	2.91	1.00																												
5865																																																																					
5866																																																																					
5867																																																																					
5723		40	National Vaccine and Serum Institute	Safety and immunogenicity of a broad-spectrum mosaic vaccine as a booster dose against SARS-CoV-2 Omicron and other circulating variants	https://doi.org/10.1101/2022.09.05.22279589	Pre-print	09/06/2022	human		BBIBP-CorV			NVSI-06-09				Heterologous						1	Neutralization	Live virus replication assay	CPE	Omicron	B.1.1.529	BA.2		TCID50 GMT			days post booster1	0	39.19	14		953.36	24.33	8.37																												
5724		40	National Vaccine and Serum Institute	Safety and immunogenicity of a broad-spectrum mosaic vaccine as a booster dose against SARS-CoV-2 Omicron and other circulating variants	https://doi.org/10.1101/2022.09.05.22279589	Pre-print	09/06/2022	human		BBIBP-CorV			BBIBP-CorV				Homologous						1	Neutralization	Live virus replication assay	CPE	Omicron	B.1.1.529	BA.4		TCID50 GMT			days post booster1	0	42.14	14		113.51	2.69	1.00																												
5725		40	National Vaccine and Serum Institute	Safety and immunogenicity of a broad-spectrum mosaic vaccine as a booster dose against SARS-CoV-2 Omicron and other circulating variants	https://doi.org/10.1101/2022.09.05.22279589	Pre-print	09/06/2022	human		BBIBP-CorV			NVSI-06-09				Heterologous						1	Neutralization	Live virus replication assay	CPE	Omicron	B.1.1.529	BA.4		TCID50 GMT			days post booster1	0	40.59	14		910.19	22.42	8.32																												
5726		40	National Vaccine and Serum Institute	Safety and immunogenicity of a broad-spectrum mosaic vaccine as a booster dose against SARS-CoV-2 Omicron and other circulating variants	https://doi.org/10.1101/2022.09.05.22279589	Pre-print	09/06/2022	human		BBIBP-CorV			BBIBP-CorV				Homologous						1	Neutralization	Live virus replication assay	CPE	Omicron	B.1.1.529	BA.5		TCID50 GMT			days post booster1	0	34.95	14		165.39	4.73	1.00																												
5727		40	National Vaccine and Serum Institute	Safety and immunogenicity of a broad-spectrum mosaic vaccine as a booster dose against SARS-CoV-2 Omicron and other circulating variants	https://doi.org/10.1101/2022.09.05.22279589	Pre-print	09/06/2022	human		BBIBP-CorV			NVSI-06-09				Heterologous						1	Neutralization	Live virus replication assay	CPE	Omicron	B.1.1.529	BA.5		TCID50 GMT			days post booster1	0	36.95	14		999.85	27.06	5.72																												
5728		40	National Vaccine and Serum Institute	Safety and immunogenicity of a broad-spectrum mosaic vaccine as a booster dose against SARS-CoV-2 Omicron and other circulating variants	https://doi.org/10.1101/2022.09.05.22279589	Pre-print	09/06/2022	human		BBIBP-CorV			BBIBP-CorV				Homologous						1	Neutralization	Live virus replication assay	CPE	beta	B.1.351	B.1.351		TCID50 GMT			days post booster1			14		465.69		1.00																												
5729		40	National Vaccine and Serum Institute	Safety and immunogenicity of a broad-spectrum mosaic vaccine as a booster dose against SARS-CoV-2 Omicron and other circulating variants	https://doi.org/10.1101/2022.09.05.22279589	Pre-print	09/06/2022	human		BBIBP-CorV			NVSI-06-09				Heterologous						1	Neutralization	Live virus replication assay	CPE	beta	B.1.351	B.1.351		TCID50 GMT			days post booster1			14		3075.59		6.60																												
5730		40	National Vaccine and Serum Institute	Safety and immunogenicity of a broad-spectrum mosaic vaccine as a booster dose against SARS-CoV-2 Omicron and other circulating variants	https://doi.org/10.1101/2022.09.05.22279589	Pre-print	09/06/2022	human		BBIBP-CorV			BBIBP-CorV				Homologous						1	Neutralization	Live virus replication assay	CPE	delta	B.1.617.1	B.1.617.1		TCID50 GMT			days post booster1			14		395.09		1.00																												
5731		40	National Vaccine and Serum Institute	Safety and immunogenicity of a broad-spectrum mosaic vaccine as a booster dose against SARS-CoV-2 Omicron and other circulating variants	https://doi.org/10.1101/2022.09.05.22279589	Pre-print	09/06/2022	human		BBIBP-CorV			NVSI-06-09				Heterologous						1	Neutralization	Live virus replication assay	CPE	delta	B.1.617.1	B.1.617.1		TCID50 GMT			days post booster1			14		2831.5		7.17																												
5732		41	Pfizer	Pfizer Quarterly Corporate Performance  Second Quarter 2022	https://s28.q4cdn.com/781576035/files/doc_financials/2022/q2/Q2-2022-Earnings-Charts-FINAL.pdf	Press release	07/28/2022	mice		BNT162b2			BNT162b2				Homologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		pVNT50 GMT								9870		1.00																												
5733		41	Pfizer	Pfizer Quarterly Corporate Performance  Second Quarter 2022	https://s28.q4cdn.com/781576035/files/doc_financials/2022/q2/Q2-2022-Earnings-Charts-FINAL.pdf	Press release	07/28/2022	mice		BNT162b2			BNT162b2 OMI (BA.1)				Heterologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		pVNT50 GMT								4150		0.42																												
5734		41	Pfizer	Pfizer Quarterly Corporate Performance  Second Quarter 2022	https://s28.q4cdn.com/781576035/files/doc_financials/2022/q2/Q2-2022-Earnings-Charts-FINAL.pdf	Press release	07/28/2022	mice		BNT162b2			BNT162b2 OMI (BA.4/5)				Heterologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		pVNT50 GMT								9870		1.00																												
5735		41	Pfizer	Pfizer Quarterly Corporate Performance  Second Quarter 2022	https://s28.q4cdn.com/781576035/files/doc_financials/2022/q2/Q2-2022-Earnings-Charts-FINAL.pdf	Press release	07/28/2022	mice		BNT162b2			Bivalent BNT162b2 OMI(BA.4/5)				Heterologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		pVNT50 GMT								5869		0.59																												
5736		41	Pfizer	Pfizer Quarterly Corporate Performance  Second Quarter 2022	https://s28.q4cdn.com/781576035/files/doc_financials/2022/q2/Q2-2022-Earnings-Charts-FINAL.pdf	Press release	07/28/2022	mice		BNT162b2			BNT162b2				Homologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.1		pVNT50 GMT								2075		1.00																												
5737		41	Pfizer	Pfizer Quarterly Corporate Performance  Second Quarter 2022	https://s28.q4cdn.com/781576035/files/doc_financials/2022/q2/Q2-2022-Earnings-Charts-FINAL.pdf	Press release	07/28/2022	mice		BNT162b2			BNT162b2 OMI (BA.1)				Heterologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.1		pVNT50 GMT								3490		1.68																												
5738		41	Pfizer	Pfizer Quarterly Corporate Performance  Second Quarter 2022	https://s28.q4cdn.com/781576035/files/doc_financials/2022/q2/Q2-2022-Earnings-Charts-FINAL.pdf	Press release	07/28/2022	mice		BNT162b2			BNT162b2 OMI (BA.4/5)				Heterologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.1		pVNT50 GMT								4150		2.00																												
5739		41	Pfizer	Pfizer Quarterly Corporate Performance  Second Quarter 2022	https://s28.q4cdn.com/781576035/files/doc_financials/2022/q2/Q2-2022-Earnings-Charts-FINAL.pdf	Press release	07/28/2022	mice		BNT162b2			Bivalent BNT162b2 OMI(BA.4/5)				Heterologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.1		pVNT50 GMT								2075		1.00																												
5868																																																																					
5869																																																																					
5870																																																																					
5741		41	Pfizer	Pfizer Quarterly Corporate Performance  Second Quarter 2022	https://s28.q4cdn.com/781576035/files/doc_financials/2022/q2/Q2-2022-Earnings-Charts-FINAL.pdf	Press release	07/28/2022	mice		BNT162b2			BNT162b2 OMI (BA.1)				Heterologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.2		pVNT50 GMT								1131		1.30																												
5742		41	Pfizer	Pfizer Quarterly Corporate Performance  Second Quarter 2022	https://s28.q4cdn.com/781576035/files/doc_financials/2022/q2/Q2-2022-Earnings-Charts-FINAL.pdf	Press release	07/28/2022	mice		BNT162b2			BNT162b2 OMI (BA.4/5)				Heterologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.2		pVNT50 GMT								5869		6.73																												
5743		41	Pfizer	Pfizer Quarterly Corporate Performance  Second Quarter 2022	https://s28.q4cdn.com/781576035/files/doc_financials/2022/q2/Q2-2022-Earnings-Charts-FINAL.pdf	Press release	07/28/2022	mice		BNT162b2			Bivalent BNT162b2 OMI(BA.4/5)				Heterologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.2		pVNT50 GMT								2691		3.09																												
5744		41	Pfizer	Pfizer Quarterly Corporate Performance  Second Quarter 2022	https://s28.q4cdn.com/781576035/files/doc_financials/2022/q2/Q2-2022-Earnings-Charts-FINAL.pdf	Press release	07/28/2022	mice		BNT162b2			BNT162b2				Homologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.2.12.1		pVNT50 GMT								951		1.00																												
5745		41	Pfizer	Pfizer Quarterly Corporate Performance  Second Quarter 2022	https://s28.q4cdn.com/781576035/files/doc_financials/2022/q2/Q2-2022-Earnings-Charts-FINAL.pdf	Press release	07/28/2022	mice		BNT162b2			BNT162b2 OMI (BA.1)				Heterologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.2.12.1		pVNT50 GMT								617		0.65																												
5746		41	Pfizer	Pfizer Quarterly Corporate Performance  Second Quarter 2022	https://s28.q4cdn.com/781576035/files/doc_financials/2022/q2/Q2-2022-Earnings-Charts-FINAL.pdf	Press release	07/28/2022	mice		BNT162b2			BNT162b2 OMI (BA.4/5)				Heterologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.2.12.1		pVNT50 GMT								4935		5.19																												
5747		41	Pfizer	Pfizer Quarterly Corporate Performance  Second Quarter 2022	https://s28.q4cdn.com/781576035/files/doc_financials/2022/q2/Q2-2022-Earnings-Charts-FINAL.pdf	Press release	07/28/2022	mice		BNT162b2			Bivalent BNT162b2 OMI(BA.4/5)				Heterologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.2.12.1		pVNT50 GMT								3200		3.36																												
5748		41	Pfizer	Pfizer Quarterly Corporate Performance  Second Quarter 2022	https://s28.q4cdn.com/781576035/files/doc_financials/2022/q2/Q2-2022-Earnings-Charts-FINAL.pdf	Press release	07/28/2022	mice		BNT162b2			BNT162b2				Homologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.4/5		pVNT50 GMT								800		1.00																												
5749		41	Pfizer	Pfizer Quarterly Corporate Performance  Second Quarter 2022	https://s28.q4cdn.com/781576035/files/doc_financials/2022/q2/Q2-2022-Earnings-Charts-FINAL.pdf	Press release	07/28/2022	mice		BNT162b2			BNT162b2 OMI (BA.1)				Heterologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.4/5		pVNT50 GMT								436		0.55																												
5750		41	Pfizer	Pfizer Quarterly Corporate Performance  Second Quarter 2022	https://s28.q4cdn.com/781576035/files/doc_financials/2022/q2/Q2-2022-Earnings-Charts-FINAL.pdf	Press release	07/28/2022	mice		BNT162b2			BNT162b2 OMI (BA.4/5)				Heterologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.4/5		pVNT50 GMT								4935		6.17																												
5751		41	Pfizer	Pfizer Quarterly Corporate Performance  Second Quarter 2022	https://s28.q4cdn.com/781576035/files/doc_financials/2022/q2/Q2-2022-Earnings-Charts-FINAL.pdf	Press release	07/28/2022	mice		BNT162b2			Bivalent BNT162b2 OMI(BA.4/5)				Heterologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.4/5		pVNT50 GMT								2075		2.59																												
5752		42	Jiangsu Provincial Center for Disease Control and Prevention	Heterologous prime-boost immunization with CoronaVac and Convidecia	https://doi.org/10.1101/2021.09.03.21263062	Pre-print	09/06/2021	human		CoronaVac			CoronaVac				Homologous						1	Neutralization	Live virus replication assay	CPE	BetaCoV/Jiangsu/JS02/2020	Wuhan-Hu-1	Wuhan-Hu-1		PRNT50 GMT			days post booster1	0	2.2	14		33.6	15.27	1.00	28		35.3	16.05	1.00																							
5753		42	Jiangsu Provincial Center for Disease Control and Prevention	Heterologous prime-boost immunization with CoronaVac and Convidecia	https://doi.org/10.1101/2021.09.03.21263062	Pre-print	09/06/2021	human		CoronaVac			Ad5-nCoV				Heterologous						1	Neutralization	Live virus replication assay	CPE	BetaCoV/Jiangsu/JS02/2020	Wuhan-Hu-1	Wuhan-Hu-1		PRNT50 GMT			days post booster1	0	2.5	14		197.4	78.96	5.17	28		150.3	60.12	3.75																							
5754		42	Jiangsu Provincial Center for Disease Control and Prevention	Heterologous prime-boost immunization with CoronaVac and Convidecia	https://doi.org/10.1101/2021.09.03.21263062	Pre-print	09/06/2021	human		CoronaVac			CoronaVac				Homologous						2	Binding	ELISA						Anti-RBD IgG GMT			days post booster1	0	10.9	14		369	33.85	1.00	28		318.4	29.21	1.00																							
5755		42	Jiangsu Provincial Center for Disease Control and Prevention	Heterologous prime-boost immunization with CoronaVac and Convidecia	https://doi.org/10.1101/2021.09.03.21263062	Pre-print	09/06/2021	human		CoronaVac			Ad5-nCoV				Heterologous						2	Binding	ELISA						Anti-RBD IgG GMT			days post booster1	0	14.7	14		3090.1	210.21	6.21	28		1992.1	135.52	4.64																							
5756		42	Jiangsu Provincial Center for Disease Control and Prevention	Heterologous prime-boost immunization with CoronaVac and Convidecia	https://doi.org/10.1101/2021.09.03.21263062	Pre-print	09/06/2021	human		CoronaVac			CoronaVac				Homologous						3	Binding	ELISA						Anti-N IgG GMT			days post booster1	0	6.2	14		26.4	4.26	1.00																												
5757		42	Jiangsu Provincial Center for Disease Control and Prevention	Heterologous prime-boost immunization with CoronaVac and Convidecia	https://doi.org/10.1101/2021.09.03.21263062	Pre-print	09/06/2021	human		CoronaVac			Ad5-nCoV				Heterologous						3	Binding	ELISA						Anti-N IgG GMT			days post booster1	0	6.2	14		6.1	0.98	0.23																												
5758		43	Clover Biopharmaceuticals	Heterologous boosting of neutralizing activity against Delta and Omicron SARS-CoV-2 variants in CoronaVac-primed adults; a randomized study with SCB-2019 vaccine	https://doi.org/10.1101/2022.12.06.22283103	Pre-print	12/06/2022	human		CoronaVac			CoronaVac				Homologous						1	Neutralization	Live virus replication assay	Microneutralization	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		MN50 GMT			days post booster1			15		161		1.00																												
5871																																																																					
5872																																																																					
5873																																																																					
5759		43	Clover Biopharmaceuticals	Heterologous boosting of neutralizing activity against Delta and Omicron SARS-CoV-2 variants in CoronaVac-primed adults; a randomized study with SCB-2019 vaccine	https://doi.org/10.1101/2022.12.06.22283103	Pre-print	12/06/2022	human		CoronaVac			SCB-2019				Heterologous						1	Neutralization	Live virus replication assay	Microneutralization	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		MN50 GMT			days post booster1			15		810		5.03																												
5760		43	Clover Biopharmaceuticals	Heterologous boosting of neutralizing activity against Delta and Omicron SARS-CoV-2 variants in CoronaVac-primed adults; a randomized study with SCB-2019 vaccine	https://doi.org/10.1101/2022.12.06.22283103	Pre-print	12/06/2022	human		CoronaVac			CoronaVac				Homologous						1	Neutralization	Live virus replication assay	Microneutralization	delta	B.1.617.2	B.1.617.2		MN50 GMT			days post booster1			15		170.4		1.00																												
5761		43	Clover Biopharmaceuticals	Heterologous boosting of neutralizing activity against Delta and Omicron SARS-CoV-2 variants in CoronaVac-primed adults; a randomized study with SCB-2019 vaccine	https://doi.org/10.1101/2022.12.06.22283103	Pre-print	12/06/2022	human		CoronaVac			SCB-2019				Heterologous						1	Neutralization	Live virus replication assay	Microneutralization	delta	B.1.617.2	B.1.617.2		MN50 GMT			days post booster1			15		538.4		3.16																												
5762		43	Clover Biopharmaceuticals	Heterologous boosting of neutralizing activity against Delta and Omicron SARS-CoV-2 variants in CoronaVac-primed adults; a randomized study with SCB-2019 vaccine	https://doi.org/10.1101/2022.12.06.22283103	Pre-print	12/06/2022	human		CoronaVac			CoronaVac				Homologous						1	Neutralization	Live virus replication assay	Microneutralization	Omicron	B.1.1.529	BA.1		MN50 GMT			days post booster1			15		67.1		1.00																												
5763		43	Clover Biopharmaceuticals	Heterologous boosting of neutralizing activity against Delta and Omicron SARS-CoV-2 variants in CoronaVac-primed adults; a randomized study with SCB-2019 vaccine	https://doi.org/10.1101/2022.12.06.22283103	Pre-print	12/06/2022	human		CoronaVac			SCB-2019				Heterologous						1	Neutralization	Live virus replication assay	Microneutralization	Omicron	B.1.1.529	BA.1		MN50 GMT			days post booster1			15		223		3.32																												
5764		43	Clover Biopharmaceuticals	Heterologous boosting of neutralizing activity against Delta and Omicron SARS-CoV-2 variants in CoronaVac-primed adults; a randomized study with SCB-2019 vaccine	https://doi.org/10.1101/2022.12.06.22283103	Pre-print	12/06/2022	human		CoronaVac			CoronaVac				Homologous						1	Neutralization	Live virus replication assay	Microneutralization	Omicron	B.1.1.529	BA.2		MN50 GMT			days post booster1			15		141.5		1.00																												
5765		43	Clover Biopharmaceuticals	Heterologous boosting of neutralizing activity against Delta and Omicron SARS-CoV-2 variants in CoronaVac-primed adults; a randomized study with SCB-2019 vaccine	https://doi.org/10.1101/2022.12.06.22283103	Pre-print	12/06/2022	human		CoronaVac			SCB-2019				Heterologous						1	Neutralization	Live virus replication assay	Microneutralization	Omicron	B.1.1.529	BA.2		MN50 GMT			days post booster1			15		535.7		3.79																												
5766		43	Clover Biopharmaceuticals	Heterologous boosting of neutralizing activity against Delta and Omicron SARS-CoV-2 variants in CoronaVac-primed adults; a randomized study with SCB-2019 vaccine	https://doi.org/10.1101/2022.12.06.22283103	Pre-print	12/06/2022	human		CoronaVac			CoronaVac				Homologous						1	Neutralization	Live virus replication assay	Microneutralization	Omicron	B.1.1.529	BA.4		MN50 GMT			days post booster1			15		42.5		1.00																												
5767		43	Clover Biopharmaceuticals	Heterologous boosting of neutralizing activity against Delta and Omicron SARS-CoV-2 variants in CoronaVac-primed adults; a randomized study with SCB-2019 vaccine	https://doi.org/10.1101/2022.12.06.22283103	Pre-print	12/06/2022	human		CoronaVac			SCB-2019				Heterologous						1	Neutralization	Live virus replication assay	Microneutralization	Omicron	B.1.1.529	BA.4		MN50 GMT			days post booster1			15		154.9		3.64																												
5768		43	Clover Biopharmaceuticals	Heterologous boosting of neutralizing activity against Delta and Omicron SARS-CoV-2 variants in CoronaVac-primed adults; a randomized study with SCB-2019 vaccine	https://doi.org/10.1101/2022.12.06.22283103	Pre-print	12/06/2022	human		CoronaVac			CoronaVac				Homologous						1	Neutralization	Live virus replication assay	Microneutralization	Omicron	B.1.1.529	BA.5		MN50 GMT			days post booster1			15		73.3		1.00																												
5769		43	Clover Biopharmaceuticals	Heterologous boosting of neutralizing activity against Delta and Omicron SARS-CoV-2 variants in CoronaVac-primed adults; a randomized study with SCB-2019 vaccine	https://doi.org/10.1101/2022.12.06.22283103	Pre-print	12/06/2022	human		CoronaVac			SCB-2019				Heterologous						1	Neutralization	Live virus replication assay	Microneutralization	Omicron	B.1.1.529	BA.5		MN50 GMT			days post booster1			15		253.3		3.46																												
5770		44	Aix-Marseille University	Immunogenicity and Safety of Beta-Adjuvanted Recombinant Booster Vaccine	https://doi.org/10.1056/NEJMc2206711	Peer-reviewed publication	07/28/2022	human		BNT162b2			BNT162b2				Homologous						1	Neutralization	Live virus replication assay	CPE	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		VNT100 GMT			days post booster1	0	96	15		1364.4	14.21	1.00																												
5771		44	Aix-Marseille University	Immunogenicity and Safety of Beta-Adjuvanted Recombinant Booster Vaccine	https://doi.org/10.1056/NEJMc2206711	Peer-reviewed publication	07/28/2022	human		BNT162b2			MVD614				Heterologous						1	Neutralization	Live virus replication assay	CPE	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		VNT100 GMT			days post booster1	0	86.6	15		1168.4	13.49	0.95																												
5772		44	Aix-Marseille University	Immunogenicity and Safety of Beta-Adjuvanted Recombinant Booster Vaccine	https://doi.org/10.1056/NEJMc2206711	Peer-reviewed publication	07/28/2022	human		BNT162b2			MVB.1.351				Heterologous						1	Neutralization	Live virus replication assay	CPE	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		VNT100 GMT			days post booster1	0	84	15		1801.4	21.45	1.51																												
5773		44	Aix-Marseille University	Immunogenicity and Safety of Beta-Adjuvanted Recombinant Booster Vaccine	https://doi.org/10.1056/NEJMc2206711	Peer-reviewed publication	07/28/2022	human		BNT162b2			BNT162b2				Homologous						1	Neutralization	Live virus replication assay	CPE	beta	B.1.351	B.1.351		VNT100 GMT			days post booster1	0	38.6	15		428.4	11.10	1.00																												
5774		44	Aix-Marseille University	Immunogenicity and Safety of Beta-Adjuvanted Recombinant Booster Vaccine	https://doi.org/10.1056/NEJMc2206711	Peer-reviewed publication	07/28/2022	human		BNT162b2			MVD614				Heterologous						1	Neutralization	Live virus replication assay	CPE	beta	B.1.351	B.1.351		VNT100 GMT			days post booster1	0	38.6	15		416.9	10.80	0.97																												
5874																																																																					
5875																																																																					
5876																																																																					
5775		44	Aix-Marseille University	Immunogenicity and Safety of Beta-Adjuvanted Recombinant Booster Vaccine	https://doi.org/10.1056/NEJMc2206711	Peer-reviewed publication	07/28/2022	human		BNT162b2			MVB.1.351				Heterologous						1	Neutralization	Live virus replication assay	CPE	beta	B.1.351	B.1.351		VNT100 GMT			days post booster1	0	33.2	15		1053	31.72	2.86																												
5776		44	Aix-Marseille University	Immunogenicity and Safety of Beta-Adjuvanted Recombinant Booster Vaccine	https://doi.org/10.1056/NEJMc2206711	Peer-reviewed publication	07/28/2022	human		BNT162b2			BNT162b2				Homologous						1	Neutralization	Live virus replication assay	CPE	delta	B.1.617.2	B.1.617.2		VNT100 GMT			days post booster1	0	41.5	15		553.1	13.33	1.00																												
5777		44	Aix-Marseille University	Immunogenicity and Safety of Beta-Adjuvanted Recombinant Booster Vaccine	https://doi.org/10.1056/NEJMc2206711	Peer-reviewed publication	07/28/2022	human		BNT162b2			MVD614				Heterologous						1	Neutralization	Live virus replication assay	CPE	delta	B.1.617.2	B.1.617.2		VNT100 GMT			days post booster1	0	45.9	15		491.3	10.70	0.80																												
5778		44	Aix-Marseille University	Immunogenicity and Safety of Beta-Adjuvanted Recombinant Booster Vaccine	https://doi.org/10.1056/NEJMc2206711	Peer-reviewed publication	07/28/2022	human		BNT162b2			MVB.1.351				Heterologous						1	Neutralization	Live virus replication assay	CPE	delta	B.1.617.2	B.1.617.2		VNT100 GMT			days post booster1	0	39.2	15		849.4	21.67	1.63																												
5779		44	Aix-Marseille University	Immunogenicity and Safety of Beta-Adjuvanted Recombinant Booster Vaccine	https://doi.org/10.1056/NEJMc2206711	Peer-reviewed publication	07/28/2022	human		BNT162b2			BNT162b2				Homologous						1	Neutralization	Live virus replication assay	CPE	Omicron	B.1.1.529	BA.1.1		VNT100 GMT			days post booster1	0	19.1	15		139.5	7.30	1.00																												
5780		44	Aix-Marseille University	Immunogenicity and Safety of Beta-Adjuvanted Recombinant Booster Vaccine	https://doi.org/10.1056/NEJMc2206711	Peer-reviewed publication	07/28/2022	human		BNT162b2			MVD614				Heterologous						1	Neutralization	Live virus replication assay	CPE	Omicron	B.1.1.529	BA.1.1		VNT100 GMT			days post booster1	0	22.5	15		123.9	5.51	0.75																												
5781		44	Aix-Marseille University	Immunogenicity and Safety of Beta-Adjuvanted Recombinant Booster Vaccine	https://doi.org/10.1056/NEJMc2206711	Peer-reviewed publication	07/28/2022	human		BNT162b2			MVB.1.351				Heterologous						1	Neutralization	Live virus replication assay	CPE	Omicron	B.1.1.529	BA.1.1		VNT100 GMT			days post booster1	0	17.4	15		253.2	14.55	1.99																												
5782		44	Aix-Marseille University	Immunogenicity and Safety of Beta-Adjuvanted Recombinant Booster Vaccine	https://doi.org/10.1056/NEJMc2206711	Peer-reviewed publication	07/28/2022	human		BNT162b2			BNT162b2				Homologous						2	Binding	ELISA						Anti-S1 GMT			days post booster1	0	253.6	15		2405.4	9.49	1.00																												
5783		44	Aix-Marseille University	Immunogenicity and Safety of Beta-Adjuvanted Recombinant Booster Vaccine	https://doi.org/10.1056/NEJMc2206711	Peer-reviewed publication	07/28/2022	human		BNT162b2			MVD614				Heterologous						2	Binding	ELISA						Anti-S1 GMT			days post booster1	0	277.1	15		1875.1	6.77	0.71																												
5784		44	Aix-Marseille University	Immunogenicity and Safety of Beta-Adjuvanted Recombinant Booster Vaccine	https://doi.org/10.1056/NEJMc2206711	Peer-reviewed publication	07/28/2022	human		BNT162b2			MVB.1.351				Heterologous						2	Binding	ELISA						Anti-S1 GMT			days post booster1	0	206.8	15		2240.8	10.84	1.14																												
5785		45	China National Biotec Group	Heterologous boost with mRNA vaccines against SARS-CoV-2 Delta/Omicron variants following an inactivated whole-virus vaccine	https://doi.org/10.1101/2022.09.06.506714	Peer-reviewed publication	03/05/2023	mice		BBIBP-CorV			BBIBP-CorV				Homologous						1	Neutralization	Live virus replication assay	Microneutralization	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		MN50 GMT			days post booster1			7		509		1.00	14		763		1.00																							
5786		45	China National Biotec Group	Heterologous boost with mRNA vaccines against SARS-CoV-2 Delta/Omicron variants following an inactivated whole-virus vaccine	https://doi.org/10.1101/2022.09.06.506714	Peer-reviewed publication	03/05/2023	mice		BBIBP-CorV			ZSVG-02-O	3	?g		Heterologous						1	Neutralization	Live virus replication assay	Microneutralization	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		MN50 GMT			days post booster1			7		2097		4.12	14		4572		5.99																							
5787		45	China National Biotec Group	Heterologous boost with mRNA vaccines against SARS-CoV-2 Delta/Omicron variants following an inactivated whole-virus vaccine	https://doi.org/10.1101/2022.09.06.506714	Peer-reviewed publication	03/05/2023	mice		BBIBP-CorV			ZSVG-02-O	10	?g		Heterologous						1	Neutralization	Live virus replication assay	Microneutralization	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		MN50 GMT			days post booster1			7		1980		3.89	14		2508		3.29																							
5788		45	China National Biotec Group	Heterologous boost with mRNA vaccines against SARS-CoV-2 Delta/Omicron variants following an inactivated whole-virus vaccine	https://doi.org/10.1101/2022.09.06.506714	Peer-reviewed publication	03/05/2023	mice		BBIBP-CorV			ZSVG-02-O	30	?g		Heterologous						1	Neutralization	Live virus replication assay	Microneutralization	Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		MN50 GMT			days post booster1			7		1589		3.12	14		1980		2.60																							
5789		45	China National Biotec Group	Heterologous boost with mRNA vaccines against SARS-CoV-2 Delta/Omicron variants following an inactivated whole-virus vaccine	https://doi.org/10.1101/2022.09.06.506714	Peer-reviewed publication	03/05/2023	mice		BBIBP-CorV			BBIBP-CorV				Homologous						1	Neutralization	Live virus replication assay	Microneutralization	delta	B.1.617.2	B.1.617.2		MN50 GMT			days post booster1			7		142		1.00	14		281		1.00																							
5790		45	China National Biotec Group	Heterologous boost with mRNA vaccines against SARS-CoV-2 Delta/Omicron variants following an inactivated whole-virus vaccine	https://doi.org/10.1101/2022.09.06.506714	Peer-reviewed publication	03/05/2023	mice		BBIBP-CorV			ZSVG-02-O	3	?g		Heterologous						1	Neutralization	Live virus replication assay	Microneutralization	delta	B.1.617.2	B.1.617.2		MN50 GMT			days post booster1			7		1184		8.34	14		1544		5.49																							
5791		45	China National Biotec Group	Heterologous boost with mRNA vaccines against SARS-CoV-2 Delta/Omicron variants following an inactivated whole-virus vaccine	https://doi.org/10.1101/2022.09.06.506714	Peer-reviewed publication	03/05/2023	mice		BBIBP-CorV			ZSVG-02-O	10	?g		Heterologous						1	Neutralization	Live virus replication assay	Microneutralization	delta	B.1.617.2	B.1.617.2		MN50 GMT			days post booster1			7		924		6.51	14		1079		3.84																							
5792		45	China National Biotec Group	Heterologous boost with mRNA vaccines against SARS-CoV-2 Delta/Omicron variants following an inactivated whole-virus vaccine	https://doi.org/10.1101/2022.09.06.506714	Peer-reviewed publication	03/05/2023	mice		BBIBP-CorV			ZSVG-02-O	30	?g		Heterologous						1	Neutralization	Live virus replication assay	Microneutralization	delta	B.1.617.2	B.1.617.2		MN50 GMT			days post booster1			7		924		6.51	14		1061		3.78																							
5793		45	China National Biotec Group	Heterologous boost with mRNA vaccines against SARS-CoV-2 Delta/Omicron variants following an inactivated whole-virus vaccine	https://doi.org/10.1101/2022.09.06.506714	Peer-reviewed publication	03/05/2023	mice		BBIBP-CorV			BBIBP-CorV				Homologous						1	Neutralization	Live virus replication assay	Microneutralization	Omicron	B.1.1.529	BA.1.1		MN50 GMT			days post booster1			7		17		1.00	14		32		1.00																							
5794		45	China National Biotec Group	Heterologous boost with mRNA vaccines against SARS-CoV-2 Delta/Omicron variants following an inactivated whole-virus vaccine	https://doi.org/10.1101/2022.09.06.506714	Peer-reviewed publication	03/05/2023	mice		BBIBP-CorV			ZSVG-02-O	3	?g		Heterologous						1	Neutralization	Live virus replication assay	Microneutralization	Omicron	B.1.1.529	BA.1.1		MN50 GMT			days post booster1			7		653		38.41	14		1291		40.34																							
5795		45	China National Biotec Group	Heterologous boost with mRNA vaccines against SARS-CoV-2 Delta/Omicron variants following an inactivated whole-virus vaccine	https://doi.org/10.1101/2022.09.06.506714	Peer-reviewed publication	03/05/2023	mice		BBIBP-CorV			ZSVG-02-O	10	?g		Heterologous						1	Neutralization	Live virus replication assay	Microneutralization	Omicron	B.1.1.529	BA.1.1		MN50 GMT			days post booster1			7		1007		59.24	14		1980		61.88																							
5796		45	China National Biotec Group	Heterologous boost with mRNA vaccines against SARS-CoV-2 Delta/Omicron variants following an inactivated whole-virus vaccine	https://doi.org/10.1101/2022.09.06.506714	Peer-reviewed publication	03/05/2023	mice		BBIBP-CorV			ZSVG-02-O	30	?g		Heterologous						1	Neutralization	Live virus replication assay	Microneutralization	Omicron	B.1.1.529	BA.1.1		MN50 GMT			days post booster1			7		585		34.41	14		1269		39.66																							
5797		45	China National Biotec Group	Heterologous boost with mRNA vaccines against SARS-CoV-2 Delta/Omicron variants following an inactivated whole-virus vaccine	https://doi.org/10.1101/2022.09.06.506714	Peer-reviewed publication	03/05/2023	mice		BBIBP-CorV			BBIBP-CorV				Homologous	BBIBP-CorV			Homologous	Injected 14 days post boost1	2	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.1.1		MN50 GMT			days post booster1			14		153		1.00	14		32		1.00						days post boost2	0	153	14		810	5.29	1.00										
5798		45	China National Biotec Group	Heterologous boost with mRNA vaccines against SARS-CoV-2 Delta/Omicron variants following an inactivated whole-virus vaccine	https://doi.org/10.1101/2022.09.06.506714	Peer-reviewed publication	03/05/2023	mice		BBIBP-CorV			ZSVG-02-O	1	?g		Heterologous	ZSVG-02-O	1	?g	Heterologous	Injected 14 days post boost1	2	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.1.1		MN50 GMT			days post booster1			14		351		2.29	14		1291		40.34						days post boost2	0	351	14		4783	13.63	2.57										
5799		45	China National Biotec Group	Heterologous boost with mRNA vaccines against SARS-CoV-2 Delta/Omicron variants following an inactivated whole-virus vaccine	https://doi.org/10.1101/2022.09.06.506714	Peer-reviewed publication	03/05/2023	mice		BBIBP-CorV			ZSVG-02-O	10	?g		Heterologous	ZSVG-02-O	10	?g	Heterologous	Injected 14 days post boost1	2	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.1.1		MN50 GMT			days post booster1			14		629		4.11	14		1980		61.88						days post boost2	0	629	14		10581	16.82	3.18										
5800		45	China National Biotec Group	Heterologous boost with mRNA vaccines against SARS-CoV-2 Delta/Omicron variants following an inactivated whole-virus vaccine	https://doi.org/10.1101/2022.09.06.506714	Peer-reviewed publication	03/05/2023	mice		BBIBP-CorV			ZSVG-02-O	30	?g		Heterologous	ZSVG-02-O	30	?g	Heterologous	Injected 14 days post boost1	2	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.1.1		MN50 GMT			days post booster1			14		1091		7.13	14		1269		39.66						days post boost2	0	1091	14		10304	9.44	1.78										
5801		45	China National Biotec Group	Heterologous boost with mRNA vaccines against SARS-CoV-2 Delta/Omicron variants following an inactivated whole-virus vaccine	https://doi.org/10.1101/2022.09.06.506714	Peer-reviewed publication	03/05/2023	mice		BBIBP-CorV			BBIBP-CorV				Homologous	BBIBP-CorV			Homologous	Injected 14 days post boost1	2	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.4/5		MN50 GMT			days post booster1			14		42		1.00	14		32		1.00						days post boost2	0	42	14		121	2.88	1.00										
5802		45	China National Biotec Group	Heterologous boost with mRNA vaccines against SARS-CoV-2 Delta/Omicron variants following an inactivated whole-virus vaccine	https://doi.org/10.1101/2022.09.06.506714	Peer-reviewed publication	03/05/2023	mice		BBIBP-CorV			ZSVG-02-O	1	?g		Heterologous	ZSVG-02-O	1	?g	Heterologous	Injected 14 days post boost1	2	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.4/5		MN50 GMT			days post booster1			14		54		1.29	14		1291		40.34						days post boost2	0	54	14		171	3.17	1.10										
5803		45	China National Biotec Group	Heterologous boost with mRNA vaccines against SARS-CoV-2 Delta/Omicron variants following an inactivated whole-virus vaccine	https://doi.org/10.1101/2022.09.06.506714	Peer-reviewed publication	03/05/2023	mice		BBIBP-CorV			ZSVG-02-O	10	?g		Heterologous	ZSVG-02-O	10	?g	Heterologous	Injected 14 days post boost1	2	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.4/5		MN50 GMT			days post booster1			14		181		4.31	14		1980		61.88						days post boost2	0	181	14		976	5.39	1.87										
5804		45	China National Biotec Group	Heterologous boost with mRNA vaccines against SARS-CoV-2 Delta/Omicron variants following an inactivated whole-virus vaccine	https://doi.org/10.1101/2022.09.06.506714	Peer-reviewed publication	03/05/2023	mice		BBIBP-CorV			ZSVG-02-O	30	?g		Heterologous	ZSVG-02-O	30	?g	Heterologous	Injected 14 days post boost1	2	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.4/5		MN50 GMT			days post booster1			14		402		9.57	14		1269		39.66						days post boost2	0	402	14		1242	3.09	1.07										
5805		46	Jiangsu Provincial Center for Disease Control and Prevention	Safety, immunogenicity and protection of heterologous boost with an aerosolised Ad5-nCoV after two-dose inactivated COVID-19 vaccines in adults: a multicentre, open-label phase 3 trial	https://doi.org/10.1016/S1473-3099(23)00350-X	Peer-reviewed publication	06/20/2023	human		Inactivated vaccine	0.5	mL	Inactivated vaccine	0.5	mL	CoronaVac; BBIBP-CorV; WIBP-CorV or KCONVAC	Homologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.4/5		GMT			days post booster1	0	15.2	14		19.1	1.26	1.00	28		17.2	1.13	1.00	84		15.9	1.05	1.00																		
5806		46	Jiangsu Provincial Center for Disease Control and Prevention	Safety, immunogenicity and protection of heterologous boost with an aerosolised Ad5-nCoV after two-dose inactivated COVID-19 vaccines in adults: a multicentre, open-label phase 3 trial	https://doi.org/10.1016/S1473-3099(23)00350-X	Peer-reviewed publication	06/20/2023	human		Inactivated vaccine	0.5	mL	Aerosolised Ad5-nCoV	0.1	mL		Heterologous						1	Neutralization	Pseudotyped virus assay	Luciferase	Omicron	B.1.1.529	BA.4/5		GMT			days post booster1	0	15.3	14		91.4	5.97	4.75	28		107.7	7.04	6.22	84		64.1	4.19	4.01																		
5877																																																																					
5878																																																																					
5807		46	Jiangsu Provincial Center for Disease Control and Prevention	Safety, immunogenicity and protection of heterologous boost with an aerosolised Ad5-nCoV after two-dose inactivated COVID-19 vaccines in adults: a multicentre, open-label phase 3 trial	https://doi.org/10.1016/S1473-3099(23)00350-X	Peer-reviewed publication	06/20/2023	human		Inactivated vaccine	0.5	mL	Inactivated vaccine	0.5	mL	CoronaVac; BBIBP-CorV; WIBP-CorV or KCONVAC	Homologous						2	Binding	ELISA		Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		Anti-RBD IgG GMC			days post booster1	0	28.1	14		297	10.57	1.00	28		253	9.00	1.00	84		143.9	5.12	1.00																		
5808		46	Jiangsu Provincial Center for Disease Control and Prevention	Safety, immunogenicity and protection of heterologous boost with an aerosolised Ad5-nCoV after two-dose inactivated COVID-19 vaccines in adults: a multicentre, open-label phase 3 trial	https://doi.org/10.1016/S1473-3099(23)00350-X	Peer-reviewed publication	06/20/2023	human		Inactivated vaccine	0.5	mL	Aerosolised Ad5-nCoV	0.1	mL		Heterologous						2	Binding	ELISA		Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		Anti-RBD IgG GMC			days post booster1	0	28.3	14		2201.8	77.80	7.36	28		4354.8	153.88	17.09	84		3486.4	123.19	24.06																		
5809		46	Jiangsu Provincial Center for Disease Control and Prevention	Safety, immunogenicity and protection of heterologous boost with an aerosolised Ad5-nCoV after two-dose inactivated COVID-19 vaccines in adults: a multicentre, open-label phase 3 trial	https://doi.org/10.1016/S1473-3099(23)00350-X	Peer-reviewed publication	06/20/2023	human		Inactivated vaccine	0.5	mL	Inactivated vaccine	0.5	mL	CoronaVac; BBIBP-CorV; WIBP-CorV or KCONVAC	Homologous						3	Binding	ELISA		Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		%inhibition			days post booster1	0	6.7	14		96.7	14.43	1.00	28		96.6	14.42	1.00																							
5810		46	Jiangsu Provincial Center for Disease Control and Prevention	Safety, immunogenicity and protection of heterologous boost with an aerosolised Ad5-nCoV after two-dose inactivated COVID-19 vaccines in adults: a multicentre, open-label phase 3 trial	https://doi.org/10.1016/S1473-3099(23)00350-X	Peer-reviewed publication	06/20/2023	human		Inactivated vaccine	0.5	mL	Aerosolised Ad5-nCoV	0.1	mL		Heterologous						3	Binding	ELISA		Wuhan-Hu-1	Wuhan-Hu-1	Wuhan-Hu-1		%inhibition			days post booster1	0	3.3	14		93.3	28.27	1.96	28		96.6	29.27	2.03																							
5811		46	Jiangsu Provincial Center for Disease Control and Prevention	Safety, immunogenicity and protection of heterologous boost with an aerosolised Ad5-nCoV after two-dose inactivated COVID-19 vaccines in adults: a multicentre, open-label phase 3 trial	https://doi.org/10.1016/S1473-3099(23)00350-X	Peer-reviewed publication	06/20/2023	human		Inactivated vaccine	0.5	mL	Inactivated vaccine	0.5	mL	CoronaVac; BBIBP-CorV; WIBP-CorV or KCONVAC	Homologous						3	Binding	ELISA		Beta	B.1.351	B.1.351		%inhibition			days post booster1			14		83.3		1.00	28		58.6		1.00																							
5812		46	Jiangsu Provincial Center for Disease Control and Prevention	Safety, immunogenicity and protection of heterologous boost with an aerosolised Ad5-nCoV after two-dose inactivated COVID-19 vaccines in adults: a multicentre, open-label phase 3 trial	https://doi.org/10.1016/S1473-3099(23)00350-X	Peer-reviewed publication	06/20/2023	human		Inactivated vaccine	0.5	mL	Aerosolised Ad5-nCoV	0.1	mL		Heterologous						3	Binding	ELISA		Beta	B.1.351	B.1.351		%inhibition			days post booster1			14		86.7		1.04	28		93.1		1.59																							
5813		46	Jiangsu Provincial Center for Disease Control and Prevention	Safety, immunogenicity and protection of heterologous boost with an aerosolised Ad5-nCoV after two-dose inactivated COVID-19 vaccines in adults: a multicentre, open-label phase 3 trial	https://doi.org/10.1016/S1473-3099(23)00350-X	Peer-reviewed publication	06/20/2023	human		Inactivated vaccine	0.5	mL	Inactivated vaccine	0.5	mL	CoronaVac; BBIBP-CorV; WIBP-CorV or KCONVAC	Homologous						3	Binding	ELISA		delta	B.1.617.2	AY.4		%inhibition			days post booster1			14		90		1.00	28		62.1		1.00																							
5814		46	Jiangsu Provincial Center for Disease Control and Prevention	Safety, immunogenicity and protection of heterologous boost with an aerosolised Ad5-nCoV after two-dose inactivated COVID-19 vaccines in adults: a multicentre, open-label phase 3 trial	https://doi.org/10.1016/S1473-3099(23)00350-X	Peer-reviewed publication	06/20/2023	human		Inactivated vaccine	0.5	mL	Aerosolised Ad5-nCoV	0.1	mL		Heterologous						3	Binding	ELISA		delta	B.1.617.2	AY.4		%inhibition			days post booster1			14		93.3		1.04	28		93.1		1.50																							
5815		46	Jiangsu Provincial Center for Disease Control and Prevention	Safety, immunogenicity and protection of heterologous boost with an aerosolised Ad5-nCoV after two-dose inactivated COVID-19 vaccines in adults: a multicentre, open-label phase 3 trial	https://doi.org/10.1016/S1473-3099(23)00350-X	Peer-reviewed publication	06/20/2023	human		Inactivated vaccine	0.5	mL	Inactivated vaccine	0.5	mL	CoronaVac; BBIBP-CorV; WIBP-CorV or KCONVAC	Homologous						3	Binding	ELISA		Omicron	B.1.1.529	BA.2		%inhibition			days post booster1			14		33.3		1.00	28		13.8		1.00																							
5816		46	Jiangsu Provincial Center for Disease Control and Prevention	Safety, immunogenicity and protection of heterologous boost with an aerosolised Ad5-nCoV after two-dose inactivated COVID-19 vaccines in adults: a multicentre, open-label phase 3 trial	https://doi.org/10.1016/S1473-3099(23)00350-X	Peer-reviewed publication	06/20/2023	human		Inactivated vaccine	0.5	mL	Aerosolised Ad5-nCoV	0.1	mL		Heterologous						3	Binding	ELISA		Omicron	B.1.1.529	BA.2		%inhibition			days post booster1			14		76.7		2.30	28		93.1		6.75																							
5817		46	Jiangsu Provincial Center for Disease Control and Prevention	Safety, immunogenicity and protection of heterologous boost with an aerosolised Ad5-nCoV after two-dose inactivated COVID-19 vaccines in adults: a multicentre, open-label phase 3 trial	https://doi.org/10.1016/S1473-3099(23)00350-X	Peer-reviewed publication	06/20/2023	human		Inactivated vaccine	0.5	mL	Inactivated vaccine	0.5	mL	CoronaVac; BBIBP-CorV; WIBP-CorV or KCONVAC	Homologous						3	Binding	ELISA		Omicron	B.1.1.529	BA.2	L452M	%inhibition			days post booster1			14		33.3		1.00	28		17.2		1.00																							
5818		46	Jiangsu Provincial Center for Disease Control and Prevention	Safety, immunogenicity and protection of heterologous boost with an aerosolised Ad5-nCoV after two-dose inactivated COVID-19 vaccines in adults: a multicentre, open-label phase 3 trial	https://doi.org/10.1016/S1473-3099(23)00350-X	Peer-reviewed publication	06/20/2023	human		Inactivated vaccine	0.5	mL	Aerosolised Ad5-nCoV	0.1	mL		Heterologous						3	Binding	ELISA		Omicron	B.1.1.529	BA.2	L452M	%inhibition			days post booster1			14		76.7		2.30	28		93.1		5.41																							
5819		46	Jiangsu Provincial Center for Disease Control and Prevention	Safety, immunogenicity and protection of heterologous boost with an aerosolised Ad5-nCoV after two-dose inactivated COVID-19 vaccines in adults: a multicentre, open-label phase 3 trial	https://doi.org/10.1016/S1473-3099(23)00350-X	Peer-reviewed publication	06/20/2023	human		Inactivated vaccine	0.5	mL	Inactivated vaccine	0.5	mL	CoronaVac; BBIBP-CorV; WIBP-CorV or KCONVAC	Homologous						3	Binding	ELISA		Omicron	B.1.1.529	BA.2	L452R	%inhibition			days post booster1			14		26.7		1.00	28		13.8		1.00																							
5879																																																																					
5820		46	Jiangsu Provincial Center for Disease Control and Prevention	Safety, immunogenicity and protection of heterologous boost with an aerosolised Ad5-nCoV after two-dose inactivated COVID-19 vaccines in adults: a multicentre, open-label phase 3 trial	https://doi.org/10.1016/S1473-3099(23)00350-X	Peer-reviewed publication	06/20/2023	human		Inactivated vaccine	0.5	mL	Aerosolised Ad5-nCoV	0.1	mL		Heterologous						3	Binding	ELISA		Omicron	B.1.1.529	BA.2	L452R	%inhibition			days post booster1			14		76.7		2.87	28		93.1		6.75																							
5821		46	Jiangsu Provincial Center for Disease Control and Prevention	Safety, immunogenicity and protection of heterologous boost with an aerosolised Ad5-nCoV after two-dose inactivated COVID-19 vaccines in adults: a multicentre, open-label phase 3 trial	https://doi.org/10.1016/S1473-3099(23)00350-X	Peer-reviewed publication	06/20/2023	human		Inactivated vaccine	0.5	mL	Inactivated vaccine	0.5	mL	CoronaVac; BBIBP-CorV; WIBP-CorV or KCONVAC	Homologous						3	Binding	ELISA		Omicron	B.1.1.529	BA.2.12.1		%inhibition			days post booster1			14		50		1.00	28		17.2		1.00																							
5822		46	Jiangsu Provincial Center for Disease Control and Prevention	Safety, immunogenicity and protection of heterologous boost with an aerosolised Ad5-nCoV after two-dose inactivated COVID-19 vaccines in adults: a multicentre, open-label phase 3 trial	https://doi.org/10.1016/S1473-3099(23)00350-X	Peer-reviewed publication	06/20/2023	human		Inactivated vaccine	0.5	mL	Aerosolised Ad5-nCoV	0.1	mL		Heterologous						3	Binding	ELISA		Omicron	B.1.1.529	BA.2.12.1		%inhibition			days post booster1			14		76.7		1.53	28		93.1		5.41																							
5823		46	Jiangsu Provincial Center for Disease Control and Prevention	Safety, immunogenicity and protection of heterologous boost with an aerosolised Ad5-nCoV after two-dose inactivated COVID-19 vaccines in adults: a multicentre, open-label phase 3 trial	https://doi.org/10.1016/S1473-3099(23)00350-X	Peer-reviewed publication	06/20/2023	human		Inactivated vaccine	0.5	mL	Inactivated vaccine	0.5	mL	CoronaVac; BBIBP-CorV; WIBP-CorV or KCONVAC	Homologous						3	Binding	ELISA		Omicron	B.1.1.529	BA.3		%inhibition			days post booster1			14		40		1.00	28		13.8		1.00																							
5824		46	Jiangsu Provincial Center for Disease Control and Prevention	Safety, immunogenicity and protection of heterologous boost with an aerosolised Ad5-nCoV after two-dose inactivated COVID-19 vaccines in adults: a multicentre, open-label phase 3 trial	https://doi.org/10.1016/S1473-3099(23)00350-X	Peer-reviewed publication	06/20/2023	human		Inactivated vaccine	0.5	mL	Aerosolised Ad5-nCoV	0.1	mL		Heterologous						3	Binding	ELISA		Omicron	B.1.1.529	BA.3		%inhibition			days post booster1			14		76.7		1.92	28		93.1		6.75																							
5825		46	Jiangsu Provincial Center for Disease Control and Prevention	Safety, immunogenicity and protection of heterologous boost with an aerosolised Ad5-nCoV after two-dose inactivated COVID-19 vaccines in adults: a multicentre, open-label phase 3 trial	https://doi.org/10.1016/S1473-3099(23)00350-X	Peer-reviewed publication	06/20/2023	human		Inactivated vaccine	0.5	mL	Inactivated vaccine	0.5	mL	CoronaVac; BBIBP-CorV; WIBP-CorV or KCONVAC	Homologous						3	Binding	ELISA		Omicron	B.1.1.529	BA.4		%inhibition			days post booster1			14		56.7		1.00	28		24.1		1.00																							
5826		46	Jiangsu Provincial Center for Disease Control and Prevention	Safety, immunogenicity and protection of heterologous boost with an aerosolised Ad5-nCoV after two-dose inactivated COVID-19 vaccines in adults: a multicentre, open-label phase 3 trial	https://doi.org/10.1016/S1473-3099(23)00350-X	Peer-reviewed publication	06/20/2023	human		Inactivated vaccine	0.5	mL	Aerosolised Ad5-nCoV	0.1	mL		Heterologous						3	Binding	ELISA		Omicron	B.1.1.529	BA.4		%inhibition			days post booster1			14		83.3		1.47	28		93.1		3.86																							
5827		46	Jiangsu Provincial Center for Disease Control and Prevention	Safety, immunogenicity and protection of heterologous boost with an aerosolised Ad5-nCoV after two-dose inactivated COVID-19 vaccines in adults: a multicentre, open-label phase 3 trial	https://doi.org/10.1016/S1473-3099(23)00350-X	Peer-reviewed publication	06/20/2023	human		Inactivated vaccine	0.5	mL	Inactivated vaccine	0.5	mL	CoronaVac; BBIBP-CorV; WIBP-CorV or KCONVAC	Homologous						3	Binding	ELISA		Omicron	B.1.1.529	BA.5		%inhibition			days post booster1			14		56.7		1.00	28		24.1		1.00																							
5828		46	Jiangsu Provincial Center for Disease Control and Prevention	Safety, immunogenicity and protection of heterologous boost with an aerosolised Ad5-nCoV after two-dose inactivated COVID-19 vaccines in adults: a multicentre, open-label phase 3 trial	https://doi.org/10.1016/S1473-3099(23)00350-X	Peer-reviewed publication	06/20/2023	human		Inactivated vaccine	0.5	mL	Aerosolised Ad5-nCoV	0.1	mL		Heterologous						3	Binding	ELISA		Omicron	B.1.1.529	BA.5		%inhibition			days post booster1			14		83.3		1.47	28		93.1		3.86																							
5829																																																																					
5830																																																																					
5831																																																																					
5832																																																																					
5833																																																																					
5834																																																																					
5835																																																																					
5836																																																																					
5837																																																																					
5838																																																																					
5839																																																																					
5840																																																																					
5841																																																																					
5842																																																																					
5843																																																																					
5844																																																																					
5845																																																																					
5846																																																																					
5847																																																																					
5848																																																																					
5849																																																																					
5850																																																																					
5851																																																																					
5852																																																																					
5853																																																																					
5928																																																																					
5929																																																																					
5930																																																																					
5931																																																																					
5932																																																																					
5933																																																																					
5934																																																																					
5935																																																																					
5936																																																																					
5937																																																																					
5938																																																																					
5939																																																																					
5940																																																																					
5941																																																																					
5942																																																																					
5943																																																																					
5944																																																																					
5945																																																																					


---Column List---   

column_name	data_type	is_nullable
id	integer	NO
report_number	character varying	YES
hb_report_number	character varying	YES
data_provider	character varying	YES
data_title	character varying	YES
data_source	character varying	YES
data_source_type	character varying	YES
data_date	character varying	YES
sample_source	character varying	YES
sample_info	character varying	YES
vac_prime	character varying	YES
vac_prime_dose	character varying	YES
vac_prime_dose_unit	character varying	YES
vac_boost1	character varying	YES
vac_boost1_dose	character varying	YES
vac_boost1_dose_unit	character varying	YES
boost1_info	character varying	YES
boost1_class	character varying	YES
vac_boost2	character varying	YES
vac_boost2_dose	character varying	YES
vac_boost2_dose_unit	character varying	YES
boost2_class	character varying	YES
boost2_info	character varying	YES
experiment_id	character varying	YES
assay_cat	character varying	YES
assay_type	character varying	YES
assay_type_mod	character varying	YES
viral_name	character varying	YES
viral_lineage	character varying	YES
viral_sublineage	character varying	YES
viral_mutation	character varying	YES
vaccine_activity	character varying	YES
vaccine_activity_unit	character varying	YES
vaccine_activity_description	character varying	YES
boost1_time_unit	character varying	YES
boost1_time0	character varying	YES
boost1_activity0	character varying	YES
boost1_time1	character varying	YES
boost1_time1_info	character varying	YES
boost1_activity1	character varying	YES
boost1_activitiy1_norm	character varying	YES
boost1_effect1	character varying	YES
boost1_time2	character varying	YES
boost1_time2_info	character varying	YES
boost1_activity2	character varying	YES
boost1_activity2_norm	character varying	YES
boost1_effect2	character varying	YES
boost1_time3	character varying	YES
boost1_time3_info	character varying	YES
boost1_activity3	character varying	YES
boost1_activity3_norm	character varying	YES
boost1_effect3	character varying	YES
boost2_time_unit	character varying	YES
boost2_time0	character varying	YES
boost2_activity0	character varying	YES
boost2_time1	character varying	YES
boost2_time1_info	character varying	YES
boost2_activity1	character varying	YES
boost2_activitiy1_norm	character varying	YES
boost2_effect1	character varying	YES
boost2_time2	character varying	YES
boost2_time2_info	character varying	YES
boost2_activity2	character varying	YES
boost2_activity2_norm	character varying	YES
boost2_effect2	character varying	YES
boost2_time3	character varying	YES
boost2_time3_info	character varying	YES
boost2_activity3	character varying	YES
boost2_activity3_norm	character varying	YES
boost2_effect3	character varying	YES
